UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~March~~June 3130, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File No. 000-53570

ACTIVECARE, INC.

(Exact name of registrant as specified in its charter)

Delaware	87-0578125
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)

1365 West Business Park Drive, Suite 100

Orem, UT 84058

(Address of principal executive offices)

(877) 219-6050

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of ~~May~~January 1830, ~~2017~~2018, the registrant had 239,100 shares of common stock outstanding.

ActiveCare, Inc.

Quarterly Report on Form 10-Q

Table of Contents

Page PART I – FINANCIAL INFORMATION 3 Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations (Unaudited) 5 Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to Condensed Consolidated Financial Statements (Unaudited) 8 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 3238 Item 3. Quantitative and Qualitative Disclosures About Market Risk 4153 Item 4. Controls and Procedures 4153 PART II – OTHER INFORMATION 4153 Item 1. Legal Proceedings 4153 Item 1A. Risk Factors 53 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 4153 Item 3. Defaults Upon Senior Securities 4154 Item 4. Mine Safety Disclosures 4154 Item 5. Other Information 4254 Item 6. Exhibits 4254 SIGNATURES 4355

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ActiveCare, Inc.

Condensed Consolidated Balance Sheets (Unaudited)

	March 31,		September 30,
	June 30,		September 30,
	2017		2016
Assets
Current assets:
Cash	$	~~492~~114,~~506~~440	$	167,737
Accounts receivable, net		~~791~~643,~~205~~857		487,001
Inventory		~~703~~501,~~512~~769		204,736
Prepaid expenses and other		728,169		644,857
Note receivable		500,000		-
Total current assets		2,715,392		1,504,331
Prepaid expenses and other		56,555		644,857
Property and equipment, net		67,492		86,734
Total current assets		1,816,621		1,504,331
Deposits and other assets		17,846		17,846
Property and equipment, net		56,445		86,734
Domain name, net		8,938		9,295
Deposits and other assets		12,970		17,846
Total assets	$	2,809,668	$	1,618,206
Domain name, net		8,759		9,295
Total assets	$	1,894,795	$	1,618,206

See accompanying notes to condensed consolidated financial statements.

ActiveCare, Inc.

Condensed Consolidated Balance Sheets (Unaudited) (continued)

	March 31,			September 30,
	June 30,			September 30,
	2017			2016
Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable	$	43,~~135~~453,~~637~~795		$	1,700,448
Accounts payable, related party		~~187~~242,~~841~~568			291,753
Accrued expenses		57,~~125~~765,~~009~~437			2,101,711
Current portion of notes payable		7,131,781			3,722,899
Contingent liabilities		750,000			-
Notes payable, related party		3,875,335			3,898,124
Current portion of notes payable		9,501,544			3,722,899
Dividends payable		674,902			606,545
Notes payable, related party		3,869,683			3,898,124
Derivatives liability		4,296,127			2,054,071
Dividends payable		733,880			606,545
Total current liabilities		25,426,632			14,375,551
Derivatives liability		4,231,983			2,054,071
Notes payable, net of current portion		6,131,837			7,353,856
Total current liabilities		30,548,890			14,375,551
Total liabilities		31,558,469			21,729,407
Notes payable, net of current portion		5,889,170			7,353,856
Total liabilities		36,438,060			21,729,407
Stockholders' deficit:
Preferred stock, $.00001 par value: 10,000,000 shares authorized; 45,000 shares of Series D; 70,070 shares of Series E; and 0 and 43,220 shares of Series G issued and outstanding, respectively		2			1
Preferred stock, $.00001 par value: 10,000,000 shares authorized; 45,000 shares of Series D; 70,070 shares of Series E; and 43,220 and 0 shares of Series G issued and outstanding, respectively		2			1
Common stock, $.00001 par value: 200,000,000 shares authorized; 232,100 and 232,100 shares outstanding, respectively		2			2
Common stock, $.00001 par value: 200,000,000 shares authorized; 239,100 and 232,100 shares outstanding, respectively		2			2
Additional paid-in capital, common and preferred		88,~~706~~786,~~988~~513			88,067,410
Accumulated deficit		(~~117~~123,~~455~~329,~~793~~782	)		(108,178,614	)
Total stockholders' deficit		(2834,~~748~~543,~~801~~265	)		(20,111,201	)
Total liabilities and stockholders' deficit	$	$21,~~809~~894,~~668~~795		$	1,618,206

See accompanying notes to condensed consolidated financial statements.

ActiveCare, Inc.

Condensed Consolidated Statements of Operations (Unaudited)

	Three Months Ended						~~Six~~Nine Months Ended
	March 31,						March 31,
	June 30,						June 30,
	2017			2016			2017			2016
Revenues:
Chronic illness monitoring supplies revenues	$	1,~~666~~037,~~701~~179		$	1,~~259~~858,~~851~~926		$	34,~~274~~311,~~777~~955		$	34,~~113~~972,~~268~~196
Chronic illness monitoring fee revenues		~~186~~159,~~794~~025			~~337~~317,~~045~~156			~~440~~599,~~313~~339			~~571~~888,~~298~~453
Total Chronic illness monitoring revenues		1,~~853~~196,~~495~~204			12,~~596~~176,~~896~~082			34,~~715~~911,~~090~~294			35,~~684~~860,~~566~~649
Cost of revenues:
Chronic illness monitoring supplies cost of revenues		1733,~~121,784~~143			1,~~144~~269,~~293~~828			23,~~320~~054,~~943~~086			23,~~609~~878,~~144~~972
Chronic illness monitoring fee cost of revenues		~~103~~114,~~238~~954			~~117~~112,~~444~~486			~~204~~319,~~230~~184			~~245~~358,~~950~~436
Total Chronic illness monitoring cost of revenues		1848,~~225,022~~097			1,~~261~~382,~~737~~314			23,~~525~~373,~~173~~270			24,~~855~~237,~~094~~408
Gross profit		~~628~~348,~~473~~107			~~335~~793,~~159~~768			1,~~189~~538,~~917~~024			~~829~~1,~~472~~623,241
Operating expenses:
Selling, general and administrative (including $627,626, $1,073,481, $639,580 and $2,253,403, respectively, of stock-based compensation)		1,946,678			2,427,790			3,156,975			4,774,494
Selling, general and administrative (including $1,461,457, $1,004,211, $2,101,037 and $3,257,614, respectively, of stock-based compensation)		3,225,054			2,169,603			6,382,027			6,944,098
Research and development		8356,~~338~~191			5857,~~503~~611			~~250~~307,~~945~~137			81139,~~412~~023
Total operating expenses		23,~~030~~281,~~016~~245			2,~~486~~227,~~293~~214			36,~~407~~689,~~920~~164			47,~~855~~083,~~906~~121
Loss from operations		(12,~~401~~933,~~543~~138	)		(21,~~151~~433,~~134~~446	)		(25,~~218~~151,~~003~~140	)		(45,~~026~~459,~~434~~880	)
Other income (expense):
Interest expense, net		(32,~~102~~198,~~211~~631	)		(~~630~~813,~~821~~517	)		(46,~~657~~856,~~627~~258	)		(1,~~121~~935,~~970~~486	)
Loss on extinguishment of debt		(494,995	)		(3,043,416	)		(2,499,212	)		(3,043,416	)
Loss on settlement		(750,000	)		-			(750,000	)		-
(Loss) gain on disposal of property and equipment		-			(355	)		-			245
Gain on derivatives liability		64,145			5,603,411			230,163			2,796,542
Loss on induced conversions of debt		-			(379,132	)		-			(379,132	)
Loss on extinguishment of debt		-			(15,393	)		(2,499,212	)		(3,058,809	)
Gain on liability settlements		-			286,241			-			286,241
Gain on disposal of property and equipment		-			-			-			245
(Loss) gain on derivatives liability		143,962			(2,853,180	)		166,019			(2,806,869	)
Gain on liability settlements		-			8,859			-			295,099
Total other expense		(3,453,244	)		(6,620,663	)		(6,990,820	)		(7,064,901	)
Loss on induced conversions of debt		-			-			-			(379,132	)
Net loss		(4,854,787	)		(8,771,797	)		(9,208,823	)		(11,091,335	)
Other income		2,614			-			2,614			-
Deemed dividends on redemption of preferred stock		-			(6,484,236	)		-			(6,484,236	)
Total other income (expense)		(2,881,872	)		4,783,360			(9,872,693	)		(2,281,541	)
Dividends on preferred stock		(34,178	)		(249,921	)		(68,356	)		(653,469	)
Net income (loss)		(5,815,010	)		3,349,914			(15,023,833	)		(7,741,421	)
Net loss attributable to common stockholders	$	(4,888,965	)	$	(15,505,954	)	$	(9,277,179	)	$	(18,229,040	)
Deemed dividends on redemption of preferred stock		-			-			-			(6,484,236	)
Net loss per common share - basic	$	(21.06	)	$	(90.56	)	$	(39.97	)	$	(109.97	)
Dividends on preferred stock		(58,978	)		(45,781	)		(127,335	)		(699,250	)
Net loss per common share - diluted	$	(21.31	)	$	(90.56	)	$	(39.97	)	$	(109.97	)
Net loss attributable to common stockholders	$	(5,873,988	)	$	3,304,133		$	(15,151,168	)	$	(14,924,907	)
Weighted average common shares outstanding – basic		232,100			171,223			232,100			165,766
Net loss per common share - basic	$	(24.77	)	$	15.18		$	(64.81	)	$	(81.57	)
Weighted average common shares outstanding – diluted		232,381			171,223			232,100			165,766
Net loss per common share - diluted	$	(24.77	)	$	(3.78	)	$	(64.81	)	$	(82.78	)
Weighted average common shares outstanding – basic		237,100			217,595			233,767			182,979
Weighted average common shares outstanding – diluted		237,100			260,266			233,767			201,928

See accompanying notes to condensed consolidated financial statements.

ActiveCare, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

	Six Months Ended
	Nine Months Ended
	March 31,
	June 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(915,~~208~~023,~~823~~833	)	$	(117,~~091~~741,~~335~~421	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discounts		34,~~672~~081,~~368~~912			~~548~~904,~~102~~115
Loss on extinguishment of debt		2,499,212			3,~~043~~058,~~416~~809
Stock-based compensation expense		~~485~~1,~~119~~705,975			12,~~951~~801,~~551~~432
Stock and warrants issued for services		154,461			301,852
Loss on settlement		750,000			-
Depreciation and amortization		22,418			26,682
Stock and warrants issued and accrued for services		395,062			456,182
Loss (gain) on derivatives liability		(166,019	)		2,806,869
Increase in note payable principal recorded as interest expense to convert accounts payable into notes payable		482,500			-
Stock accrued for interest expense		144,000			-
Depreciation and amortization		33,643			39,353
Gain on derivatives liability		(230,163	)		(2,796,542	)
Gain on disposal of property and equipment		-			(245	)
Loss on induced conversions of debt		-			379,132
Gain on liability settlements		-			(~~286~~295,~~241~~099	)
Changes in operating assets and liabilities:
Accounts receivable		(~~379~~241,~~402~~844	)		(~~268~~44,~~210~~459	)
Inventory		(~~498~~297,~~776~~033	)		~~353~~414,~~090~~110
Prepaid expenses and other		~~143~~815,~~310~~799			(12178,~~323~~053	)
Accounts payable		2,~~126~~470,~~132~~310			(~~589~~732,~~607~~265	)
Accrued expenses		~~671~~1,~~865~~796,360			~~592~~931,~~829~~492
Net cash used in operating activities		(~~478~~618,~~135~~100	)		(2,~~244~~803,~~438~~459	)
Cash flows from investing activities:
Proceeds from sale of property and equipment		-			600
Purchases of property and equipment		(2,818	)		(5,004	)
Net cash used in investing activities		(2,818	)		(4,404	)
Investment in contingent note receivable		(500,000	)		-
Net cash used in investing activities		(502,818	)		(4,404	)
Cash flows from financing activities:
Proceeds from issuance of notes payable, net		34,~~321~~421,489			45,~~623~~709,~~379~~287
Proceeds from issuance of related-party notes payable, net		-			250,000
Proceeds from issuance of warrants in connection with notes payable		-			2,967
Principal payments on related-party notes payable		(2228,~~789~~441	)		-(7,795	)
Principal payments on notes payable		(23,~~492~~325,~~978~~427	)		(23,~~402~~175,~~693~~603	)
Net cash provided by financing activities		~~805~~1,~~722~~067,621			2,~~223~~778,~~653~~856
Net increase (decrease) in cash		324,769			(25,189	)
Net decrease in cash		(53,297	)		(29,007	)
Cash, beginning of the period		167,737			172,436
Cash, end of the period	$	~~492~~114,~~506~~440		$	~~147~~143,~~247~~429

See accompanying notes to condensed consolidated financial statements.

ActiveCare, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited) (continued)

	Six Months Ended
	Nine Months Ended
	March 31,
	June 30,
	2017		2016
Supplemental Cash Flow Information:
Cash paid for interest	$	~~271~~379,~~541~~589	$	97191,~~517~~943
Non-Cash Investing and Financing Activities:
Issuance of warrants for the purchase of common stock for loan origination fees	$	2,103,341	$	101,058
Issuance of warrants to purchase shares of common stock for loan origination fees	$	2,103,341	$	201,058
Accrual of a liability to issue warrants to purchase shares of common stock for loan forbearance fees		148,677		-
Accrual of a liability to issue shares of common stock for loan origination fees		125,000		~~100,000~~-
Dividends on preferred stock		68127,~~356~~335		~~653~~699,~~469~~250
Accrual of a liability to issue shares of common stock for loan forbearance fees		60,000		-
Deemed dividend on the redemption of preferred stock and accrued dividends for notes payable, common stock and exchange of warrants		-		6,484,236
Conversion of accounts payable and accrued liabilities to notes payable		-		2,555,189
Assignment of related-party notes payable to an unrelated third party		-		263,082
Issuance of shares of common stock for consulting services		-		227,500
Accrual of a liability to issue warrants to purchase shares of common stock for loan origination fees		-		130,246
Cancellation and reissuance of shares of common stock		-		121,~~450~~250
Accrual of a liability to issue shares of common stock for services		-		107,500
Conversion of related-party accounts payable and accrued liabilities to related-party notes payable		-		84,404
Issuance of shares of common stock for related-party loan origination fee		-		70,000
Issuance of shares of common stock for loan extension fees		-		31,250
Issuance of shares of common stock for dividends		-		1,434
Accrual of a liability to issue shares of common stock for loan amendment fees		-		28,500
Issuance of shares of common stock for dividends		-		12,434
Accrual of a liability to issue shares of common stock for services		-		7,600

See accompanying notes to condensed consolidated financial statements.

ActiveCare, Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Basis of Presentation

The unaudited interim condensed consolidated financial statements of ActiveCare, Inc. (the "Company" or "ActiveCare") have been prepared in accordance with Article 8 of Regulation S-X, promulgated by the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with US generally accepted accounting principles ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying interim condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the Company's financial position as of ~~March~~June 3130, 2017 and September 30, 2016, and the results of its operations for the three and ~~six~~nine months ended ~~March~~June 3130, 2017 and 2016 and its cash flows for the ~~six~~nine months ended ~~March~~June 3130, 2017 and 2016. These financial statements should be read in conjunction with the annual consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form 10-K for the year ended September 30, 2016. The results of operations for the three and ~~six~~nine months ended ~~March~~June 3130, 2017 may not be indicative of the results for the full fiscal year ending September 30, 2017.

Going Concern

The Company continues to incur negative cash flows from operating activities and net losses. The Company had minimal cash, negative working capital and negative total equity as of ~~March~~June 3130, 2017 and September 30, 2016. In addition, ~~and~~the Company is in technical default on certain notes payable although the lenders in each case are working with ~~respect~~the Company to ~~certain~~resolve ~~debt~~the defaults. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

In order for the Company to eliminate substantial doubt about its ability to continue as a going concern, it must achieve profitability, generate positive cash flows from operating activities and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management's plans with respect to this uncertainty consist of raising additional capital by issuing debt or equity securities and increasing the sales of the Company's services and products. There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to achieve operating profits. If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and services and may have to cease operations.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the balance sheet dates and the reported amounts of revenues and expenses for the reporting periods. Actual results could differ from these estimates.

Fair Value of Financial Instruments

The Company measures the fair values of its assets and liabilities using the US GAAP hierarchy. The carrying amounts reported in the condensed consolidated balance sheets for cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to the short-term nature of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. The carrying amounts reported for notes payable approximate fair values because the underlying instruments are at interest rates which approximate current market rates.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period's presentation. The reclassifications had no effect on the previously reported net loss.

2. Net Loss per Common Share

Basic net loss per common share ("Basic EPS") is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period.

Diluted net loss per common share ("Diluted EPS") is computed by dividing net loss available to common stockholders by the sum of the weighted average number of common shares outstanding and the weighted-average dilutive potential common shares outstanding. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect.

Potential common shares consist of shares issuable upon the exercise of common stock warrants ~~and options~~, shares issuable from restricted stock grants, and shares issuable pursuant to convertible notes and convertible Series D and Series E preferred stock. The following table reflects the calculation of basic and diluted net loss per common share for the periods indicated:

	Three Months Ended March 31,						Six Months Ended March 31,
	Three Months Ended June 30,						Nine Months Ended June 30,
	2017			2016			2017			2016
Numerator:
Net loss attributable to common stockholders	$	(45,~~888~~873,~~965~~988	)	$	~~(15~~3,~~505~~304,~~954~~133	)	$	(915,~~277~~151,~~179~~168	)	$	(1814,~~229~~924,~~040~~907	)
Effect of dilutive securities on net loss:
Common stock options and warrants		(63,550	)		-			-			-
Common stock warrants		-			(2,427,640	)		-			-
Total net loss for purpose of calculating diluted net loss per common share	$	(4,952,515	)	$	(15,505,954	)	$	(9,277,179	)	$	(18,229,040	)
Convertible debt		-			(1,860,373	)		-			(1,790,407	)
Total net loss for purpose of calculating diluted net loss per common share	$	(5,873,988	)	$	(983,880	)	$	(15,151,168	)	$	(16,715,314	)
Number of shares used in per common share calculations:
Total shares for purposes of calculating basic net loss per common share		~~232~~237,100			~~171~~217,~~223~~595			~~232~~233,~~100~~767			~~165~~182,~~766~~979
Weighted-average effect of dilutive securities:
Common stock options and warrants		281			-			-			-
Common stock warrants		-			3,337			-			-
Total shares for purpose of calculating diluted net loss per common share		232,381			171,223			232,100			165,766
Convertible debt		-			39,334			-			18,949
Total shares for purpose of calculating diluted net loss per common share		237,100			260,266			233,767			201,928
Net loss per common share:
Basic	$	(2124.0677	)	$	~~(90~~15.5618	)	$	(3964.9781	)	$	(~~109~~81.9757	)
Diluted	$	(2124.3177	)	$	(903.5678	)	$	(3964.9781	)	$	(~~109~~82.9778	)

The effect of dilutive securities on the numerator for purposes of calculating diluted loss per common share is related to the convertible debt and related warrants due to the reduction of the gain on derivatives liability for warrants that were in the money.

As of ~~March~~June 3130, 2017 and 2016, there were certain outstanding potential common shares that were not included in the computation of Diluted EPS as their effect would be anti-dilutive for the three and ~~six~~nine months then ended. The potential common shares outstanding consist of the following:

	Three Months Ended March 31,				Six Months Ended March 31,
	Three Months Ended June 30,				Nine Months Ended June 30,
	2017		2016		2017		2016
Common stock options and warrants		112,074		43,031		112,074		43,031
Common stock warrants		109,174		18,346		109,174		42,378
Series D convertible preferred stock		450		450		450		450
Series E convertible preferred stock		961		961		961		961
Convertible debt		~~135~~158,~~417~~798		~~126~~95,~~262~~799		~~135~~158,~~417~~798		~~126~~95,~~262~~799
Restricted shares of common stock		15		15		15		15
Liability to issue common stock and warrants		~~172~~358,~~500~~097		-2,246		~~172~~358,~~500~~097		-2,246
Total common stock equivalents		~~421~~627,~~417~~495		~~170~~117,~~719~~817		~~421~~627,~~417~~495		~~170~~141,~~719~~849

3. Recent Accounting Pronouncements

In May 2014, August 2015 and May 2016, the Financial Accounting Standards Board (FASB) issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2015-14 Revenue from Contracts with Customers, Deferral of the Effective Date, ~~and~~ ASU 2016-12 Revenue from Contracts with Customers, Narrow-Scope Improvements and Practical Expedients, ASU 2017-13 Revenue Recognition, Revenue from Contracts with Customers, Leases, and Leases: Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments, and ASU 2017-14 Income Statement—Reporting Comprehensive Income, Revenue Recognition, and Revenue from Contracts with Customers, respectively, which implement ASC Topic 606. ASC Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance under US GAAP, including industry-specific guidance. It also requires entities to disclose both quantitative and qualitative information that enable financial statements users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amendments in these ASUs are effective for annual periods beginning after December 15, 2017, and interim periods therein, which will be effective for the Company for the quarter ending December 31, 2018. Early adoption is permitted for annual periods beginning after December 15, 2016. These ASUs may be applied retrospectively to all prior periods presented, or retrospectively with a cumulative adjustment to retained earnings in the year of adoption. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. This standard sets forth management's responsibility to evaluate, each reporting period, whether there is substantial doubt about the Company's ability to continue as a going concern, and if so, to provide related disclosures. ASU 2014-15 is effective for annual reporting periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016, which will be effective for the Company for the quarter ending December 31, 2017. The Company is assessing the impact, if any, of implementing this guidance on its evaluation of going concern.

In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory. The purpose of ASU 2015-11 is to more closely align the measurement of inventory in ~~U.S.~~US GAAP with the measurement of inventory in International Financial Reporting Standards. ASU 2015-11 requires entities to measure most inventory at the "lower of cost or net realizable value." Additionally, some of the amendments are designed to more clearly articulate the requirements for the measurement and disclosure of inventory. ASU 2015-11 is effective for fiscal years and interim periods beginning after December 15, 2016, which will be effective for the Company for the quarter ending December 31, 2017. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

In February 2016, the FASB issued ASU 2016-02, Leases. The purpose of ASU 2016-02 is to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018, which will be effective for the Company for the quarter ending December 31, 2019. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

In March 2016, the FASB issued ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting. The purpose of ASU 2016-09 is to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equities or liabilities, and classification of amounts in the statement of cash flows. ASU 2016-09 is effective for fiscal years and interim periods beginning after December 15, 2016, which will be effective for the Company for the quarter ending December 31, 2017. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. The amendments in this update provided guidance on eight specific cash flow issues. This update is to provide specific guidance on each of the eight issues, thereby reducing the diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years and interim periods beginning after December 15, 2017, which will be effective for the Company for the quarter ending December 31, 2018. Early adoption is permitted. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

4In May 2017, the FASB issued ASU 2017-09, Stock Compensation: Scope of Modification Accounting. ~~Accounts~~ ~~Receivable~~The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years and interim periods beginning after December 15, 2017, which will be effective for the Company for the quarter ending December 31, 2018. Early adoption is permitted. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. Specific reserves are estimated by management based on certain assumptions and variables, including the customer's financial condition, age of the customer's receivables and changes in payment histories. Accounts receivable are written off when management determines the likelihood of collection is remote. A receivable is considered to be past due if any portion of the receivable balance has not been received by the contractual payment date. Interest is not charged on accounts receivable that are past due. The Company recorded an allowance for doubtful accounts of $111,461 and $75,161 as of March 31, 2017 and September 30, 2016, respectively.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815). The amendments in Part I of this update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down-round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for fiscal years and interim periods beginning after December 15, 2018, which will be effective for the Company for the quarter ending December 31, 2019. Early adoption is permitted. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

4. Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. Specific reserves are estimated by management based on certain assumptions and variables, including the customer's financial condition, age of the customer's receivables and changes in payment histories. Accounts receivable are written off when management determines the likelihood of collection is remote. A receivable is considered to be past due if any portion of the receivable balance has not been received by the contractual payment date. Interest is not charged on accounts receivable that are past due. The Company recorded an allowance for doubtful accounts of $25,468 and $75,161 as of June 30, 2017 and September 30, 2016, respectively. During the three months ended June 30, 2017, the Company wrote off approximately $103,000 of accounts receivable that were previously allowed against.

5. Inventory

Inventory is recorded at the lower of cost or market value, cost being determined using the first-in, first-out ("FIFO") method. Inventory consists of diabetic supplies. Inventory held by distributors is reported as inventory until the supplies are shipped to the end user by the distributor. The Company estimates an inventory reserve for obsolescence and excessive quantities. Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term. Inventory consists of the following as of:

	March 31, 2017			September 30, 2016
	June 30, 2017			September 30, 2016
Finished goods	$	~~705~~503,~~220~~477		$	206,444
Inventory reserve		(1,708	)		(1,708	)
Net inventory	$	~~703~~501,~~512~~769		$	204,736

6. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following as of:

	March 31, 2017		September 30, 2016
	June 30, 2017		September 30, 2016
Prepaid legal and professional fees	$	581,216	$	333,741
Prepaid information technology services	$	38,081	$	57,073
Prepaid information technology services		76,410		57,073
Other		12,249		112,117
Other		52,650		112,117
Prepaid insurance		6,225		14,602
Prepaid insurance		10,163		14,602
Prepaid legal and professional fees		-		333,741
Research and development		~~7,730~~-		96,346
Line of credit acquisition fees		-		30,978
Total prepaid expenses and other current assets	$	~~728~~56,~~169~~555	$	644,857

7. Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are determined using the straight-line method over the estimated useful lives of the assets, which range between 3 and 7 years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the terms of the lease. Expenditures for maintenance and repairs are expensed as incurred. Upon the sale or disposal of property and equipment, any gains or losses are included in operations. Property and equipment consisted of the following as of:

	March 31, 2017			September 30, 2016
	June 30, 2017			September 30, 2016
Software	$	47,974		$	47,974
Leasehold improvements		98,023			98,023
Furniture		68,758			68,758
Equipment		5247,~~590~~191			49,772
Total property and equipment		~~267~~261,~~345~~946			264,527
Accumulated depreciation and amortization		(~~199~~205,~~853~~501	)		(177,793	)
Property and equipment, net	$	6756,~~492~~445		$	86,734

Assets to be disposed of are reported at the lower of the carrying amounts or fair values, less the estimated costs to sell or dispose. During the ~~six~~nine months ended ~~March~~June 3130, 2016, the Company recorded a gain on the disposal of property and equipment of $245. Depreciation expense for the ~~six~~nine months ended ~~March~~June 3130, 2017 and 2016, was $2233,~~060~~107 and $2638,~~325~~817, respectively.

8. Accrued Expenses

Accrued expenses consisted of the following as of:

	March 31, 2017		September 30, 2016
	June 30, 2017		September 30, 2016
Liability to issue warrants for the purchase shares of common stock	$	2,081,254	$	-
Interest	$	2,694,545	$	1,206,387
Interest		1,891,928		1,206,387
Liability to issue warrants for the purchase shares of common stock		2,081,254		-
Liability to issue common stock		~~475~~2,000,933		240,000
Payroll expense		209,773		207,052
Finance fees		333,000		-
Other		125,579		89,828
Payroll expense		329,615		207,052
Warranty liability		104,805		134,330
Other		141,394		89,828
Finance Fees		91,333		-
Deferred revenue		85,399		111,803
Deferred revenue		87,589		111,803
Warranty liability		58,300		134,330
Commissions and fees		5740,~~748~~997		52,311
Severance		-		60,000
Total accrued expenses	$	57,~~125~~765,~~009~~437	$	2,101,711

9. Notes Payable

The Company had the following notes payable outstanding as of:

	March 31,		September 30,
	June 30,		September 30,
	2017		2016
Unsecured notes payable with interest at 10% per annum, due November 2018. The notes may go into default in the event other notes payable go into default subsequent to the effective date of the note. In February 2016, the Company redeemed all 5,361 shares of its Series F Convertible Preferred Stock ("Series F preferred") plus accrued dividends of $673,948 for 20,005 shares of common stock with a fair value of $1,600,000 containing certain temporary restrictions, and $5,900,000 of notes payable. Payments on the notes are partially or fully convertible at the Company's option at the lesser of (i) 80% of the per share price of the common stock to be offered in the proposed offering that is described in the Form S-1 filed on July 19, 2016 (the "Offering"), (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering to a maximum of 39,334 shares of common stock. The conversion rate is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. A note may only be converted if the holder owns less than 4.99% of the Company's common stock after conversion. The Company recorded a derivative liability of $2,461,899 related to the conversion feature of the notes. In connection with the redemption of the Series F preferred stock, the Company issued new warrants in exchange for warrants held by the Series F preferred stockholders for the purchase of 11,070 shares of common stock at an exercise price of the lesser of (i) 80% of the per share price of the common stock of the Offering, (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering, adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. The Company is also required to issue additional warrants for the purchase of up to 16,000 shares of common stock exercisable at $0.50 per share, also adjustable, that vest upon certain events of default. The fair value of $1,344,608 related to the new warrants was recorded as a derivative (see Notes 12 and 15). The fair value of the stock, conversion feature, warrants and $25,000 of fees, in excess of the carrying value of the Series F preferred stock were recorded as a deemed dividend of $6,484,236. During the three months ended March 31, 2017, the Company entered into letter agreements related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the Offering, which also removes the maximum share limitation conversion (see Note 17).	$	5,900,000	$	5,900,000
Unsecured notes payable with interest at 10% per annum, due November 2018. The notes may go into default in the event other notes payable go into default subsequent to the effective date of the note. Some of the notes are currently in technical default. However, as of the time of this report, the lenders have informally agreed to work with the Company until such time as the note can be repaid. In February 2016, the Company redeemed all 5,361 shares of its Series F Convertible Preferred Stock ("Series F preferred") plus accrued dividends of $673,948 for 20,005 shares of common stock with a fair value of $1,600,000 containing certain temporary restrictions, and $5,900,000 of notes payable. Payments on the notes are partially or fully convertible at the Company's option at the lesser of (i) 80% of the per share price of the common stock to be offered in the proposed offering that is described in the Form S-1 filed on July 19, 2016 (the "Offering"), (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering to a maximum of 39,334 shares of common stock. The conversion rate is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. A note may only be converted if the holder owns less than 4.99% of the Company's common stock after conversion. The Company recorded a derivative liability of $2,461,899 related to the conversion feature of the notes. In connection with the redemption of the Series F preferred stock, the Company issued new warrants in exchange for warrants held by the Series F preferred stockholders for the purchase of 11,070 shares of common stock at an exercise price of the lesser of (i) 80% of the per share price of the common stock of the Offering, (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering, adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. The Company is also required to issue additional warrants for the purchase of up to 16,000 shares of common stock exercisable at $0.50 per share, also adjustable, that vest upon certain events of default. On December 11, 2017, the Company entered into Securities Purchase Agreements that adjusted the conversion rate to exercise price per share equal to the lesser of (i) 80% of the per share price of common stock in a contemplated private placement of securities of up to $5,000,000, contemplated to take place within six months of the effective date (the "Private Placement") (ii) $3.00 per share, (iii) 80% of the offering price in the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement, in each case subject to adjustment (see Note 18). The fair value of $1,344,608 related to the new warrants was recorded as a derivative (see Notes 12 and 15). The fair value of the stock, conversion feature, warrants and $25,000 of fees, in excess of the carrying value of the Series F preferred stock were recorded as a deemed dividend of $6,484,236. During the three months ended March 31, 2017, the Company entered into letter agreements related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the Offering, which also removes the maximum share limitation conversion, which have expired (see Note 17). Subsequent to June 30, 2017, the Company received letters related to the notes wherein the lenders waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 (see Note 18). In December 2017, the Company entered into those certain forbearance and lock up letter agreements with four of the eight debtors, with principal balances in the aggregate amount of $1,134,658, whereby the debtors agreed that, without prior written consent of the Company, the debtors will not, directly or indirectly, (i) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, (ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, whether any such transaction is to be settled by delivery of common stock or other securities, in cash or otherwise, (iii) except as provided for, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of the Company, or (iv) publicly disclose the intention to do any of the foregoing for a period of the earlier of (a) June 5, 2018 or (2) the consummation of a qualified offering, herein deemed as an offering by the Company of $3,000,000 or more. Additionally, the Debt Holders agreed that they will forbear from enforcing their rights and remedies against any defaults which may exist historically, currently or in the future through June 5, 2018 under the existing loan documents. The agreements automatically terminate upon the earlier of (i) inability to raise a minimum of $550,000 in capital on or before December 31, 2017; (ii) June 5, 2018; or (iii) the consummation of a qualified offering of at least $3,000,000 by the Company. In addition, two of the five debtor agreements waive their rights to default litigation only through December 31, 2017 and any new financing must receive their prior consent unless it is common equity (see Note 18). On January 12, 2018, the Company received letters from four of the debtors where the debtors forbear against any historical and future events of default and remedies through February 15, 2018. Further, the maturity date was extended through February 15, 2018. As part of the letters, the Company agreed not to initiate any new financing arrangements without the consent of the debtors. (see Note 18). On December 11, 2017, the Company borrowed an aggregate additional $300,000 from two of the lenders under new note payable agreements (see Note 18).	$	5,900,000	$	5,900,000

Unsecured note payable with a vendor with interest at 0.65% per annum, due January 2018, issued in March 2016 upon the conversion of $2,523,937 in accounts payable to the vendor.			1,773,937				2,223,937
Secured note payable to a third party with interest at 12.75% per annum, due February 2019. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the note payable agreement in conjunction with a line of credit. The Company initially borrowed $1,500,000 and may borrow additional amounts under the note payable agreement up to a total balance of $3,000,000 as the Company meets certain milestones. The interest rate may also reduce to 11.25% per annum as the Company meets certain milestones. In conjunction with the note and related line of credit, the Company issued warrants to the lender to purchase 24,032 shares of common stock at $32.50 per share with a fair market value of $3,732,100 (see Notes 12 and 15), which resulted in a loss on derivative of $2,309,461. The Company has recorded discounts of $1,500,000, which are being amortized to interest expense over the term of the note. In April 2016, the Company borrowed an additional $500,000 on the note and incurred additional fees of $25,000, which are being amortized to interest expense over the remaining term of the note. In September 2016, the Company entered into a forbearance agreement where the lender will forbear from exercising remedies with regard to certain breaches through October 31, 2016 and consented to the Company entering into a purchase agreement with another party and issue the note and the warrant thereunder. Effective November 1, 2016, the Company and the lender entered into a forbearance and consent under loan and security agreement. Pursuant to the terms of the forbearance agreement, the lender will forbear from exercising remedies with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the previous forbearance agreement. Additionally, the lender has provided the Company with the consent required under the existing agreements and previous forbearance agreement to make certain payments to other debt holders from the proceeds of the Offering. The lender also consented to the issuance of the Company's proposed Series G Preferred Stock to certain affiliates of the Company (see Note 13). In consideration for the new forbearance, the Company has agreed to issue the lender warrants to purchase 130,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering, which shall be subject to a 6-month lock-up agreement. The forbearance was in effect through December 31, 2016. The Company has included the $1,932,577 estimated fair value of the warrants in accrued expenses. The Company recorded a loss on extinguishment of debt of $2,043,715 on the note and its related line of credit in relation to the forbearance agreement. Effective December 31, 2016, the Company and the lender entered into a third forbearance and consent under loan and security agreement. Pursuant to the terms of the third forbearance, the lender will forbear from exercising remedies with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the previous two forbearances. Additionally, pursuant to the third forbearance, the lender has provided the Company with the consent required under the existing agreements and prior two forbearances to make certain payments from the proceeds of the Offering. In consideration for the third forbearance, the Company has agreed to issue the lender warrants to purchase 10,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering and $50,000 of common stock at 80% of the at the same issue price in of the Offering, which shall be subject to a lock-up agreement. The forbearance set forth in the third forbearance was in effect through February 15, 2017. The Company has included the $148,677 estimated fair value of the warrants and $60,000 fair value related to the shares of common stock in accrued expenses. $104,824 of the fair value of the warrants and common stock associated with the note is recorded as a discount and is being amortized to interest expense over the remaining life of the note. In February 2017 and March 2017, the lender extended the third forbearance period through March 31, 2017 and April 10, 2017, respectively. In March 2017, the Company modified the line of credit to include an additional secured borrowing of a maximum of $300,000. The Company recorded a loss on extinguishment of debt of $56,741 related to the modification.			1,319,444				1,652,778

Secured borrowings from a third party that purchased $2,325,750 of customer receivables for $1,675,000, with due dates ranging from April 2017 to September 2017, and payable in daily payments ranging from $1,500 to $4,000. The $650,750 difference between the customer receivables and cash received is being amortized to interest expense over the term of the respective notes. The secured borrowings are guaranteed by two officers of the Company and are subordinated to other notes payable. Subsequent to March 31, 2017, the borrowings were replaced by a new secured borrowing agreements for $794,000 plus $1,000,000 of new borrowings under the new agreement (See Note 18).			922,784				689,318
Unsecured note payable with a third party with no interest, was due the earlier of November 2016 or the third business day after the closing of a proposed Offering. Pursuant to the note, the Company may borrow up to $1,500,000 upon meeting certain milestones and may be converted into shares of common stock upon default. The note required a payment of common stock on the 5th trading day after the pricing of the proposed Offering, but no later than December 15, 2016. The number of common shares will equal $200,000 divided by the lowest of (i) the lowest daily closing price of the common stock during the ten days prior to delivery of the common shares or during the ten days prior to the date of the Purchase Agreement, (ii) 80% of the common stock Offering price of the Offering, (iii) 80% of the unit price Offering price of the Offering, or (iv) the exercise price of any warrants issued in the Offering. The estimated fair value of $240,000 of the stock is included in accrued liabilities and is being amortized to interest expense over the life of the note. In connection with the issuance of the note, the Company also issued 20,000 warrants to purchase shares of common stock at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock in the Offering, (ii) $25 per share, (iii) 80% of the unit price in the Offering, or (iv) the exercise price of any warrants issued in the Offering and the number of shares will reset upon the closing of the Offering. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company's common stock after exercise. The fair value of $493,590 related to the replacement warrants was recorded as a derivative (see Notes 12 and 15). Of this fair value amount, $220,000 was recorded as a debt discount and is being amortized over the life of the note and the remaining $273,590 was recorded as a loss on derivative liability. In the event of borrowing in excess of an initial $500,000, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to the initial warrants issued. In November 2016, the Company borrowed an addition $250,000 on the note and issued an additional warrant for the purchase of 10,000 shares of common stock with similar terms to the original warrants. The fair value of $286,171 related to the November 2016 warrants was recorded as a derivative (see Notes 12 and 15). The fair value was recorded as a debt discount and is being amortized over the remaining life of the note. In November 2016, the Company amended the note to extend the maturity date to the earlier of January 31, 2017 or the third business day after the closing of the Offering. In addition, the amendment adjusted the origination shares to equal 20% of the note divided by the lowest of (i) the lowest daily closing price of the common stock during the ten days prior to delivery of the shares or during the ten days prior to the date of the agreement, (ii) 80% of the common stock Offering price of the Offering, (iii) 80% of the unit price Offering price (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Offering. In December 2016. the Company borrowed an addition $250,000 on the note and issued an additional warrant for the purchase of 10,000 shares of common stock with similar terms to the original warrants. The fair value of $349,819 related to the December 2016 warrants was recorded as a derivative (see Notes 12 and 15). The fair value was recorded as a debt discount and is being amortized over the remaining life of the note. On January 3, 2017, the Company borrowed an additional $200,000 on the note and issued an additional warrant for the purchase of 8,000 shares of common stock with similar terms to the original warrants. The fair value of $567,753 related to the January 3, 2017 warrants was recorded as a derivative (see Notes 12 and 15). The fair value was recorded as a debt discount and is being amortized over the remaining life of the note. On January 30, 2017, the Company amended the note to extend the maturity date to the earlier of March 15, 2017 or the third business day after the closing of the Offering. Also on January 30, 2017. the Company borrowed the remaining $300,000 on the note and issued an additional warrant for the purchase of 12,000 shares of common stock with similar terms to the original warrants. The fair value of $899,598 related to the January 30, 2017 warrants was recorded as a derivative (see Notes 12 and 15). The fair value was recorded as a debt discount and is being amortized over the remaining life of the note. On March 3, 2017, the Company amended the note to increase the maximum sum from $1,500,000 to $2,000,000. Also on March 3, 2017, the Company borrowed an additional $200,000 on the note and issued an additional warrant for the purchase of 8,000 shares of common stock with similar terms to the original warrants. The fair value of $407,947 related to the March 3, 2017 warrants was recorded as a derivative (see Notes 12 and 15). The Company recorded a loss on extinguishment of debt of $501,969 related to the March 3, 2017 amendment and additional borrowing. Effective March 27, 2017, the Company amended the note to extend the maturity date to the earlier of April 15, 2017 or the third business day after the closing of the Offering. Additionally, the lender agreed to enter into a lock up prohibiting the sale or other transfer of all securities of the Company owned by them for a period of 6 months. In consideration for entering into the lock-up agreement the Company has agreed to pay a $340,000 fee, payable in shares of common stock at a rate of the lowest of (i) 80% of the common stock Offering price of the Offering, (ii) 80% of the unit price Offering price of the Offering (if applicable), or (iii) 80% of the exercise price of any warrants issued in the Offering. The lock-up agreement was signed subsequent to March 31, 2017.			1,700,000				500,000

Secured borrowings from a third party that purchased $3,257,600 of customer receivables for $2,100,000, with due dates ranging from January 2018 to October 2018, and payable in daily payments ranging from $5,000 to $13,000. The $1,157,600 difference between the customer receivables and cash received is being amortized to interest expense over the term of the respective notes. The secured borrowings are guaranteed by a former chief executive officer of the Company and are subordinated to other notes payable. On April 17, 2017, the Company entered into a factoring agreement which provides for an advance of $1,794,000, comprised of $1,000,000 in cash and the consolidation of $794,000 from four prior factoring agreements into the amounts owed under the factoring agreement (collectively, the "Funds"). In consideration for the Funds, the Company sold to the lender all future receipts until the total amount of $2,511,601 has been paid. The factoring agreement requires payment of the minimum daily amount of $12,999.99 for 193 days. The $2,511,601 can be reduced if repayment occurs more quickly. Repayment of the amounts owing is with recourse and secured by all accounts, chattel paper, documents, equipment, general intangibles, instruments, and inventory of the Company and subordinated to other notes payable. In June 2017, the lender verbally agreed to reduce the minimum daily amount to $5,000 and, in November 2017, verbally agreed to further reduce the minimum daily amount to $2,600 through January 7, 2018, after which the daily amount would return to $13,000. Subsequent to June 30, 2017, the Company entered into similar secured borrowings and related verbal or written reductions in the daily amounts. On January 5, 2018, the Company further modified each agreement to keep the amount of the daily payments at approximately the same level as the agreement on November 7, 2017 through mid-March 2018, except one where the lower payments are only through February 5, 2018 (see Note 18).

1,974,602

689,318

Unsecured note payable with a vendor with interest at 0.65% per annum payable at the end of each calendar year, due January 2018, issued in March 2016 upon the conversion of $2,523,937 in accounts payable to the vendor. The note requires payments of $50,000 per month in April 2016 through December 2016, $100,000 per month in January 2017 through December 2017 and the remaining balance due in January 2018. In September 2017, the Company entered into agreements with the vendor which supersedes the unsecured note payable agreement and provides new terms (see Note 18).

1,773,937

2,223,937

~~Secured~~Unsecured ~~line~~note ofpayable ~~credit~~ with a third party with no interest, atwas ~~12.25%~~due ~~per~~the ~~annum,~~earlier ~~due~~of ~~February~~November ~~2018~~2016 or the third business day after the closing of a proposed Offering. The note is ~~secured~~currently byin technical default. However, as of the ~~assets~~time of this report, the ~~Company~~lender ~~and~~has ~~may~~provided gobridge ~~into~~capital ~~default~~since going in default and has informally agreed to work with the ~~event~~Company ~~other~~until ~~notes~~such ~~payable~~time goas ~~into~~the ~~default~~note ~~subsequent~~can be repaid. Pursuant to the ~~effective~~note, ~~date~~the Company may borrow up to $1,500,000 upon meeting certain milestones and may be converted into shares of ~~the~~common ~~note~~stock upon default. The ~~Company~~note ~~entered~~required ~~into~~a payment of common stock on the ~~line~~5th trading day after the pricing of ~~credit~~the ~~agreement~~proposed inOffering, ~~conjunction~~but ~~with~~no alater ~~note~~than ~~payable~~December 15, 2016. The ~~Company~~number ~~may~~of ~~draw~~common upshares will equal $200,000 divided by the lowest of (i) the lowest daily closing price of the common stock during the ten days prior to delivery of the ~~lesser~~common shares or during the ten days prior to the date of the Purchase Agreement, (ii) 80% of ~~certain~~the ~~accounts~~common ~~receivable~~stock orOffering $1price of the Offering,~~500,000~~ ~~and~~(iii) ~~increase~~80% of the ~~maximum~~unit itprice ~~may~~Offering ~~borrow~~price ~~under~~of the ~~agreement~~Offering, upor to(iv) athe ~~total~~exercise ~~balance~~price of ~~$3,000,000~~any atwarrants issued in the Offering. The estimated fair value of $~~500~~240,000 ~~per~~of ~~increase as~~ the ~~Company~~stock ~~meets~~is ~~certain~~included ~~milestones.~~in ~~The~~accrued ~~interest~~liabilities ~~rate~~and ~~may~~is ~~also~~being ~~reduce~~amortized to ~~10.75%~~interest ~~per~~expense ~~annum~~over as the ~~Company~~life ~~meets~~of ~~certain~~the ~~milestones~~note. In ~~conjunction~~connection with the ~~line~~issuance of ~~credit~~the ~~and related~~ note, the Company also issued 20,000 warrants to purchase ~~24,032~~ shares of common stock at ~~$32.50~~an exercise price per share ~~with~~equal ato ~~fair~~the ~~market~~lesser ~~value~~of (i) 80% of $3the per share price of the common stock in the Offering,~~732,100~~ (~~see~~ii) ~~Notes~~$25 12per ~~and~~share, 15(iii) 80% of the unit price in the Offering, ~~which~~or ~~resulted~~(iv) the exercise price of any warrants issued in athe ~~loss~~Offering onand ~~derivative~~the number of ~~$2,309,461~~shares will reset upon the closing of the Offering. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company's ~~has~~common ~~recorded~~stock ~~prepaid~~after ~~expenses~~exercise. The fair value of $44493,~~665~~590 related to the replacement warrants was recorded as a derivative (see Notes 12 and 15). Of this fair value amount, ~~which~~$220,000 ~~are~~was ~~being~~recorded ~~amortized~~as toa ~~interest~~debt ~~expense~~discount and is being amortized over the ~~term~~life of the ~~line~~note ofand ~~credit~~the remaining $273,590 was recorded as a loss on derivative liability. In ~~September~~the ~~2016,~~event ~~the~~of ~~Company~~borrowing ~~entered~~in ~~into~~excess aof ~~forbearance~~an ~~agreement~~initial ~~where~~$500,000, the ~~lender~~Company will ~~forbear~~be ~~from~~required ~~exercising~~to ~~remedies~~issue additional warrants with ~~regard~~an aggregate exercise amount equal to ~~certain~~100% ~~breaches~~of ~~through~~the ~~October~~additional ~~31,~~amount ~~2016~~borrowed ~~and~~with ~~consented~~similar terms to the ~~Company~~initial ~~entering~~warrants ~~into~~issued. aIn ~~purchase~~November ~~agreement~~2016, ~~with~~the ~~another~~Company ~~party~~borrowed ~~and~~an ~~issuance~~addition of$250,000 on the note and ~~the~~issued an additional warrant ~~thereunder.~~for ~~Effective~~the ~~November~~purchase 1,of ~~2016~~10,000 shares of common stock with similar terms to the ~~Company~~original ~~and~~warrants. The fair value of $286,171 related to the ~~lender~~November ~~entered~~2016 ~~into~~warrants was recorded as a ~~forbearance~~derivative (see Notes 12 and ~~consent~~15). ~~under~~The ~~loan~~fair value was recorded as a debt discount and ~~security~~is ~~agreement.~~being ~~Pursuant~~amortized toover the ~~terms~~remaining life of the ~~forbearance~~note. ~~agreement~~In November 2016, the ~~lender~~Company ~~will~~amended ~~forbear~~the ~~from~~note ~~exercising~~to ~~remedies~~extend ~~with~~the ~~regard~~maturity date to ~~certain~~the ~~breaches~~earlier of ~~agreements~~January ~~between~~31, 2017 or the ~~Company~~third ~~and~~business day after the ~~lender,~~closing ~~including~~of the ~~existing~~Offering. ~~agreements~~In asaddition, ~~well~~the asamendment adjusted the ~~previous~~origination ~~forbearance~~shares ~~agreement.~~to ~~Additionally,~~equal 20% of the ~~lender~~note ~~has~~divided ~~provided~~by the ~~Company~~lowest ~~with~~of (i) the ~~consent~~lowest ~~required~~daily ~~under~~closing price of the ~~existing~~common ~~agreements~~stock ~~and~~during ~~previous~~the ~~forbearance~~ten ~~agreement~~days prior to ~~make~~delivery ~~certain~~of ~~payments~~the toshares ~~other~~or ~~debt~~during ~~holders~~the ~~from~~ten days prior to the ~~proceeds~~date of the ~~Offering.~~agreement, ~~The~~(ii) ~~lender~~80% ~~also~~of ~~consented~~the tocommon stock Offering price of the ~~issuance~~Offering, (iii) 80% of the ~~Company's~~unit ~~proposed~~price ~~Series~~Offering Gprice ~~Preferred~~(if ~~Stock~~applicable), toor ~~certain~~(iv) ~~affiliates~~80% of the ~~Company~~exercise ~~(see~~price ~~Note~~of ~~13).~~any Inwarrants ~~consideration~~issued ~~for~~in the ~~new~~Offering. ~~forbearance~~In December 2016, the Company ~~has~~borrowed ~~agreed~~an toaddition ~~issue~~$250,000 on the ~~lender~~note ~~warrants~~and toissued an additional warrant for the purchase ~~130~~of 10,000 shares of common stock atwith ansimilar ~~exercise~~terms ~~price equal~~ to the ~~per~~original ~~share~~warrants. ~~price~~The offair ~~the~~value ~~common~~of ~~stock~~$349,819 inrelated to the ~~Offering,~~December ~~which~~2016 ~~shall~~warrants bewas ~~subject~~recorded toas a ~~6-month~~derivative ~~lock-up~~(see ~~agreement~~Notes 12 and 15). The ~~forbearance~~fair value was inrecorded ~~effect~~as ~~through~~a ~~December~~debt ~~31,~~discount ~~2016.~~and ~~The~~is ~~Company~~being ~~has~~amortized ~~included~~over the ~~$1,932,577~~remaining ~~estimated~~life ~~fair value~~ of the ~~warrants~~note. inOn ~~accrued~~January ~~expenses.~~3, ~~The~~2017, the Company ~~recorded~~borrowed aan ~~loss~~additional $200,000 on ~~extinguishment~~the ofnote ~~debt~~and ofissued ~~$2,043,715~~an onadditional warrant for the ~~line~~purchase of ~~credit~~8,000 ~~and~~shares ~~its~~of ~~related~~common ~~secured~~stock ~~note~~with ~~payable~~similar interms ~~relation~~ to the ~~forbearance~~original ~~agreement~~warrants. ~~Effective~~The ~~December~~fair ~~31,~~value ~~2016~~of $567,753 related to the ~~Company~~January ~~and~~3, ~~the~~2017 ~~lender~~warrants ~~entered~~was ~~into~~recorded as a ~~third~~derivative ~~forbearance~~(see Notes 12 and ~~consent~~15). ~~under~~The ~~loan~~fair value was recorded as a debt discount and ~~security~~is ~~agreement.~~being ~~Pursuant~~amortized toover the ~~terms~~remaining life of the ~~third~~note. ~~forbearance~~On January 30, 2017, the ~~lender~~Company ~~will~~amended ~~forbear~~the ~~from~~note ~~exercising~~to ~~remedies~~extend ~~with~~the ~~regard~~maturity date to ~~certain~~the ~~breaches~~earlier of ~~agreements~~March ~~between~~15, 2017 or the third business day after the closing of the Offering. Also on January 30, 2017. the Company ~~and~~borrowed the ~~lender~~remaining $300,000 ~~including~~on the ~~existing~~note ~~agreements~~and asissued ~~well~~an asadditional warrant for the ~~previous~~purchase ~~two~~of ~~forbearances~~12,000 shares of common stock with similar terms to the original warrants. ~~Additionally~~The fair value of $899,598 ~~pursuant~~related to the ~~third~~January ~~forbearance~~30, ~~the~~2017 ~~lender~~warrants ~~has~~was ~~provided~~recorded ~~the~~as ~~Company~~a ~~with~~derivative ~~the~~(see ~~consent~~Notes ~~required~~12 ~~under~~and ~~the~~15). ~~existing~~The ~~agreements~~fair ~~and~~value ~~prior~~was ~~two~~recorded ~~forbearances~~as toa ~~make~~debt ~~certain~~discount ~~payments~~and ~~from~~is being amortized over the ~~proceeds~~remaining life of the ~~Offering~~note. InOn ~~consideration~~March ~~for~~3, ~~the third forbearance~~2017, the Company ~~has~~amended ~~agreed~~the note to ~~issue~~increase the ~~lender~~maximum ~~warrants~~sum tofrom ~~purchase~~$1,500,000 10to $2,000,000. ~~shares~~Also ofon ~~common~~March ~~stock~~3, at2017, anthe ~~exercise~~Company ~~price~~borrowed ~~equal~~an toadditional ~~the~~$200,000 ~~per~~on ~~share~~the ~~price~~note ofand ~~the~~issued ~~common~~an ~~stock~~additional inwarrant for the ~~Offering~~purchase ~~and~~of ~~$50~~8,000 shares of common stock atwith ~~80%~~similar ofterms ~~the~~to at the ~~same~~original ~~issue~~warrants. ~~price~~The infair value of $407,947 related to the ~~Offering~~March 3, ~~which~~2017 ~~shall~~warrants bewas ~~subject~~recorded toas a ~~lock-up~~derivative ~~agreement~~(see Notes 12 and 15). The ~~forbearance~~Company ~~set~~recorded ~~forth~~a inloss ~~thethird~~on ~~forbearance~~extinguishment ~~was~~of indebt ~~effect~~of ~~through~~$501,969 ~~February~~related 15to the March 3, 2017. ~~The~~amendment ~~Company~~and ~~has~~additional ~~included~~borrowing. ~~the~~Effective ~~$148~~March 27,~~677~~ ~~estimated~~2017, ~~fair~~the ~~value~~Company ofamended the ~~warrants~~note ~~and~~to ~~$60,000~~extend ~~fair~~the ~~value~~maturity ~~related~~date to the ~~shares~~earlier of ~~common~~April ~~stock~~15, in2017 ~~accrued~~or ~~expenses~~the third business day after the closing of the Offering. ~~$104~~Additionally,~~824~~ ofthe lender agreed to enter into a lock up prohibiting the ~~fair~~sale ~~value~~or other transfer of all securities of the ~~warrants~~Company ~~and~~owned ~~common~~by ~~stock~~them ~~associated~~for ~~with~~a period of 6 months. In consideration for entering into the ~~line~~lock-up ofagreement ~~credit~~the isCompany ~~recorded~~has agreed to pay a $340,000 fee, payable in ~~prepaid~~shares ~~expenses~~of ~~and~~common ~~other~~stock ~~assets~~at ~~and~~a israte ~~being~~of ~~amortized~~the tolowest ~~interest~~of ~~expense~~(i) ~~over~~80% of the ~~remaining~~common ~~life~~stock Offering price of the ~~line~~Offering, (ii) 80% of ~~credit.~~the Inunit ~~February~~price ~~2017~~Offering ~~and~~price ~~March~~of ~~2017~~the Offering (if applicable), ~~the~~or ~~lender~~(iii) ~~extended~~80% of the ~~third~~exercise ~~forbearance~~price ~~period~~of ~~through~~any ~~March~~warrants ~~31,~~issued ~~2017~~in ~~and~~the ~~April~~Offering. ~~10,~~The lock-up agreement was signed during April 2017, ~~respectively~~which has expired. InEffective ~~March~~April 19, 2017, the Company ~~modified~~amended the ~~line~~note ofto ~~credit~~extend tothe ~~include~~maturity andate ~~additional~~to ~~secured~~the ~~borrowing~~earlier of aMay ~~maximum~~20, of2017 ~~$300,000.~~or ~~The~~the ~~Company~~third ~~recorded~~business aday ~~loss~~after onthe ~~extinguishment~~closing of ~~debt~~the ofOffering. ~~$56~~On December 11,~~741~~ ~~related~~2017, tothe Company borrowed an additional $250,000 from the ~~modification~~lender under a new note payable agreement (see Note 18). 1,~~259~~700,~~007~~000 ~~929~~500,~~518~~000

Note payable previously secured by CareServices customer contracts. In January 2015, the note was amended to reduce the outstanding principal to $375,000, interest at 9% per annum, and payable in 15 monthly installments beginning in February 2015. The amendment released the collateralized customer contracts and the note payable is guaranteed by both a former Executive Chairman of the Board of Directors and a member of the Board of Directors. A gain on the extinguishment of the old note of $769,449 was recorded in other income. In December 2015, the note was amended to extend maturity to January 2018 payable in monthly installments beginning in July 2016, convert $31,252 from accrued interest into principal, interest at 10% per annum, and provide that the note is convertible into common stock at its fair value per share. The Company recorded a derivative in connection with the convertible feature of the note (see Note 12) and is amortizing the initial $302,690 fair value of the derivative liability over the life of the note. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016. In July 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or November 2016 and included additional default penalties and payment terms. In October 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or December 31, 2016 and included additional default penalties and payment terms. In December 2016, February 2017 and March 2017, the note was further amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or February 15, 2017, March 31, 2017, and April 30, 2017, respectively.	334,464	334,464
Unsecured note payable with interest at 12% per annum, due February 2016, convertible into common stock at $150 per share. In connection with the issuance of the note, the Company repriced previously issued warrants to purchase shares of common stock. The $22,397 increase in relative fair value of the warrants was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The note also required a payment of 6,000 shares of common stock. The fair value of $780,000 was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The maturity date was subsequently extended on two occasions for a total of 500 shares of common stock and the note was due May 2016. The $31,250 fair value of these shares was being amortized over the extension period. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $30 per share, which was below the fair value of the Company's common stock on the date of the amendment. The note may only be converted if the holder owns less than 9.99% of the Company's common stock after conversion. The Company recorded the value of the beneficial conversion feature of $381,299 to loss on termination of debt as a result of the modification. In May 2016, the note was amended to extend the maturity date to the earlier of an equity raise of $10,000,000 or October 2016 which required a payment of 600 shares of common stock. The $28,500 fair value of these shares has been included in accrued liabilities and was amortized over the extension period. In October 2016, the Company extended the maturity date of the note month-by-month through no later than April 30, 2017 for a fee of $5,000 per month extended.	300,000	300,000
Secured note payable with interest at 12.75% per annum, due May 2017. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the agreement in conjunction with a modification to another note payable and line of credit. The note requires payment of a $3,000 modification fee and requires payment of a fee of $50,000 for each thirty days that the loan is outstanding. The Company recorded a loss on extinguishment of debt of $56,741 related to the modification.	300,000	-
Unsecured note payable with interest at 12.25% per annum, due May 2017, subordinated to other notes payable. The note requires payment of a $3,000 closing fee and requires payment of a fee of $50,000 for each thirty days that the loan is outstanding. The $3,000 closing fee is being amortized to interest expense over the remaining term of the note and the $50,000 fees are being accrued as incurred.	300,000	-

Secured note payable to a third party with interest at 12.75% per annum, due February 2019, in default. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the note payable agreement in conjunction with a line of credit. The Company initially borrowed $1,500,000 and may borrow additional amounts under the note payable agreement up to a total balance of $3,000,000 as the Company meets certain milestones. The interest rate may also reduce to 11.25% per annum as the Company meets certain milestones. In conjunction with the note and related line of credit, the Company issued warrants to the lender to purchase 24,032 shares of common stock at $32.50 per share with a fair market value of $3,732,100 (see Notes 12 and 15), which resulted in a loss on derivative of $2,309,461. The Company has recorded discounts of $1,500,000, which are being amortized to interest expense over the term of the note. In April 2016, the Company borrowed an additional $500,000 on the note and incurred additional fees of $25,000, which are being amortized to interest expense over the remaining term of the note. In September 2016, the Company entered into a forbearance agreement where the lender will forbear from exercising remedies with regard to certain breaches through October 31, 2016 and consented to the Company entering into a purchase agreement with another party and issue the note and the warrant thereunder. Effective November 1, 2016, the Company and a lender entered into a forbearance and consent under a loan and security agreement (the "November Forbearance Agreement"). Pursuant to the terms of the November Forbearance Agreement, the lender will forbear from exercising remedies (the "November Forbearance") with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the previous forbearance agreement. Additionally, pursuant to the November Forbearance Agreement, the lender has provided the Company with the consent required under the existing agreements and previous forbearance agreement to make certain payments from the proceeds of the Offering. These payments include, but are not limited to (i) payments to holders of the Company's Series E Preferred, (ii) third party note and receivable payments and (iii) repayment of an unsecured note payable issued in September 2016. The lender also consented to the issuance of the Company's Series G Preferred Stock to certain affiliates of the Company. In consideration for the November Forbearance, the Company has agreed to issue the lender warrants to purchase 130,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering, which shall be subject to a 12-month lock-up agreement. The Company has included the $1,932,577 estimated fair value of the warrants in accrued expenses as of June 30, 2017. The Forbearance set forth in the November Forbearance Agreement was in effect through December 31, 2016. The Company recorded a loss on extinguishment of debt of $2,043,715 on the note and its related line of credit in relation to the forbearance agreement. Effective December 31, 2016, the Company and the lender entered into a forbearance and consent under loan and security agreement (the "December Forbearance"). Pursuant to the terms of the December Forbearance, the lender will forbear from exercising remedies with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the previous two forbearances. Additionally, pursuant to the December Forbearance, the lender has provided the Company with the consent required under the Existing Agreements and prior two forbearances to make certain payments from the proceeds of the Offering. In consideration for the December Forbearance, the Company has agreed to issue the lender warrants to purchase 10,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering and $50,000 of common stock at 80% of the at the same issue price in of the Offering, which shall be subject to a lock-up agreement. The $148,677 estimated fair value of the warrants and $60,000 fair value of the stock has been included in accrued expenses as of June 30, 2017. $104,824 of the fair value of the warrants and common stock associated with the note is recorded as a discount and is being amortized to interest expense over the remaining life of the note. The forbearance set forth in the December Forbearance was in effect through February 15, 2017. On February 15, 2017, the lender extended the December Forbearance period through March 31, 2017. On March 28, 2017, the lender extended the December Forbearance period through April 10, 2017. In March 2017, the Company modified the line of credit to include an additional secured borrowing of a maximum of $300,000. The Company recorded a loss on extinguishment of debt of $56,741 related to the modification. The Company has accrued default interest of $15,470 on the note payable.

1,152,778

1,652,778

Unsecured note payable with interest at 12% per annum, due September 2016, subordinated to other notes payable. In connection with the issuance of the note, the Company issued 2,000 shares of common stock. The $100,000 fair value of the stock was amortized to interest expense over the term of the note. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering (see Note 17).		250,000			250,000
Secured note payable to a third party with interest at 18% per annum, due June 2017. The note was secured by shares of the Company's common stock held by, and other assets of an entity controlled by, a former Executive Chairman of the Board of Directors. The note was guaranteed by a former Executive Chairman of the Board of Directors and his related entity and may go into default in the event other notes payable go into default subsequent to the effective date of the note. Payments on the note were convertible at the holder's option into common stock at 75% of its fair value if not paid by its respective due date, which is subject to a 20 trading day true-up and is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of other certain raises. The Company recognized a derivative liability related to the conversion feature with a fair value of $181,670, which was recognized as a loss on termination of debt. In June 2016, $13,713 of principal and $11,287 of accrued interest converted into 953 shares of common stock, pursuant to the terms of the note. In August 2016, $64,654 of principal and $10,346 of accrued interest converted into 9,203 shares of common stock, pursuant to the terms of the note. This note was terminated by paying the remaining principal and accrued interest in cash with no additional consideration.		-			162,539
Unsecured notes with interest at 18% per annum, due April 2013, in default. The Company issued 20,000 shares of Series D preferred stock as loan origination fees. The $195,000 fair value of the preferred stock was amortized over the original term of the note. Principal of $50,000 and accrued interest of $13,333 were converted to common stock in December 2013. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering (see Note 17).		64,261			64,261
Total notes payable before discount		14,423,897			13,006,815
Less discount		(1,160,279	)		(1,930,060	)
Total notes payable		13,263,618			11,076,755
Less current portion		(7,131,781	)		(3,722,899	)
Notes payable, net of current portion	$	6,131,837		$	7,353,856

Secured line of credit with a third party with interest at 12.25% per annum, due February 2018, in default. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the line of credit agreement in conjunction with a note payable. The Company may draw up to the lesser of 80% of certain accounts receivable or $1,500,000 and increase the maximum it may borrow under the agreement up to a total balance of $3,000,000 at $500,000 per increase as the Company meets certain milestones. The interest rate may also reduce to 10.75% per annum as the Company meets certain milestones. In conjunction with the line of credit and related note, the Company issued warrants to purchase 24,032 shares of common stock at $32.50 per share with a fair market value of $3,732,100 (see Notes 12 and 15), which resulted in a loss on derivative of $2,309,461. The Company has recorded prepaid expenses of $44,665, which are being amortized to interest expense over the term of the line of credit. In September 2016, the Company entered into a forbearance agreement where the lender will forbear from exercising remedies with regard to certain breaches through October 31, 2016 and consented to the Company entering into a purchase agreement with another party and issuance of the note and the warrant thereunder. Effective November 1, 2016, the Company and a lender entered into a forbearance and consent under a loan and security agreement (the "November Forbearance Agreement"). Pursuant to the terms of the November Forbearance Agreement, the lender will forbear from exercising remedies (the "November Forbearance") with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the previous forbearance agreement. Additionally, pursuant to the November Forbearance Agreement, the lender has provided the Company with the consent required under the existing agreements and previous forbearance agreement to make certain payments from the proceeds of the Offering. These payments include, but are not limited to (i) payments to holders of the Company's Series E Preferred, (ii) third party note and receivable payments and (iii) repayment of an unsecured note payable issued in September 2016. The lender also consented to the issuance of the Company's Series G Preferred Stock to certain affiliates of the Company. In consideration for the November Forbearance, the Company has agreed to issue the lender warrants to purchase 130,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering, which shall be subject to a 12-month lock-up agreement. The Company has included the $1,932,577 estimated fair value of the warrants in accrued expenses as of June 30, 2017. The Forbearance set forth in the November Forbearance Agreement was in effect through December 31, 2016. The Company recorded a loss on extinguishment of debt of $2,043,715 on the note and its related line of credit in relation to the forbearance agreement. Effective December 31, 2016, the Company and the lender entered into a forbearance and consent under loan and security agreement (the "December Forbearance"). Pursuant to the terms of the December Forbearance, the lender will forbear from exercising remedies with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the previous two forbearances. Additionally, pursuant to the December Forbearance, the lender has provided the Company with the consent required under the Existing Agreements and prior two forbearances to make certain payments from the proceeds of the Offering. In consideration for the December Forbearance, the Company has agreed to issue the lender warrants to purchase 10,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering and $50,000 of common stock at 80% of the at the same issue price in of the Offering, which shall be subject to a lock-up agreement. The $148,677 estimated fair value of the warrants and $60,000 fair value of the stock has been included in accrued expenses as of June 30, 2017. $104,824 of the fair value of the warrants and common stock associated with the note is recorded as a discount and is being amortized to interest expense over the remaining life of the note. The forbearance set forth in the December Forbearance was in effect through February 15, 2017. On February 15, 2017, the lender extended the December Forbearance period through March 31, 2017. On March 28, 2017, the lender extended the December Forbearance period through April 10, 2017. In March 2017, the Company modified the line of credit to include an additional secured borrowing of a maximum of $300,000. The Company recorded a loss on extinguishment of debt of $56,741 related to the modification. The Company has accrued default interest of $16,997 on the note payable.

1,259,007

929,518

10. Related-Party Notes Payable

Unsecured note payable with interest at 18% per annum, with no maturity date. The note payable is from a verbal agreement with the lender which converted $617,500 of advances into $1,100,000 of principal on the note payable. The additional $482,500 of principal plus agreed upon fees of $95,226 have been included in accrued liabilities and were booked to interest expense immediately. During November 2017, the Company amended the note to be callable at any time, due May 30, 2018, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date (see Note 18).	1,100,000	-

Unsecured note payable with interest at 2.8% of total revenue per annum, with no maturity date. The note payable is from a verbal agreement with the lender which converted a $350,000 advance into the note payable. Agreed upon fees of $143,987 and a future payoff fee of 20%, or $70,000, have been included in accrued liabilities and were booked to interest expense immediately. During November 2017, the Company amended the note to where the Company is required to pay any outstanding interest at the end of the first month following a quarter end, the lender may call all amounts due under the note payable as due and payable after February 28, 2018, given 15 calendar days notice, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date (see Note 18).	350,000	-

Note payable previously secured by CareServices customer contracts. In January 2015, the note was amended to reduce the outstanding principal to $375,000, interest at 9% per annum, and payable in 15 monthly installments beginning in February 2015. The amendment released the collateralized customer contracts and the note payable is guaranteed by both a former Executive Chairman of the Board of Directors and a member of the Board of Directors. A gain on the extinguishment of the old note of $769,449 was recorded in other income. In December 2015, the note was amended to extend maturity to January 2018 payable in monthly installments beginning in July 2016, convert $31,252 from accrued interest into principal, interest at 10% per annum, and provide that the note is convertible into common stock at its fair value per share. The Company recorded a derivative in connection with the convertible feature of the note (see Note 12) and is amortizing the initial $302,690 fair value of the derivative liability over the life of the note. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016. In July 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or November 2016 and included additional default penalties and payment terms. In October 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or December 31, 2016 and included additional default penalties and payment terms. In October 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or December 31, 2016 and included additional default penalties and payment terms. In December 2016, February 2017 and March 2017, the note was further amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or February 15, 2017, March 31, 2017, and April 30, 2017, respectively. Subsequent to June 30, 2017, the Company received a letter related to the note wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 and later sent an additional letter where the lender waived any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018 (see Note 18).	334,464	334,464

Unsecured note payable with interest at 12% per annum, due February 2016, convertible into common stock at $150 per share. In connection with the issuance of the note, the Company repriced previously issued warrants to purchase shares of common stock. The $22,397 increase in relative fair value of the warrants was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The note also required a payment of 6,000 shares of common stock. The fair value of $780,000 was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The maturity date was subsequently extended on two occasions for a total of 500 shares of common stock and the note was due May 2016. The $31,250 fair value of these shares was being amortized over the extension period. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $30 per share, which was below the fair value of the Company's common stock on the date of the amendment. The note may only be converted if the holder owns less than 9.99% of the Company's common stock after conversion. The Company recorded the value of the beneficial conversion feature of $381,299 to loss on termination of debt as a result of the modification. In May 2016, the note was amended to extend the maturity date to the earlier of an equity raise of $10,000,000 or October 2016 which required a payment of 600 shares of common stock. The $28,500 fair value of these shares has been included in accrued liabilities and was amortized over the extension period. During September 2017, the Board of Directors granted 200 shares of Series H Preferred Stock for extension fees. In October 2016, the Company extended the maturity date of the note month-by-month through no later than April 30, 2017 for a fee of $5,000 per month extended. In October 2017, the Company entered into a settlement agreement related to the note where the Company borrowed an additional $200,000 and modified the terms of the note payable to become secured by inventory owned by the Company, requires issuance of 3,000 shares of Series H Preferred Stock, which were authorized for grant by the Board of Directors on September 5, 2017 and are required to be able to convert the lender's shares into 300,000 shares of the Company's common stock, and requires payments of $8,600 for 72 consecutive weeks. If any payment is late, the Company is required to issue the lender an additional 86 shares of Series H Preferred Stock per late payment and an additional 172 shares of Series H Preferred stock if late payments are not cured within 30 days and for each subsequent 30-day period the note is in default. The amended note also requires payment of a key man life insurance policy on a former Executive Chairman of the Board of Directors naming the lender as the benefactor. The fair value of the shares will be amortized over the life of the amended note. The note terms are adjustable for any terms subsequently provided to other investors (see Note 18).	300,000	300,000

The Company had the following related-party notes payable outstanding as of:

	March 31,		September 30,
	2017		2016
Secured borrowings from entities controlled by an officer who purchased a $2,813,175 customer receivable for $1,710,500. The Company repurchased the receivable for $1,950,000 less cash received by the entities through March 2015. The $239,500 difference between the buyback and cash received plus $253,500 of loan origination fees was amortized to interest expense through March 2015. In September 2015, the note was modified to extend the maturity date to January 2017, with interest at 18% per annum. The Company added $81,600 of extension fees and issued 6,000 shares of common stock to a lender as part of the modification. The note is convertible into common stock at $150 per share. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $30 per share, which was below the fair value of the Company's stock on the date of the amendment. The conversion of the note is now limited to a maximum of 40,000 common shares in combination with other convertible notes payable held by the lenders. The note has a default penalty of 8,407 shares of common stock, in combination with other convertible notes held by the lenders, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering (see Note 17).	$	1,721,100	$	1,721,100
Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due January 2017, convertible into common stock at $150 per share. The Company issued 6,000 shares of common stock to a lender as loan origination fees. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and reduced the conversion price to $30 per share, which was below the fair value of the Company's stock on the date of the amendment. The conversion of the note is now limited to a maximum of 40,000 common shares in combination with other convertible notes payable held by the lender. The note has a default penalty of 8,407 shares of common stock, in combination with other convertible notes held by the lender, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering (see Note 17).		1,303,135		1,303,135
Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with interest at 18% per annum, due January 2017. In February 2016, notes payable to the same entity, with outstanding balances of $511,005 plus accrued interest of $30,999 combined into this note. The note is subordinated to notes payable to unrelated parties and is convertible into shares of common stock at $30 per share, which was below the fair value of the Company's stock on the date of the agreement. The conversion of the note is limited to a maximum of 18,500 common shares. The Company recorded the value of the beneficial conversion feature of $632,339 to loss on termination of debt. The note has a default penalty of 1,469 shares of common stock if not paid by maturity. The note may only be converted if the holder owns less than 4.99% of the Company's common stock after conversion. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering (see Note 17).		542,004		542,004

Unsecured note payable to an entity controlled by an officer with interest at 12% per annum, due September 2016, subordinated to other third party notes payable. In connection with the issuance of the note, the Company issued 2,000 shares of common stock. The $70,000 fair value of the stock is being amortized to interest expense over the term of the note. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering (see Note 17).		250,000			250,000
Secured note payable with interest at 12.25% per annum, due May 2017, in default. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the agreement in conjunction with a modification to another note payable and line of credit. The note requires payment of a $3,000 modification fee and requires payment of a fee of $50,000 for each thirty days that the loan is outstanding. The Company recorded a loss on extinguishment of debt of $56,741 related to the modification. The Company has accrued default interest of $4,050 on the note payable..		300,000			-
Unsecured note payable to a former officer with interest at 12% per annum, due September 2013. This note is in default and is convertible into common stock at $375 per share.		26,721			26,721
Unsecured note payable with interest at 12.75% per annum, due June 2017, in default, subordinated to other notes payable. The note requires payment of a $3,000 closing fee and requires payment of a fee of $50,000 for each thirty days that the loan is outstanding. The $3,000 closing fee is being amortized to interest expense over the remaining term of the note and the $50,000 fees are being accrued as incurred. On January 12, 2018, the lender forbore against any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018 in exchange for 12,000 shares of common stock (see Note 18).		300,000			-
Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due on demand. In February 2016, the note was amended to subordinate the note to other notes payable also issued during February 2016. The note is convertible into shares of common stock at $30 per share, which was below the fair value of the Company's stock on the date of the amendment. The conversion of the note is now limited to a maximum of 40,000 common shares in combination with other convertible notes payable held by the entity. The note has a default penalty of 8,407 shares of common stock, in combination with other convertible notes held by the entity, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. In January 2017 and February 2017, the note was amended to extend the maturity date to February 15, 2017 and April 30, 2017, respectively.		25,463			25,463
Unsecured note payable with interest at 12% per annum, due September 2016, in default, subordinated to other notes payable. In connection with the issuance of the note, the Company issued 2,000 shares of common stock. The $100,000 fair value of the stock was amortized to interest expense over the term of the note. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering, which has expired (see Note 17). On January 12, 2018, the lender forbore against any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018 in exchange for 12,000 shares of common stock (see Note 18).		250,000			250,000
Unsecured note payable to a former officer with interest at 15% per annum, due June 2012, in default. The note included a $3,000 loan origination fee added to the principal and is convertible into common stock at $250 per share.		6,912			17,227
Unsecured cash advance with fees at $1,000 per day for the first 15 days and $1,500 per day thereafter, with no maturity date. The terms of the advance are verbal. During November 2017, the Company amended the advance to be callable at any time, due May 30, 2018, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date (see Note 18).		100,000			-
Unsecured note payable to a former officer with interest at 12% per annum, due on demand.		-			12,474
Unsecured notes with interest at 18% per annum, due April 2013, in default. The Company issued 20,000 shares of Series D preferred stock as loan origination fees. The $195,000 fair value of the preferred stock was amortized over the original term of the note. Principal of $50,000 and accrued interest of $13,333 were converted to common stock in December 2013. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering, which has expired (see Note 17).		64,261			64,261
Total notes payable, related-party		3,875,335			3,898,124
Secured note payable to a third party with interest at 18% per annum, due June 2017. The note was secured by shares of the Company's common stock held by, and other assets of an entity controlled by, a former Executive Chairman of the Board of Directors. The note was guaranteed by a former Executive Chairman of the Board of Directors and his related entity and may go into default in the event other notes payable go into default subsequent to the effective date of the note. Payments on the note were convertible at the holder's option into common stock at 75% of its fair value if not paid by its respective due date, which is subject to a 20 trading day true-up and is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of other certain raises. The Company recognized a derivative liability related to the conversion feature with a fair value of $181,670, which was recognized as a loss on termination of debt. In June 2016, $13,713 of principal and $11,287 of accrued interest converted into 953 shares of common stock, pursuant to the terms of the note. In August 2016, $64,654 of principal and $10,346 of accrued interest converted into 9,203 shares of common stock, pursuant to the terms of the note. This note was terminated by paying the remaining principal and accrued interest in cash with no additional consideration.		-			162,539
Less current portion		(3,875,335	)		(3,898,124	)
Notes payable, related-party, net of current portion	$	-		$	-

Total notes payable before discount		16,859,049			13,006,815

Less discount		(1,468,335	)		(1,930,060	)

Total notes payable		15,390,714			11,076,755

Less current portion		(9,501,544	)		(3,722,899	)

Notes payable, net of current portion	$	5,889,170		$	7,353,856

10. Related-Party Notes Payable

The Company had the following related-party notes payable outstanding as of:

	June 30,		September 30,
	2017		2016
Secured borrowings from entities controlled by an officer who purchased a $2,813,175 customer receivable for $1,710,500. The note is currently in technical default. However, as of the time of this report, the lender has informally agreed to work with the Company until such time as the note can be repaid. The Company repurchased the receivable for $1,950,000 less cash received by the entities through March 2015. The $239,500 difference between the buyback and cash received plus $253,500 of loan origination fees was amortized to interest expense through March 2015. In September 2015, the note was modified to extend the maturity date to January 2017, with interest at 18% per annum. The Company added $81,600 of extension fees and issued 6,000 shares of common stock to a lender as part of the modification. The note is convertible into common stock at $150 per share. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $30 per share, which was below the fair value of the Company's stock on the date of the amendment. The conversion of the note is now limited to a maximum of 40,000 common shares in combination with other convertible notes payable held by the lenders. The note has a default penalty of 8,407 shares of common stock, in combination with other convertible notes held by the lenders, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering, which has expired (see Note 17). Subsequent to June 30, 2017, the Company received a letter related to the note wherein the lenders waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 and later sent an additional letter where the lenders waived any historical and future events of default through January 12, 2018 and extended the maturity date through January 12, 2018 (see Note 18). In November 2017, the officer assigned $2,000,000 of principal all of the notes payable held by the related-party entities to a third party who the Company owed aggregate principal of $1,200,000 as of June 30, 2017. Interest accrued on the $2,000,000 assigned principal will continue to be payable to the related-party entities (see Note 18).	$	1,721,100	$	1,721,100


Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due January 2017, convertible into common stock at $150 per share. The note is currently in technical default. However, as of the time of this report, the lender has informally agreed to work with the Company until such time as the note can be repaid. The Company issued 6,000 shares of common stock to a lender as loan origination fees. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and reduced the conversion price to $30 per share, which was below the fair value of the Company's stock on the date of the amendment. The conversion of the note is now limited to a maximum of 40,000 common shares in combination with other convertible notes payable held by the lender. The note has a default penalty of 8,407 shares of common stock, in combination with other convertible notes held by the lender, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering, which has expired (see Note 17). Subsequent to June 30, 2017, the Company received a letter related to the note wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 and later sent an additional letter where the lenders waived any historical and future events of default through January 12, 2018 and extended the maturity date through January 12, 2018 (see Note 18). In November 2017, the officer assigned $2,000,000 of principal all of the notes payable held by the related-party entities to a third party who the Company owed aggregate principal of $1,200,000 as of June 30, 2017. Interest accrued on the $2,000,000 assigned principal will continue to be payable to the related-party entities (see Note 18).	1,303,135	1,303,135

Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with interest at 18% per annum, due January 2017. The note is currently in technical default. However, as of the time of this report, the lender has informally agreed to work with the Company until such time as the note can be repaid. In February 2016, notes payable to the same entity, with outstanding balances of $511,005 plus accrued interest of $30,999 combined into this note. The note is subordinated to notes payable to unrelated parties and is convertible into shares of common stock at $30 per share, which was below the fair value of the Company's stock on the date of the agreement. The conversion of the note is limited to a maximum of 18,500 common shares. The Company recorded the value of the beneficial conversion feature of $632,339 to loss on termination of debt. The note has a default penalty of 1,469 shares of common stock if not paid by maturity. The note may only be converted if the holder owns less than 4.99% of the Company's common stock after conversion. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering, which has expired (see Note 17). Subsequent to June 30, 2017, the Company received a letter related to the note wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 and later sent an additional letter where the lenders waived any historical and future events of default through January 12, 2018 and extended the maturity date through January 12, 2018 (see Note 18).	542,004	542,004

Unsecured note payable to an entity controlled by an officer with interest at 12% per annum, due September 2016, subordinated to other third party notes payable. The note is currently in technical default. However, as of the time of this report, the lender has informally agreed to work with the Company until such time as the note can be repaid. In connection with the issuance of the note, the Company issued 2,000 shares of common stock. The $70,000 fair value of the stock is being amortized to interest expense over the term of the note. During the three months ended March 31, 2017, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the Offering, which has expired (see Note 17). Subsequent to June 30, 2017, the Company received a letter related to the note wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 and later sent an additional letter where the lenders waived any historical and future events of default through January 12, 2018 and extended the maturity date through January 12, 2018 (see Note 18). In November 2017, the officer assigned $2,000,000 of principal all of the notes payable held by the related-party entities to a third party who the Company owed aggregate principal of $1,200,000 as of June 30, 2017. Interest accrued on the $2,000,000 assigned principal will continue to be payable to the related-party entities (see Note 18).	250,000	250,000

Unsecured note payable to a former officer with interest at 12% per annum, due September 2013. This note is in default and is convertible into common stock at $375 per share.	26,721	26,721

Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due on demand. The note is currently in technical default. However, as of the time of this report, the lender has informally agreed to work with the Company until such time as the note can be repaid. In February 2016, the note was amended to subordinate the note to other notes payable also issued during February 2016. The note is convertible into shares of common stock at $30 per share, which was below the fair value of the Company's stock on the date of the amendment. The conversion of the note is now limited to a maximum of 40,000 common shares in combination with other convertible notes payable held by the entity. The note has a default penalty of 8,407 shares of common stock, in combination with other convertible notes held by the entity, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. In January 2017 and February 2017, the note was amended to extend the maturity date to February 15, 2017 and April 30, 2017, respectively. Subsequent to June 30, 2017, the Company received a letter related to the note wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017 and later sent an additional letter where the lenders waived any historical and future events of default through January 12, 2018 and extended the maturity date through January 12, 2018 (see Note 18). In November 2017, the officer assigned $2,000,000 of principal all of the notes payable held by the related-party entities to a third party who the Company owed aggregate principal of $1,200,000 as of June 30, 2017. Interest accrued on the $2,000,000 assigned principal will continue to be payable to the related-party entities (see Note 18).		25,463			25,463

Unsecured note payable to a former officer with interest at 15% per annum, due June 2012, in default. The note included a $3,000 loan origination fee added to the principal and is convertible into common stock at $250 per share.		1,260			17,227

Unsecured note payable to a former officer with interest at 12% per annum, due on demand.		-			12,474

Total notes payable, related-party		3,869,683			3,898,124

Less current portion		(3,869,683	)		(3,898,124	)

Notes payable, related-party, net of current portion	$	-		$	-

11. Fair Value Measurements

The Company measures the fair values of its assets and liabilities using the US GAAP hierarchy levels as follows:

Level 1	The Company does not have any Level 1 inputs available to measure its assets.
Level 2	Certain of the Company's embedded derivative liabilities are measured on a recurring basis using Level 2 inputs.
Level 3	Certain of the Company's embedded derivative liabilities are measured on a recurring basis using Level 3 inputs.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Items measured at fair value on a recurring basis include embedded derivatives related to the Company's warrants and notes payable. During the ~~six~~nine months ended ~~March~~June 3130, 2017, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The following fair value hierarchy table presents information about the Company's financial liabilities measured at fair value on a recurring basis:

	Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
March 31, 2017
June 30, 2017
Derivatives liability	$	-	$	~~291~~269,~~603~~427	$	43,~~004~~962,~~524~~556	$	4,~~296~~231,~~127~~983
September 30, 2016
Derivatives liability		-		281,613		1,772,458		2,054,071

The following is a reconciliation of the opening and closing balances for the derivatives liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended March 31, 2017:22

	Derivatives Liability
Balance, September 30, 2016	$	1,772,458
Issuance of warrants recorded as derivatives		2,511,288
Gain on termination of debt resulting from payments on notes payable		(103,213	)
Gain on derivatives liability resulting from changes in fair value		(176,009	)
Balance, March 31, 2017	$	4,004,524

	Derivatives Liability
Balance, September 30, 2016	$	1,772,458
Issuance of warrants recorded as derivatives		2,511,288
Gain on termination of debt resulting from payments on notes payable		(103,213	)
Loss on derivatives liability resulting from changes in fair value		(217,977	)
Balance, June 30, 2017	$	3,962,556

The Company's embedded derivative liabilities are re-measured to fair value as of each reporting date. See Note 12 for more information about the valuation methods of derivatives and the inputs used for calculating fair value.

12. Derivatives Liability

The derivatives liability as of ~~March~~June 3130, 2017 and September 30, 2016, was $4,~~296~~231,~~127~~983 and $2,054,071, respectively. The derivatives liability as of ~~March~~June 3130, 2017 and September 30, 2016 is related to a variable conversion price adjustment on outstanding notes payable and warrants. All of the derivatives outstanding as of September 30, 2015, were eliminated during February 2016, due to the conversion of notes payable into shares of common stock.

During the ~~six~~nine months ended ~~March~~June 3130, 2017, the Company estimated the fair value of some of the embedded derivatives upon issuance at the end of each reporting period using a binomial option-pricing model with the following assumptions, according to the instrument: exercise price of $158 to $2115 per share; risk free interest rate of 0.85% to 1.0314%; expected life of 0.7853 to 1.03 years; expected dividends of 0%; volatility factor of 260.57% to ~~271~~282.7807%; and stock price of $158 to $2115. During the ~~six~~nine months ended ~~March~~June 3130, 2017, the Company estimated the fair value of the remaining embedded derivatives upon issuance and at the end of each reporting period using a Monte Carlo valuation model with the following assumptions: exercise prices ranging from $52.0050 to $25.00 per share; risk free interest rates ranging from 0.4944% to 1.99%; expected lives ranging from 0.2109 to 4.8893 years; expected dividends of 0%; volatility factors of 128% - 194%; and stock prices ranging from $52.50 to $25.00.

During fiscal year 2016, the Company estimated the fair value of some of the embedded derivatives upon issuance, at the end of each reporting period and prior to their conversion and elimination using a binomial option-pricing model with the following assumptions, according to the instrument: exercise prices ranging from $14.50 to $46.75 per share; risk free interest rates ranging from 0.16% to 1.06%; expected lives ranging from 0.05 to 2.09 years; expected dividends of 0%; volatility factors ranging from 125.33% to 510.03%; and stock prices ranging from $15 to $70. During fiscal 2016, the Company estimated the fair value of the remaining embedded derivatives upon issuance and at the end of each reporting period using a Monte Carlo valuation model with the following assumptions: exercise prices ranging from $20 to $125 per share; risk free interest rates ranging from 0.18% to 1.44%; expected lives ranging from 0.04 to 6.40 years; expected dividends of 0%; volatility factors of 129% to 140%; and stock prices ranging from $20 to $475 per share. The expected lives of the instruments were equal to the average term of the conversion option or expected exercise period of the warrants. The expected volatility is based on the historical price volatility of the Company's common stock. The risk-free interest rate represents the US Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option. The Company recognized a gain on derivatives liability for the three months ended ~~March~~June 3130, 2017 of $~~143~~64,~~961~~145 and a ~~loss~~gain on derivatives liability for the three months ended ~~March~~June 3130, 2016 of $25,~~853~~603,~~180~~411. The Company recognized a gain on derivatives liability for the ~~six~~nine months ended ~~March~~June 3130, 2017 of $~~166~~230,~~019~~163 and a ~~loss~~gain on derivatives liability for the ~~six~~nine months ended ~~March~~June 3130, 2016 of $2,~~806~~796,~~869~~542.

13. Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.00001 per share. Pursuant to the Company's Certificate of Incorporation, the Board of Directors has the authority to amend the Company's Certificate of Incorporation, without further stockholder approval, to designate and determine the preferences, limitations and relative rights of the preferred stock before any issuance of the preferred stock and to create one or more series of preferred stock, fix the number of shares of each such series, and determine the preferences, limitations and relative rights of each series of preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, and liquidation preferences.

Series D Convertible Preferred Stock

The Board of Directors has designated 1,000,000 shares of preferred stock as Series D Convertible Preferred Stock ("Series D Preferred "). The Series D Preferred votes on an as-converted basis. The Series D Preferred has a dividend rate of 8%, payable quarterly. The Company may redeem the Series D Preferred at a redemption price equal to 120% of the original purchase price with 15 days' notice. During the ~~six~~ nine months ended ~~March~~June 3130, 2017 and 2016, the Company accrued $1224,~~434~~800 and $18,617 of dividends on Series D ~~Preferred~~preferred stock, respectively, and settled $0 and $12,434 of accrued dividends, respectively, by issuing 0 and 455 shares of common stock, respectively.

On January 12, 2017, the Company entered into a letter agreement with a third-party investor, whereby the investor agreed to convert 20,000 shares of Series D Preferred of the Company owned into common stock of the Company based on current redemption value contingent upon the completion of the Offering. As of the date hereof, the current redemption value of such Series D Preferred was $72,000. Pursuant to the letter agreement, the redemption value will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by 80% of the per share price of the common stock in the Offering and all dividends cease accruing beginning July 1, 2016. The investor has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by him for a period of 12 months. If the Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 13, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with an entity affiliated with the Chief Executive Officer, whereby the entity agreed to convert 25,000 shares of Series D Preferred of the Company owned into common stock of the Company based on current redemption value, contingent upon the completion of the Offering. As of the date hereof, the current redemption value of such Series D Preferred was $300,000. Pursuant to the letter agreement, the redemption value will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by $22.50 or 13,334 shares and all dividends cease accruing beginning July 1, 2016. The entity has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 12 months. If the Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 10, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. On March 27, 2017, the Company replaced the letter agreement with a new letter agreement where the redemption value will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by $6.00 or 50,000 shares and all dividends cease accruing beginning July 1, 2016. If the Offering is not completed by April 15, 2017, the letter agreement will terminate. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

The Company did not accrue dividends on Series D Preferred during the three and six months ended March 31, 2017 due to these letter agreements.

Series E Convertible Preferred Stock

During fiscal year 2013, the Board of Directors designated shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"), convertible into common stock at $500 per share, adjustable if there are distributions of common stock or stock splits by the Company. The Series E Preferred is non-voting and receives a monthly dividend of 3.322% for 25 to 32 months. In addition, the convertibility and the redemption price of the Series E Preferred is gradually reduced by dividend payments over 25 to 32 months. After the dividend payment term, the redemption price of Series E Preferred is $0, the Series E Preferred has no convertibility to common stock and the holders are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company's gross profits payable quarterly for a two-year period.

During the three months ended ~~March~~June 3130, 2017 and 2016, the Company accrued dividends of $34,178 and $6139,~~315~~598, respectively, payable to Series E Preferred. During the ~~six~~nine months ended ~~March~~June 3130, 2017 and 2016, the Company accrued dividends of $68102,~~356~~535 and $~~145~~185,~~887~~485, respectively, payable to Series E Preferred. As of ~~March~~June 3130, 2017 and September 30, 2016, the aggregate redemption price for the Series E Preferred was $477,829.

On January 12, 2017, the Company entered into a letter agreement with a director, whereby the director agreed to convert 13,843 shares of Series E Preferred of the Company owned into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016, the aggregate amount of $181,297 consisting of accrued dividends, royalty and interest was owed to the director with respect to his Series E Preferred. Pursuant to the letter agreement, the aggregate amount will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the aggregate amount by $17.72 or 10,223 shares. The director has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned for a period of 12 months. If such Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 10, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.24

Series F Convertible Preferred Stock

During fiscal year 2014, the Board of Directors designated 7,803 shares of preferred stock as Series F Convertible Preferred Stock ("Series F Preferred"). In April 2014, the Company increased the authorized shares of Series F Preferred to 10,000. Series F Preferred is non-voting, has a stated value of $1,000 per share and is convertible into common stock at $166.85 per share (see Note 12). Series F Preferred has a dividend rate, payable quarterly, of 8% until April 30, 2015, 16% from May 1, 2015 to July 31, 2015, 20% from August 1, 2015 to October 31, 2015, and 25% thereafter. In February 2016, the Company redeemed all 5,361 outstanding shares and $673,848 of accrued dividends for 20,005 shares of common stock, $5,900,000 of notes payable and exchanged warrants for the purchase of 11,070 shares of common stock held by Series F Preferred stockholders for new warrants with new terms for the purchase of the same number of shares (see Note 15). The Company recorded a deemed dividend of $6,484,236 as a result of the transactions.

During the three and nine months ended June 30, 2016, the Company accrued dividends of $0 and $495,148, respectively, payable to Series F Preferred stockholders.

During the three and six months ended March 31, 2016, the Company accrued dividends of $182,423 and $495,148, respectively, payable to Series F Preferred stockholders.

Series G Convertible Preferred Stock

During January 2017, the Board of Directors designated 43,220 shares of preferred stock as Series G Convertible Preferred Stock ("Series F Preferred"). Series G Preferred votes on an as-converted basis, has a stated value of $500 per share. The Series G Preferred will automatically convert the stated value of such shares into fully paid and non-assessable shares of common stock (Series G Conversion Shares") of the Company upon (i) the Company's receipt of $50,000,000 or more in gross revenue in a single fiscal year, (ii) the sale of the Company via asset purchase, stock sale, merger or other business combination in which the Company and/or its stockholders receive aggregate gross proceeds of $25,000,000 or more, or (iii) the closing of an underwritten ~~Offering~~offering by the Company pursuant to which the Company receives aggregate gross proceeds of at least $10,000,000 in consideration of the purchase of shares of common stock and/or which results in the listing of the Company's common stock on the Nasdaq National Market, the Nasdaq Capital Market, the New York Stock Exchange, or the NYSE MKT. The number of Series G Conversion Shares issuable upon conversion shall equal the stated value divided by the conversion price then in effect. The conversion price of the Series G Preferred is $22.50. Upon the trigger of an automatic conversion, all of the shares of Series G Preferred owned by such ~~Holders~~holders will convert into common stock at the conversion price then in effect.

On January 31, 2017, the Company issued 32,415 shares of Series G Preferred to an entity affiliated with one of the Company's former Chief Executive ~~Officer~~Officers and 10,805 shares of Series G Preferred to a different former Chief Executive Officer and consultant to the Company. The consideration for such issuance relates to services rendered to the Company. Each of the two recipients of the Series G Preferred stock have entered into lock-up agreements, as amended, prohibiting the sale or other transfer of the Common Shares issued pursuant to the conversion of the Series G Preferred securities of the Company owned by each of them for the longer of (i) 18 months or (ii) the date the Company first has annual gross revenues in an amount of at least $20,000,000. The lock-up agreements initially expired if the Offering was not completed by February 15, 2017, whose expirations were extended to March 31, 2017 with new agreements signed during February 2017. ~~The~~As of June 30, 2017, the agreements have expired. On September 5, 2017, the Board of Directors of the Company isagreed into modify the ~~process~~terms of ~~negotiating~~the ~~extensions~~Series G Convertible Preferred stock to remove the 18-month lock-up ~~agreements~~period, however, ~~there~~no issuch noamendment ~~assurance~~to ~~that~~the Series G Preferred has not been filed with the ~~extensions~~State ~~will~~of beDelaware ~~agreed~~as ~~upon~~of the date of this filing.

Liquidation Preference

Upon any liquidation, dissolution or winding up of the Company, before any distribution or payment may be made to the holders of the common stock, the holders of the Series D Preferred, Series E Preferred, and Series F Preferred are entitled to be paid out of the assets an amount equal to $1.00 per share plus all accrued but unpaid dividends. If the assets of the Company are insufficient to make payment in full to all holders of preferred stock, then the assets shall be distributed among the holders of preferred stock ratably in proportion to the full amounts to which they would otherwise be entitled.

14. Common Stock

In April 2014, the Company amended its Certificate of Incorporation increasing the total number of authorized shares of common stock from 50,000,000 shares to 200,000,000 shares.

On January 27, 2017, the Company effected a 1-for-500 reverse stock split of its outstanding common stock, which caused the then outstanding common stock to decrease from 115,112,802 to 232,100 while keeping the authorized capitalization unchanged.

During the ~~six~~nine months ended ~~March~~June 3130, 2017, the Company ~~did~~issued ~~not~~7,000 ~~issue any~~ shares of common stock (post reverse stock split) for services provided by an independent consultant; the value on the date of grant was $70,000.

15. Common Stock Options and Warrants

The fair value of each stock option or warrant is estimated on the date of grant using a binomial option-pricing model or the Monte Carlo valuation model. The expected life of stock options or warrants represents the period of time that the stock options or warrants are expected to be outstanding, based on the simplified method. Expected volatilities are based on historical volatility of the Company's common stock, among other factors. The Company uses the simplified method within the binomial option-pricing valuation model due to the Company's short trading history. The risk-free rate related to the expected term of the stock options or warrants is based on the US Treasury yield curve in effect at the time of grant. The dividend yield is zero.

During fiscal 2016, the Company granted warrants to purchase 24,032 common shares with an exercise price of $32.50 per share in connection with the acquisition of a note payable and line of credit; warrants for the purchase of 14,786 shares vested immediately, 3,696 vested upon the disbursement of the second tranche of the related note payable, and 5,550 vest evenly in the event of three available increases on the related line of credit (see Note 9). The warrants expire in February 2023, may be exercised via cashless exercise and are puttable upon expiration or liquidation for the greater of $500,000 or up to 6.5% of the equity value of the Company, depending on the number of warrants vested. The fair value of the warrants upon grant of $3,731,969 was recorded as a derivative and the Company received cash of $2,967 upon issuance of the warrants. The Company recognized $1,419,541 as debt discount for the portion allocated to the note payable and the debt discount is being amortized over the life of the note payable to interest expense. During September 2016, the Company entered into a conditionally effective warrant cancellation agreement with the warrant holders, which has expired (see Note 17).

During February 2016, the Company exchanged warrants held by the holders of its Series F Preferred for the purchase of 11,070 shares of common stock in connection with the redemption of Series F Preferred for new warrants for the purchase of the same number of shares on different terms. The new warrants were initially exercisable for $150 per share, adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. During September 2016, the Company issued warrants for the purchase of common stock that adjusted the warrants to have an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the Offering, (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering. On December 11, 2017, the Company entered into Securities Purchase Agreements that adjusted the conversion rate to exercise price per share equal to the lesser of (i) 80% of the per share price of common stock in a contemplated private placement of securities of up to $5,000,000, contemplated to take place within six months of the effective date (the "Private Placement") (ii) $3.00 per share, (iii) 80% of the offering price in the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement, in each case subject to adjustment (see Note 18). The new warrants expire in February 2021, and may be exercised via cashless exercise . Additional warrants for the purchase of 16,000 shares of common stock may be issued in the event of default on the related notes payable, exercisable at $0.50 per share, with 25% issuable upon the first event of default, 37.5% upon the second event, and 37.5% upon the third event. The warrants issuable upon default expire in February 2026 (if issued), may be exercised via cashless exercise , and are puttable upon expiration or liquidation with the primary warrants. The new warrants may only be exercised to the extent the respective holder would own a maximum of 4.99% of the Company's common stock after exercise, but the holders may elect to increase the maximum to 9.99%. The Company recognized a deemed dividend of $6,484,236 as a result of the exchange and related redemption of Series F Preferred.

During September 2016, the Company granted warrants to purchase 20,000 shares in connection with the acquisition of a note payable at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the Offering, (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering. Upon the closing of the Offering, the number of shares issuable under the warrant will reset to an amount of shares equal to the aggregate exercise amount of the warrants (as defined therein) divided by the exercise price then in effect. The warrants expire in September 2021, and may be exercised via cashless exercise. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company's common stock after exercise. The Company recognized $220,000 of the $493,590 fair value of the warrants as a debt discount, which is being amortized over the life of the borrowing, and recognized the remaining $273,590 as a loss on derivatives liability. In the event the Company borrows additional amounts above the initial $500,000 under the note payable, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to warrants issued as part of the initial borrowing. During the nine months ended June 30, 2017, the Company borrowed an additional $1,000,000 on the note and issued warrants for the purchase of 40,000 shares of common stock with the same terms as the initial warrants. The Company recognized the $2,103,341 fair value of the warrants as debt discounts, which are being amortized over the remaining life of the borrowing. Effective March 3, 2017, the note was amended to increase the maximum principal sum from $1,500,000 to $2,000,000 under which the Company borrowed an additional $200,000 in consideration and issued the lender a warrant to purchase up to 8,000 shares of common stock with the same terms as the warrants previously issued under the previous terms of the note. The Company recognized the $407,947 fair value of the warrants as part of the total on extinguishment of debt of $501,969.

During September 2016, the Company granted warrants to purchase 20,000 shares in connection with the acquisition of a note payable at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the Offering, (ii) $25 per share, (iii) 80% of the unit price in the Offering (if applicable), or (iv) the exercise price of any warrants issued in the Offering. Upon the closing of the Offering, the number of shares issuable under the warrant will reset to an amount of shares equal to the aggregate exercise amount of the warrants (as defined therein) divided by the exercise price then in effect. The warrants expire in September 2021, and may be exercised via cashless exercise. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company's common stock after exercise. The Company recognized $220,000 of the $493,590 fair value of the warrants as a debt discount, which is being amortized over the life of the borrowing, and recognized the remaining $273,590 as a loss on derivatives liability. In the event the Company borrows additional amounts above the initial $500,000 under the note payable, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to warrants issued as part of the initial borrowing. During the six months ended March 31, 2017, the Company borrowed an additional $1,000,000 on the note and issued warrants for the purchase of 40,000 shares of common stock with the same terms as the initial warrants. The Company recognized the $2,103,341 fair value of the warrants as debt discounts, which are being amortized over the remaining life of the borrowing. Effective March 3, 2017, the note was amended to increase the maximum principal sum from $1,500,000 to $2,000,000 under which the Company borrowed an additional $200,000 in consideration and issued the lender a warrant to purchase up to 8,000 shares of common stock with the same terms as the warrants previously issued under the previous terms of the note. The Company recognized the $407,947 fair value of the warrants as part of the total on extinguishment of debt of $501,969.26

24During the nine months ended June 30, 2017, the Company measured the fair value of warrants classified as liabilities on the date of issuance and on each re-measurement date using the Monte Carlo valuation model. For this liability, the Company and specialist developed their own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company's common stock, stock price volatility, the contractual term of the warrants, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants uses Level 3 measurements. The following assumptions were used:

During the six months ended March 31, 2017, the Company measured the fair value of warrants classified as liabilities on the date of issuance and on each re-measurement date using the Monte Carlo valuation model. For this liability, the Company and specialist developed their own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company's common stock, stock price volatility, the contractual term of the warrants, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants uses Level 3 measurements. The following assumptions were used:

Exercise price	$	2.50 - $25.00
Expected term (years)		0.21 - 4.93
Volatility		128% - 194	%
Risk-free rate		0.49% - 1.99	%
Dividend rate		0	%
Common stock price	$	2.50 - $25.00

Exercise price	$	5 - $25
Expected term (years)		0.21 - 4.88
Volatility		128% - 194	%
Risk-free rate		0.49% - 1.99	%
Dividend rate		0	%
Common stock price	$	5 - $25

The following table summarizes information about stock options and warrants outstanding as of June 30, 2017:

The following table summarizes information about stock options and warrants outstanding as of March 31, 2017:

Options and Warrants	Number of Options and Warrants			Weighted- Average Exercise Price
Outstanding as of October 1, 2016		65,045		$	35.06
Granted		48,000			25.00
Forfeited		(3,871	)		357.84
Outstanding as of June 30, 2017		109,174			37.12
Exercisable as of June 30, 2017		102,225			34.46

Options and Warrants	Number of Options and Warrants			Weighted- Average Exercise Price
Outstanding as of October 1, 2016		65,045		$	35.06
Granted		48,000			25.00
Forfeited		(971	)		679.92
Outstanding as of March 31, 2017		112,074			42.63
Exercisable as of March 31, 2017		105,125			40.40

As of June 30, 2017, the outstanding warrants have an aggregate intrinsic value of $0 and the weighted average remaining term of the warrants was 4.52 years. The total compensation cost related to unvested awards not yet recognized (warrants and shares) was $38,468.

As of March 31, 2017, the outstanding warrants have an aggregate intrinsic value of $0 and the weighted average remaining term of the warrants was 4.65 years. The total compensation cost related to unvested awards not yet recognized (options, warrants, and shares) was $42,992.27

16. Related-Party Transactions Not Otherwise Disclosed

In February 2016, the Company amended a consulting agreement dated September 2015, with an entity controlled by a former Executive Chairman of the Board of Directors, effective January 2016. The amendment extended the agreement through December 2016, ~~with~~which automatically renews on a monthly ~~automatic~~basis ~~renewals~~until otherwise cancelled in accordance with the terms therein, changing the monthly compensation of $6,000 to an hourly rate of $250 per hour, and eliminated the previously included bonus structure. During May 2017, the Company granted 1,719 shares of common stock, with a value of $17,207 on the date of grant, to the consultant as a bonus for services performed. As of June 30, 2017, the shares have not been issued and the value has been included in accrued expenses. On September 5, 2017, the Company granted 1,500 shares of the Company's Series H Preferred stock to an entity controlled by a former Executive Chairman of the Board of Directors for past services rendered in addition to amounts earned under an existing consulting agreement. The shares of Series H Preferred stock have not yet been issued. The terms of the Series H Preferred stock have been approved by the Board of Directors of the Company, but no Certificate of Designation has been filed with the appropriate authoritative body. On November 13, 2017, the former Executive Chairman of the Board of Directors terminated the consulting agreement.

In July 2016, the Company entered into a Consulting Agreement with a former Executive Chairman and Chief Executive Officer of the Company. This Consulting Agreement is for an initial period of one year, and shall automatically renew for consecutive one month periods unless terminated by the Company or the former Executive Chairman and Chief Executive Officer. As consideration for the services ~~previously~~to ~~described~~be performed thereunder, the Company shall pay the former Executive Chairman and Chief Executive Officer at the rate of $250 per hour, but such compensation may not exceed $20,000 during any calendar month. During May 2017, the Company granted 10,324 shares of common stock, with a value of $103,343 on the date of grant, to the consultant as a bonus for services performed. As of June 30, 2017, the shares have not been issued and the value has been included in accrued expenses. On September 5, 2017, the agreement was replaced with a new agreement for an initial period of one year, and shall automatically renew for consecutive one month periods unless terminated by the Company or the former Executive Chairman and Chief Executive Officer. As consideration for the services, the Company shall pay the former Executive Chairman and Chief Executive Officer at the rate of $250 per hour, but such compensation may not exceed $20,000 during any calendar month, plus 1,500 shares of the Company's Series H Preferred stock. The shares of Series H Preferred stock have not yet been issued. The terms of the Series H Preferred stock have been approved by the Board of Directors of the Company, but no Certificate of Designation has been filed with the appropriate authoritative body.

In August 2016, the Company received a cash advance for $135,000 from a former Executive Chairman and Chief Executive Officer of the Company. During the ~~six~~nine months ended ~~March~~June 3130, 2017, the Company repaid the advance.

During May 2017, the Company granted 96,275 shares of common stock, with a value of $963,713 on the date of grant, to a former Executive Chairman and Chief Executive Officer of the Company, who was in office at the time, as a bonus for services performed. As of June 30, 2017, the shares have not been issued and the value has been included in accrued expenses. On September 5, 2017, the Board of Directors of the Company granted 963 shares of Series H Preferred stock to the former Executive Chairman and Chief Executive Officer of the Company in lieu of the 96,275 shares of previously granted common stock. The terms of the Series H Preferred stock have been approved by the Board of Directors of the Company, but no Certificate of Designation has been filed with the appropriate authoritative body. The Series H Preferred shares have not yet been issued.

In September 2017, the Company entered into an employment agreement with the former Executive Chairman and Chief Executive Officer of the Company, who was in office at the time, for a period of two years for services as the Executive Chairman and Chief Executive Officer of the Company. The initial term of the agreement is for two years and shall automatically renew on a year to year basis, unless terminated sooner. The base compensation is $360,000 per year plus 1,500 shares of the Company's Series H Preferred stock. The shares of Series H Preferred stock have not yet been issued. The terms of the Series H Preferred stock have been approved by the Board of Directors of the Company, but no Certificate of Designation has been filed with the appropriate authoritative body. An additional cash or stock bonus may be awarded, subject to the attainment of such individual of certain objectives as the Board of Directors of the Company shall establish from time to time. Upon certain termination conditions contained in the agreement, the Company may be required to pay severance of twice the base compensation at its highest point during the five-year period prior to termination. Effective October 12, 2017, the former Executive Chairman and Chief Executive Officer has waived any constructive termination in relation to changes in title, working conditions or duties such that his powers are diminished, reduced or otherwise changed to include powers, duties, or working conditions which are note materially consistent with title, continuing after written notice and 10 days to cure.

17. Commitments and Contingencies

During the ~~six~~nine months ended ~~March~~June 3130, 2017, the Company leased office space under a non-cancelable operating lease. In February 2015, the Company entered into a sublease agreement for part of the office space under the non-cancelable operating lease through the end of the original lease period. Payments under the sublease were made by the sublessee directly to the Company's landlord. The non-cancelable operating lease was terminated during June 2015.

25During June 2015, the Company entered into a new non-cancelable operating lease for its existing office space, excluding the previously subleased space, with payments beginning in July 2015. Future minimum rental payments under the non-cancelable operating lease as of June 30, 2017, were as follows:

During June 2015, the Company entered into a new non-cancelable operating lease for its existing office space, excluding the previously subleased space, with payments beginning in July 2015. Future minimum rental payments under the non-cancelable operating lease as of March 31, 2017, were as follows:

Years Ending September 30,

2017	$	32,908
2018		111,340

	$	144,248

Years Ending September 30,
2017	$	65,817
2018		111,340
	$	177,157

The Company's rent expense under the new non-cancelable operating lease for nine months ended June 30, 2017 and 2016, was approximately $97,000 and $94,000, respectively.

~~The~~During February 2016, the Company's ~~rent~~entered ~~expense~~into ~~under~~an ~~the~~agreement ~~new~~with ~~non-cancelable~~one ~~operating~~if ~~lease~~its ~~for~~vendors ~~six~~to ~~months~~purchase ~~ended~~a ~~March~~minimum 30of $200,000 ~~2017~~of ~~and~~inventory ~~2016,~~per quarter through January 2018. The agreement was ~~approximately~~cancelled ~~$64,000~~subsequent ~~and~~to ~~$62~~June 30,~~000,~~ ~~respectively~~2017.

During February 2016, the Company entered into an agreement with one if its vendors to purchase a minimum of $200,000 of inventory per quarter through January 2018.

During February 2016, the Company redeemed all of its Series F preferred stock in exchange for 20,005 shares of common stock and $5,900,000 of notes payable (see Note 9). As part of the redemption, the Company exchanged warrants held by the Series F Preferred stockholders for the purchase of 11,070 shares of common stock for new warrants to purchase the same number of shares with different terms. As part of the redemption, the Company may be required to issue additional warrants for the purchase of up to 16,000 shares of common stock upon three events of default on the notes payable (see Note 15).

During February 2016, the Company converted notes payable and accrued interest payable to an entity controlled by a former Executive Chairman of the Board of Directors into a convertible note payable (see Note 10). The Company may be required to issue 1,469 shares of common stock if the note is not paid by maturity.

During February 2016, the Company amended notes payable to an entity controlled by an officer of the Company to subordinate to notes payable also issued during February 2016, reduced the conversion price per share to $30 per share and limited the shares into which it is convertible (see Note 10). The Company may be required to issue 8,407 shares of common stock if the note is not paid by maturity.

During September 2016, the Company issued a note payable to a third party for up to $1,500,000. The Company initially borrowed $500,000 under the note and may borrow up to $1,500,000 upon meeting certain milestones. The Company subsequently drew an additional $1,000,000 under the note and issued additional warrants for the purchase of 40,000 shares of common stock at similar terms to warrants issued as part of the initial borrowing. During March 2017, the note was amended to increase the maximum principal sum from $1,500,000 to $2,000,000 under which the Company borrowed an additional $200,000 in consideration and issued the lender a warrant to purchase up to 8,000 shares of common stock with the same terms as the warrants previously issued under the previous terms of the note. In the event the Company borrows any part of the remaining $300,000 available, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to warrants issued as part of the initial borrowing.

During September 2016, the Company entered into a conditionally effective warrant cancellation agreement (the "Warrant Cancellation Agreement") with certain warrant holders who were issued the warrants in connection with a secured note payable and line of credit. Pursuant to the terms of the Warrant Cancellation Agreement, upon the Company's consummation of an equity financing of at least $15,000,000, the warrant holders agree to terminate and cancel the warrants they currently hold. As an inducement to enter into the Warrant Cancellation Agreement, the warrant holders will receive upon termination and cancelation of the warrants an aggregate of 10,800 shares of the Company's common stock, which will be subject to a 6-month lock-up agreement. Additionally, if the warrant holders terminate and cancel the warrants, the Company will issue the related note holder a new unsecured promissory note with an initial principal amount of $180,000, no cash interest, and a three-year term. In lieu of cash interest, the principal of the note will increase in the amount $3,333 each month not to exceed a maximum of $300,000.

During November 2016, the Company and a lender entered into a forbearance and consent under a loan and security agreement (the "November Forbearance Agreement"). Pursuant to the terms of the November Forbearance Agreement, the lender will forbear from exercising remedies (the "November Forbearance") with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the September Forbearance Agreement. Additionally, pursuant to the November Forbearance Agreement, the lender has provided the Company with the consent required under the Existing Agreements and September Forbearance Agreement to make certain payments from the proceeds of the Offering. These payments include, but are not limited to (i) payments to holders of the Company's Series E Preferred, (ii) third party note and receivable payments and (iii) repayment of an unsecured note payable issued in September 2016. The lender also consented to the issuance of the Company's Series G Preferred Stock to certain affiliates of the Company. In consideration for the November Forbearance, the Company has agreed to issue the lender warrants to purchase 130,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering, which shall be subject to a 12-month lock-up agreement. The $1,932,577 estimated fair value of the warrants has been included in accrued expenses as of March 31, 2017. The Forbearance set forth in the November Forbearance Agreement was in effect through December 31, 2016. Effective December 31, 2016, the Company and the lender entered into a forbearance and consent under loan and security agreement (the "December Forbearance"). Pursuant to the terms of the December Forbearance, the lender will forbear from exercising remedies with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the September Forbearance and November Forbearance. Additionally, pursuant to the December Forbearance, the lender has provided the Company with the consent required under the Existing Agreements, September Forbearance and November Forbearance to make certain payments from the proceeds of the Company's Offering. In consideration for the December Forbearance, the Company has agreed to issue the lender warrants to purchase 10,000 shares of common stock at an exercise price equal to the per share price of the common stock in the Offering and $50,000 of common stock at 80% of the at the same issue price in of the Offering, which shall be subject to a lock-up agreement. The $148,677 estimated fair value of the warrants and $60,000 fair value of the stock has been included in accrued expenses as of March 31, 2017. The forbearance set forth in the December Forbearance was in effect through February 15, 2017. On February 15, 2017, the lender extended the December Forbearance period through March 31, 2017. On March 28, 2017, the lender extended the December Forbearance period through April 10, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

Effective November 1, 2016, the Board approved the 2016 Incentive Stock Option plan providing for the issuance of options to purchase up to 377,250 shares. No shares have been approved under the Plan as of March 31, 2017.

On January 12, 2017, the Company entered into letter agreements (together the "Note Holder Letter Agreements") with eight (8) investors (each a "Note Holder" and together the "Note Holders") holding convertible notes payable whereby the Note Holders agreed to convert all monies due them under the Notes into restricted shares of common stock (the "Note Conversion Shares") and warrants to purchase common stock (the "Note Conversion Warrants" and together with the Note Conversion Shares, the "Note Conversion Securities"), all contingent upon the completion of the Company's contemplated public Offering of securities. As incentive to enter into the Note Holder Letter Agreements, the Company agreed to add approximately $1,687,811 to the outstanding principal and interest as of October 31, 2016, effectively making the total obligation due to Note Holders an aggregate of $8,000,000 (the "Total Note Obligation"). Pursuant to the Note Holder Letter Agreements, the Total Note Obligation will automatically convert upon consummation of the Offering into the Note Conversion Securities at the combined price per share and warrant paid by investors in the Offering (the "Conversion Price"). The terms of the Note Conversion Warrants will be substantially similar to the Warrants being included in the Offering, except such Note Conversion Warrants will be a restricted security and will not publicly trade on NASDAQ. In addition, the Note Holders currently hold warrants to purchase an aggregate of 11,070 shares that will be terminated upon the consummation of the Offering. In consideration of such termination, the Note Holders will be issued new warrants to purchase an identical number of shares of Common Stock at an exercise price equal to the Conversion Price, as defined in the agreements. Each person entering into the Note Holder Letter Agreements have entered into lock-up agreements prohibiting the sale or other transfer of any securities of the Company owned by such persons for a period of 6 months. If such Offering is not completed by February 15, 2017, the Note Holder Letter Agreements and lock-up agreements will terminate. During February 2017, prior to the expiration of the existing agreements, the Note Holders signed amendments to their respective Note Holder Letter Agreements and lock-up agreements to extend the expiration dates to March 31, 2017. During March 2017, prior to the expiration of the existing agreements, the Note Holders signed amendments to their respective Note Holder Letter Agreements and lock-up agreements to extend the expiration dates to April 30, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with a third-party lender, whereby the lender agreed to convert all monies due under that certain subordinated promissory note into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016, the aggregate amount of $101,814 was owed pursuant to the note. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the aggregate amount owed by 80% of the per share price of the common stock in the Offering. The lender has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned for a period of 6 months. If such Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 13, 2017, the Company signed an amendment to the letter agreement and signed a new lock-up agreement to extend the expiration dates to March 31, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with a third-party lender, whereby the lender agreed to convert all monies due him under that certain subordinated promissory note into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016 the aggregate amount of $265,616 was owed pursuant to the note. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the aggregate amount owed by 80% of the per share price of the common stock in the Offering. The lender has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by him for a period of 6 months. The letter agreement extends the due date of the note to the earlier of the completion of the Offering or February 15, 2017. On February 10, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with a third-party vendor, whereby such vendor agreed to convert all monies due from the Company pursuant to certain accounts payable into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016, the aggregate amount of $73,667 was owed to the vendor. Pursuant to the letter agreement, the aggregate amount owed will automatically convert upon consummation of the Offering of securities into such number of restricted shares of the Company's common stock calculated by dividing the aggregate amount owed by the per share price of the common stock in the Offering. The vendor has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 6 months. If such Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 13, 2017, the Company signed an amendment to the letter agreement and signed a new lock-up agreement to extend the expiration dates to March 31, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with a director of the Company whereby the director agreed to convert a portion of monies due him from the Company from unpaid board service fees into common stock of the Company, contingent upon the completion of the Offering. As of October 31, 2016, the aggregate amount of $42,500 was owed to the director. Pursuant to the letter agreement, the unpaid fees will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the unpaid fees by $17.50 or 2,426 shares. The director has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by him for a period of 12 months. If such Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 10, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a second letter agreement with the director, whereby the director agreed to convert 13,843 shares of Series E Preferred of the Company owned into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016, the aggregate amount of $181,297 consisting of accrued dividends, royalty and interest was owed to the director with respect to his Series E Preferred. Pursuant to the second letter agreement, the aggregate amount will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the aggregate amount by $17.72 or 10,223 shares. The director has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned for a period of 12 months. If such Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 10, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with entities controlled by the Chief Executive Officer, whereby each of such parties agreed to convert all monies due pursuant to three separate promissory notes into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016, the aggregate amount of $3,876,737 was owed to the holders pursuant to the notes payable. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the aggregate amount owed by $22.50, or 172,300 shares, exclusive of interest accruing subsequent to September 30, 2016. Each of the parties subject to the letter agreement have entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by such parties for a period of 12 months. The letter agreement extends the due date of the notes to the earlier of the Offering or February 15, 2017. On February 10, 2017, the Company signed an amendment to the letter agreement and signed a new lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. On March 27, 2017, the Company replaced the letter agreement with a new letter agreement where the redemption value will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by $6.00 per share. If the Offering is not completed by April 15, 2017, the letter agreement will terminate. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with an entity controlled by a former Executive Chairman and a current consultant to the Company, whereby the entity agreed to convert all monies due it under a promissory note into common stock of the Company, contingent upon the completion of the Offering. As of September 30, 2016, the aggregate amount of $602,145 was owed to the entity pursuant to the promissory note. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by 80% of the per share price of the common stock in the Offering, exclusive of interest accruing subsequent to September 30, 2016. The entity has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 6 months. If the Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 13, 2017, the Company signed an amendment to the letter agreement and signed a new lock-up agreement to extend the expiration dates to March 31, 2017. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

On January 12, 2017, the Company entered into a letter agreement with an entity affiliated with the Chief Executive Officer, whereby the entity agreed to convert 25,000 shares of Series D Preferred of the Company owned into common stock of the Company based on current redemption value, contingent upon the completion of the Offering. As of the date hereof, the current redemption value of such Series D Preferred was $300,000. Pursuant to the letter agreement, the redemption value will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by $22.50 or 13,334 shares and all dividends cease accruing beginning July 1, 2016. The entity has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 12 months. If the Offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. On February 10, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to March 31, 2017. On March 27, 2017, the Company signed an amendment to the letter agreement and lock-up agreement to extend the expiration dates to April 30, 2017. On March 27, 2017, the Company replaced the letter agreement with a new letter agreement where the redemption value will automatically convert upon consummation of the Offering into such number of restricted shares of the Company's common stock calculated by dividing the redemption value by $6.00 or 50,000 shares and all dividends cease accruing beginning July 1, 2016. If the Offering is not completed by April 15, 2017, the letter agreement and lock-up agreement will terminate. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

Effective April 1, 2017, the Company entered into a letter agreement (the "Telecare Letter Agreement"), with Telecare Medical Supply, LLC, the sole supplier of our cellular glucometers and other testing supplies ("Telecare"), and the payee of a certain Non-Negotiable Promissory Note in the original principal amount of approximately $2,524,000 (the "Amended and Restated Telecare Note"). Pursuant to the Telcare Letter Agreement, Telecare has agreed to convert all monies due it from the Company pursuant to the Telecare Note into restricted shares of common stock (the "Telecare Conversion Shares"), all contingent upon the completion of this offering. As of March 31, 2016, Telecare is owed the principal amount of $1,773,937 ("Telecare Principal Amount"), along with accrued interest of $3,675 through March 31, 2017 (the "Telecare Interest Amount" and, together with the Principal Amount, the "Telecare Note Obligation"). As incentive to enter into the Telecare Letter Agreement, the Company agreed to add approximately $502,388 to the Telecare Note Obligation effectively making the total obligation due to Telecare an aggregate of $2,280,000 (the "Total Telecare Obligation"). Pursuant to the Telecare Letter Agreement, the Total Telecare Obligation will automatically convert upon consummation of the Offering into the Telecare Conversion Shares at the combined price per share and warrant paid by investors in the Offering (the "Conversion Price"). If the Offering is not completed by April 30, 2017, the letter agreement and lock-up agreement will terminate. The Company is in the process of negotiating an extension to the letter agreement and lock-up agreement, however, there is no assurance that an extension will be agreed upon.

OnDuring ~~May~~September 282016, ~~2015,~~the anCompany ~~investor~~entered into a conditionally effective warrant cancellation agreement (the "Warrant Cancellation Agreement") with certain warrant holders who were issued the warrants in connection with a secured note payable and line of credit. Pursuant to the terms of the Warrant Cancellation Agreement, upon the Company's ~~filed~~consummation aof ~~lawsuit~~an ~~claiming~~equity ~~damages~~financing of at least $115,000,000, ~~exclusive~~the ofwarrant ~~interest~~holders ~~and~~agree ~~costs~~to ~~against~~terminate and cancel the ~~Company,~~warrants athey ~~former~~currently ~~Executive~~hold. ~~Chairman,~~As an ~~entity~~inducement ~~controlled~~to byenter ~~another~~into ~~former~~the ~~Executive~~Warrant ~~Chairman~~Cancellation Agreement, the warrant holders will receive upon termination and 4Gcancelation ~~Biometrics,~~of athe ~~wholly~~warrants ~~owned~~an ~~subsidiary~~aggregate of 10,800 shares of the Company's common stock, ~~for~~which ~~breach~~will ofbe ~~contract. The~~subject ~~Company~~to ~~has~~a ~~engaged~~6-month ~~legal~~lock-up ~~counsel~~agreement. ~~regarding~~Additionally, if the ~~matter. It~~warrant isholders ~~not~~terminate ~~possible~~and tocancel ~~predict~~the warrants, the ~~outcome~~Company ofwill issue the ~~matter~~related atnote ~~this~~holder ~~time~~a new unsecured promissory note with an initial principal amount of $180,000, no cash interest, and a three-year term. ~~The~~ ~~Company~~In ~~intends~~lieu toof ~~vigorously~~cash ~~dispute~~interest, the ~~claims~~principal ~~and~~of ~~believes~~the itnote ~~has~~will ~~meritorious~~increase ~~defenses~~in the amount $3,333 each month not to exceed a maximum of $300,000.

On April 17, 2017 the Company entered into a Joint Venture Agreement, effective March 31, 2017 (the "JV Agreement") with Colorado Choice Health Plans ("CCHP"), a customer. Under the JV Agreement: (i) CCHP is providing various services to the Company to improve the Company's diabetes programs, (ii) the Company loaned CCHP $500,000 under a debenture note (recorded as a note receivable in the accompanying consolidated condensed balance sheets), and (iii) the JV Agreement will terminate upon the later of (a) repayment of the debenture note or (b) the one year anniversary of the JV Agreement. The debenture note: (i) bears interest at the rate of five percent per annum, (ii) is subordinated to the rights of CCHP policyholders, claimants and beneficiary claims and all other classes of CCHP creditors other than subordinated debenture holders, (iii) does not become a liability of CCHP until and unless the Commissioner of the Colorado Department of Regulatory Agencies, Division of Insurance ("Division of Insurance") authorizes repayment of the debenture agreement, and shall be treated by CCHP as surplus until the time of such approval, (iv) is only repayable from available funds in excess of CCHP's minimum net surplus required to be maintained by the Division of Insurance, and (v) is otherwise repayable on March 31, 2018, assuming approval by the Division of Insurance.

On May 28, 2015, an investor of the Company filed a lawsuit claiming damages of $1,000,000 exclusive of interest and costs against the Company, a former Executive Chairman, an entity controlled by another former Executive Chairman, and 4G Biometrics, a wholly owned subsidiary of the Company, for breach of contract. The Company has engaged legal counsel regarding the matter. The Company has assessed a high probability of settling the matter for $750,000 in cash, equity, or a combination thereof. The Company has accrued a contingent liability of $750,000 and loss on settlement as of June 30, 2017.

On November 4, 2015, the Company received a demand for payment of $275,000 from a former employee of the Company and former principal of 4G Biometrics whose employment was terminated for cause. On December 4, 2015, the Company filed a complaint against the former owners of 4G Biometrics, including this former employee, seeking damages in excess of $300,000 related to alleged misrepresentations made to induce the Company to acquire 4G Biometrics. Between February 4, 2016 and February 8, 2016, the Company settled the complaint with each of the former owners of 4G Biometrics and all parties released each other from all outstanding claims, including any current monetary obligations to each party, excluding one former owner of 4G Biometrics who continues to be employed by the Company. A Stipulation for Order of Dismissal with Prejudice of all Claims and Counterclaims has been filed and is in the process of being approved. The settlement resulted in the termination of $39,863 of related-party accounts payable.

18. Subsequent Events

Subsequent to March 31, 2017, the Company entered into the following agreements and transactions:

(1) On April 17, 2017, the Company entered into a factoring agreement with an existing third party lender. The factoring agreement provides for an advance of $1,794,000, comprised of $1,000,000 in cash and the consolidation of $794,000 from four prior factoring agreements into the amounts owed under the factoring agreement (collectively, the "Funds"). In consideration for the Funds, the Company sold to the lender all future receipts until the total amount of $2,511,601 has been paid. The factoring agreement requires payment of the minimum daily amount of $12,999.99 for 193 days. The $1,794,000 can be reduced if repayment occurs more quickly. Repayment of the amounts owing is with recourse and secured by all accounts, chattel paper, documents, equipment, general intangibles, instruments, and inventory of the Company. The lender, however, has subordinated its security interest to other notes payable. The amount owed to the lender is personally guaranteed by the Company's Chief Executive Officer.

(2) On April 17, 2017, the Company and a customer entered into a Joint Venture Agreement, effective March 31, 2017 (the "JV Agreement") with Colorado Choice Health Plans ("CCHP"). Under the JV Agreement: (i) CCHP is providing various services to the Company to improve the Company's diabetes programs, (ii) the Company loaned CCHP $500,000 under a debenture note, and (iii) the JV Agreement will terminate upon the later of (a) repayment of the debenture note or (b) the one year anniversary of the JV Agreement. The debenture note: (i) bears interest at the rate of five percent per annum, (ii) is subordinated to the rights of CCHP policyholders, claimants and beneficiary claims and all other classes of CCHP creditors other than subordinated debenture holders, (iii) does not become a liability of CCHP until and unless the Commissioner of the Colorado Department of Regulatory Agencies, Division of Insurance ("Division of Insurance") authorizes repayment of the debenture agreement, and shall be treated by CCHP as surplus until the time of such approval, (iv) is only repayable from available funds in excess of CCHP's minimum net surplus required to be maintained by the Division of Insurance, and (v) is otherwise repayable on March 31, 2018, assuming approval by the Division of Insurance.

(3) On April 19, 2017, the Company amended a note payable, with balance of $1,700,000 as of March 31, 2017, to extend the maturity date to the earlier of May 20, 2017 or the third business day after the closing of the Offering. Additionally, the date by which the origination shares must be delivered was extended to the fifth trading day after the pricing of the Offering, but in no case later than May 20, 2017.

(4) During April 2017, the Company received a letter from a significant customer dated April 25, 2017 notifying the Company of the termination its customer agreement effective July 1, 2017. This customer represented 56% and 47% of revenues during the three and six months ended March 31, 2017, respectively.

~~(5) During April, 2017 the Company issued 7,000 shares of common stock to business development contractor pursuant to a services arrangement in consideration for services rendered~~18. Subsequent Events

~~(6)~~Subsequent ~~Effective~~to ~~April~~June 330, 2017, the Company entered into ~~a letter agreement (~~the ~~"Telecare~~following ~~Letter~~agreements ~~Agreement"), with Telecare Medical Supply, LLC, the sole supplier of our cellular glucometers~~ and other testing supplies ("Telecare"), and the payee of a certain Non-Negotiable Promissory Note in the original principal amount of approximately $2,524,000 (the "Amended and Restated Telecare Note"). Pursuant to the Telcare Letter Agreement, Telecare has agreed to convert all monies due it from the Company pursuant to the Telecare Note into restricted shares of common stock (the "Telecare Conversion Shares"), all contingent upon the completion of this offering. As of March 31, 2017, Telecare is owed the principal amount of $1,773,937 ("Telecare Principal Amount"), along with accrued interest of $3,675 through March 31, 2017 (the "Telecare Interest Amount" and, together with the Principal Amount, the "Telecare Note Obligation"). As incentive to enter into the Telecare Letter Agreement, the Company agreed to add approximately $502,388 to the Telecare Note Obligation effectively making the total obligation due to Telecare an aggregate of $2,280,000 (the "Total Telecare Obligation"). Pursuant to the Telecare Letter Agreement, the Total Telecare Obligation will automatically convert upon consummation of the Offering into the Telecare Conversion Shares at the combined price per share and warrant paid by investors in the Offering (the "Conversion Price"). If the Offering is not completed by April 30, 2017, the letter agreement and lock-up agreement will terminate.transactions:

(7) As of the date of this report, notes payable due to unrelated parties with total principal amounts of $11,501,114, owing as of March 31, 2017, are past due, in default, and unpaid. In addition, notes payable due to related parties with total principal amounts of $3,875,335, as of March 31, 2017, are past due, in default and unpaid. These defaults include obligations owed to Partners for Growth, which are in excess of $2,875,000 and which are secured by substantially all assets of the Company.

(1)	On August 2, 2017, the Company received a cash advance from a third party in the amount of $100,000, which incurs fees of $1,500 per day until repaid. During November 2017, the Company amended the advance to be callable at any time, due May 30, 2018, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date.

(2)	On August 7, 2017, the Company received a cash advance from a third party in the amount of $50,000, which incurs fees of $750 per day until repaid. During November 2017, the Company amended the advance to be callable at any time, due May 30, 2018, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date.

(3)	During August 2017, the Company received letters related to unsecured notes payable with third parties with principal balances totaling $5,900,000 as of June 30, 2017 where the lenders waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017.

(4)	During August 2017, the Company received a letter related to an unsecured note payable with a third party with a principal balance of $334,464 as of June 30, 2017 wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017. On December 18, 2017, another letter was received wherein the lender waived any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018.

(5)	During August 2017, the Company received a letter related to secured and unsecured notes payable with entities controlled by the Company's former chief executive officer and Executive Chairman of the Board of Directors, who was in office at the time, with principal balances of $1,721,100, $1,303,135, $250,000 and $25,463 as of June 30, 2017, wherein the lenders waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017. On December 18, 2017, another letter was received wherein the lender waived any historical and future events of default through January 12, 2018 and extended maturity date was extended through January 12, 2018.

(6)	During August 2017, the Company received a letter related to an unsecured note payable with a former Executive Chairman of the Board of Directors with a principal balance of $542,004 as of June 30, 2017 wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017. On December 18, 2017, another letter was received wherein the lender waived any historical and future events of default through January 12, 2018 and extended maturity date was extended through January 12, 2018.

(7)	During July 2017, the Company granted 1,562 shares of common stock, with a value of $12,496 on the date of grant, to the former Executive Chairman and Chief Executive Officer of the Company, who was in office at the time, as a bonus for services performed during the three months ended June 30, 2017. The value of the shares has been included in accrued expenses as of June 30, 2017.

(8)	On August 16, 2017, the Company sold $248,500 of future customer receipts to a third party for $175,000 in cash. The $73,500 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note and is guaranteed by the Company's former Executive Chairman and Chief Executive Officer, who was in office at the time.

(9)	During July 2017, the Company granted 50,000 shares of common stock, with a value of $400,000 on the date of grant, to a third party as part of a one-year consulting agreement. The value of the shares will be amortized to selling, general and administrative expenses evenly over the service period. On September 5, 2017, the Board of Directors granted the issuance of 500 shares of Series H Preferred stock in lieu of the 50,000 shares of common stock, to which the third party has verbally agreed. The Series H Preferred shares have not yet been issued.

(10)	During July 2017, the Company granted 3,937 shares of common stock to employees for bonuses. The $31,500 fair value of the shares has been included in accrued expenses as of June 30, 2017.

(11)	On August 28, 2017, the Company sold $224,850 of future customer receipts to a third party for $150,000 in cash. The $74,850 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note and is guaranteed by the Company's former Executive Chairman and Chief Executive Officer, who was in office at the time.

(12)	On August 31, 2017, the Company sold $119,920 of future customer receipts to a third party for $80,000 in cash. The $39,920 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note and is guaranteed by the Company's former Executive Chairman and Chief Executive Officer, who was in office at the time.

(13)	On September 5, 2017, the Board of Directors of the Company modified the terms of the Series G Convertible Preferred stock to remove the 18-month lock-up period. The amendment has not been filed with the State of Delaware as of the date of this filing.

(14)	On September 5, 2017, the Board of Directors of the Company ratified a change to the Series H Preferred stock, previously contemplated and approved by the Board of Directors, to where each share of the Series H Preferred stock is convertible into 100 shares of the Company's common stock, is limited to a total ownership of 4.99% of the outstanding common stock at the time of conversion, is to be non-voting stock, does not bear interest or dividends, and is transferable with the same terms. The Certificate of Designation for the Series H Preferred stock has not been filed with the State of Delaware as of the time of this filing and no shares had been issued prior to September 5, 2017.

(15)	On September 5, 2017, the Company entered into a consulting agreement with a former Executive Chairman and Chief Executive Officer of the Company, which replaced and existing consulting agreement, for certain consulting services to the Company including, but not limited to (i) developing business plans, (ii) making introductions to potential customers and/or suppliers, (iii) identifying qualified employees and other service providers, (iv) sales, marketing, manufacturing and other operating activities, and (v) meeting with the Company's and its affiliates' respective managers, officers, employees, agents, and other service providers regarding the business, prospects and affairs of the Company and its affiliates. The former officer may not engage in and shall not be entitled to any fees or consideration for (i) negotiating the purchase and/or sale of Company securities, (ii) making recommendations regarding transactions involving Company securities, (iii) or any other matters involving transactions of Company securities. The agreement is for one year and includes compensation of $250.00 per hour, but such compensation may not exceed $20,000 during any calendar month, plus 1,500 shares of the Company's Series H Preferred stock. The shares of Series H Preferred stock have not been issued at the time of this filing.

(16)	On September 5, 2017, the Company renewed an existing license and royalty agreement with an entity controlled by a former Executive Chairman and Chief Executive Officer of the Company (the "licensee"). Under the agreement, the licensee receives the right to make, sell and use products related to the Company's intellectual property regarding diabetics, cellular, GPS and CareCenter arena and generally characterized as the CareCenter Technology in a certain region. The Company shall receive a royalty of 15% of the licensee's gross sales price for the product. The initial term is for three years whereby the licensee must achieve a minimum royalty of $10,000 per month to maintain the agreement, whereby the agreement will be extended for one addition year unless terminated. If the minimum monthly royalty is not maintained, the licensee may pay a sum to bring the total payment up to $360,000 within 60 days of the end of the three-year term to extend the agreement for one additional year. The Company may terminate the agreement if the licensee does not commence to manufacture, distribute and sell product within a 6-month period after the execution of the agreement.

(17)	On September 5, 2017, the Company granted 1,500 shares of the Company's Series H Preferred stock to an entity controlled by a former Executive Chairman of the Board of Directors for past services rendered in addition to amounts earned under an existing consulting agreement. The shares of Series H Preferred stock have not been issued at the time of this filing.

(18)	On September 5, 2017, the Company entered into an employment agreement with the former Executive Chairman and Chief Executive Officer of the Company, who was in office at the time, for a period of two years for services as the Executive Chairman and Chief Executive Officer of the Company. The initial term of the agreement is for two years and shall automatically renew on a year to year basis, unless terminated sooner. The base compensation is $360,000 per year plus 1,500 shares of the Company's Series H Preferred stock. The shares of Series H Preferred stock have not yet been issued. The terms of the Series H Preferred stock have been approved by the Board of Directors of the Company, but no Certificate of Designation has been filed with the appropriate authoritative body. An additional cash or stock bonus may be awarded, subject to the attainment of such individual and ActiveCare objectives as the Board of Directors of the Company shall establish from time to time as determined by the Board of Directors of the Company. Upon certain termination conditions upon termination of the agreement, the Company may be required to pay severance of twice the base compensation of the former Executive Chairman and Chief Executive Officer at its highest point during the five-year period prior to termination. In addition, the Board of Directors approved compensation at a level of $360,000 per year retroactive from July 2017, when the former Executive Chairman and Chief Executive Officer was appointed, until the employment agreement was signed. Effective October 12, 2017, the agreement was amended to waive any constructive termination in relation to changes in title, working conditions or duties such that his powers are diminished, reduced or otherwise changed to include powers, duties, or working conditions which are note materially consistent with title, continuing after written notice and 10 days to cure.

(19)	On September 5, 2017, the Board of Directors granted 963 shares of Series H Preferred stock to the former Executive Chairman and Chief Executive Officer of the Company, who was in office at the time, in lieu of 96,275 shares of previously granted common stock as a bonus for services performed. The Series H Preferred shares have not yet been issued.

(20)	On September 5, 2017, the Board of Directors granted 200 shares of Series H Preferred stock to the holder of an unsecured note payable with a balance of $300,000 as of June 30, 2017 for the extension of the note payable. The Series H Preferred shares have not yet been issued.

(21)	From September 21, 2017 through December 1, 2017, the Company received cash advances totaling $230,000 from an entity controlled by the Company's former Executive Chairman and Chief Executive Officer, who was in office at the time, and repaid $10,000 plus the reimbursement of bank fees of $200.

(22)	On September 25, 2017, the Company entered into agreements with its primary product vendor that supersedes all prior agreements with the vendor. Under the agreements, the vendor will provide all products and services to the Company's service members as they are assigned to the vendor. In return, the vendor will pay the Company a fee for services rendered to the vendor and to the members for monitoring and reporting. The Company also earns commissions on all members assigned under the agreement to be paid upon completion of certain milestones met with each individual member. The agreements also modify the terms of an existing note payable to the vendor. The note accrues interest at 0.65% per annum, is reduced by the amount of commissions earned by the Company under the agreements and matures on September 25, 2019. The agreements also add interest fees on existing accounts payable at 0.65% per annum and the accounts payable are reduced by the amount of commissions earned by the Company under the agreements for a minimum of 24 months.

(23)	On September 27, 2017, the Company received a cash advance from a third party in the amount of $40,000, which incurs fees of $600 per day until repaid.

(24)	In October 2017, the Company entered into a settlement agreement related to an unsecured note payable with a principal balance of $300,000 as of June 30, 2017. As part of the agreement, the lender lent the Company an additional $200,000 which has been added to the principal balance of the note payable. The agreement modified the terms of the note payable to become secured by inventory owned by the Company, requires issuance of 3,000 shares of Series H Preferred Stock, which were granted by the Board of Directors on September 5, 2017 and are required to be able to convert the lender's shares into 300,000 shares of the Company's common stock, and requires payments of $8,600 for 72 consecutive weeks. If any payment is late, the Company is required to issue the lender an additional 86 shares of Series H Preferred Stock per late payment and an additional 172 shares of Series H Preferred stock if late payments are not cured within 30 days and for each subsequent 30-day period the note is in default. The amended note also requires payment of a key man life insurance policy on a former Executive Chairman of the Board of Directors naming the lender as the benefactor. The fair value of the shares will be amortized over the life of the amended note. The note terms are adjustable for any terms subsequently provided to other investors.

(25)	On November 7, 2017, the Company entered into individual agreements related to secured borrowings from four different parties that each previously purchased customer receivables that require daily payments. The agreements modified each agreement to reduce the amount of the respective daily payment to approximately half of the amount previously drawn through January 7, 2018, whereafter the amount of the payment returns to the payment required under the respective agreement plus an additional amount equal to the amount shorted during the period of lower payments divided by the number of remaining payments remaining on the original term of the respective note payable. Three of the four agreements are verbal. On January 5, 2018, the Company further modified each agreement to keep the amount of the daily payments at approximately the same level as the agreement on November 7, 2017 through mid-March 2018, except one where the lower payments are only through February 5, 2018. Three of the four agreements are verbal.

(26)	On November 13, 2017, an entity controlled by a former Executive Chairman of the Board of Directors, with whom we contracted for consulting, terminated the existing consulting arrangement.

(27)	On November 13, 2017, the Company entered into a sales broker agreement with an entity controlled by a former Executive Chairman of the Board (the "Sales Broker"). Under the Sales Broker agreement, the Company will provide services to certain customers referred to the Company and the Sales Broker will receive administration fees in the amount of 15% of gross revenues, as defined by the Sales Broker agreement, as long as the Company services the respective customer even in the event the Sales Broker agreement is terminated. The Sales Broker will promote the Company, its services and products, and introduce potential customers to the Company as a sales representative. The initial term of the Sales Broker agreement is one year, which automatically renews for additional one-year periods until cancelled by either party.

(28)	On November 30, 2017, the Company signed a letter of understanding with a former consultant where the Company agreed to convert $100,000 of past consulting fees owed into an equivalent value of equity in the Company upon a qualifying capital raise.

(29)	On November 10, 2017, the Company signed a formal agreement replacing a former verbal agreement with an unsecured note holder, with principal due of $350,000 as of June 30, 2017. The new agreement memorialized previously agreed upon terms whereby the lender converted a $350,000 advance into an unsecured note payable, with interest at 2.8% of revenues, for $143,987 in fees and a future payoff fee of 20% of the principal, or $70,000, which are included in accrued liabilities and interest expense as of June 30, 2017. The written agreement adjusted the verbal agreement to where the Company is required to pay any outstanding interest at the end of the first month following a quarter end. The lender may call all amounts due under the note payable as due and payable after February 28, 2018, given 15 calendar days notice, and the written agreement includes a most favored nations clause in relation to conversion features.

(30)	On November 27, 2017, the Company signed a formal agreement memorializing previous agreements with the holder of an unsecured note and cash advance, with aggregate principal due of $1,200,000 as of June 30, 2017, as well as additional advances with aggregate principal of $190,000 that were received subsequent to June 30, 2017. The new agreement memorialized the terms of the note payable whereby the lender converted $617,500 in advances into a $1,100,000 unsecured note payable, with interest at 18% per annum for $95,226 in fees, which have been included in accrued liabilities and interest expense as of June 30, 2017. In addition, the new agreement allows for advances to incur fees at 1.5% of the advance principal per calendar day until paid in full. The written agreement adjusted the verbal agreements to where the note payable and advance balances and fees may be called by the lender at any time and are due by May 30, 2018, and the new agreement includes a most favored nations clause in relation to conversion features on the note payable and advances. The new agreement also assigned $2,000,000 of note payable principal held by an entity controlled by an officer of the Company to the lender. All interest accrued on the assigned balance is payable to the officer.

(31)	On December 6, 2017 the Company entered into those certain forbearance and lock up letter agreements with three (3) debtors which held convertible debentures in the aggregate principal amount of $1,109,345 at the time of the agreements, whereby the debtors agreed that, without prior written consent of the Company, the debtors will not, directly or indirectly, (i) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of common stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, (ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, whether any such transaction is to be settled by delivery of common stock or other securities, in cash or otherwise, (iii) except as provided for, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of the Company, or (iv) publicly disclose the intention to do any of the foregoing for a period of the earlier of (a) June 5, 2018 or (2) the consummation of a qualified offering, herein deemed as an offering by the Company of $3,000,000 or more. Additionally, the Debt Holders agreed that they will forbear from enforcing their rights and remedies against any defaults which may exist historically, currently or in the future through June 5, 2018 under the existing loan documents. The agreements automatically terminate upon the earlier of (i) inability to raise a minimum of $550,000 in capital on or before December 31, 2017; (ii) June 5, 2018; or (iii) the consummation of a qualified offering of at least $3,000,000 by the Company. In addition, two (2) of the debtor agreements waive their rights to default litigation only through December 31, 2017 and any new financing must receive their prior consent unless it is common equity.

(32)	Effective December 11, 2017, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with four accredited investors, including the Company's new Chief Executive Officer in connection with the closing of a bridge financing (the "Bridge Financing") in the gross amount of $600,000. The three remaining accredited investors hold notes payable with an aggregate principal balance of $3,865,865 as of June 30, 2017. Pursuant to the Purchase Agreements, the Investors purchased from the Company (i) Promissory Notes in the aggregate principal amount of $631,578.06 (the "Notes") due and payable six months from the Effective Date and (ii) Common Stock Purchase Warrants (the "Warrant"), exercisable for five years from the date of issuance, to purchase up that certain amount of shares with an aggregate exercise amount equal to $600,000 at an exercise price per share equal to the lesser of (i) 80% of the per share price of common stock in the companies contemplated private placement of securities of up to $5,000,000, contemplated to take place within six months of the effective date (the "Private Placement") (ii) $3.00 per share, (iii) 80% of the offering price in the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement, in each case subject to adjustment hereunder (the "Exercise Price"). The Notes were issued in favor of the Investors with an original issue discount equal to five percent (5%). Additionally, pursuant to the Purchase Agreement, the Company will issue the investors common stock (the "Origination Shares") worth 30% of the purchase price paid by each investor (the "Origination Dollar Amount") on the 5th trading day after the pricing of the Private Placement, but in no event later than six months from the Effective Date. The Origination Dollar amount will divided by the lowest of (i) $3.00 (subject to adjustment for stock splits), (ii) 80% of the common stock offering price in the Private Placement, (iii) 80% of the offering price of the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement. At the closing of the Private Placement the Note shall automatically convert into a subscription into the Private Placement in an amount equal to 125% of the Note balance, subject to certain conditions as outlined therein. If the Company fails to repay the balance due under the Note on its Maturity the Investors have the right, at any time, at their election, to convert all or part of the outstanding and unpaid principal sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company pursuant to the following conversion formula: number of shares receivable upon conversion equals the dollar amount being converted divided by the Conversion Price. The Conversion Price is the lesser of $3.00 (subject to adjustment for stock splits) or 60% of the lowest trade price in the 25 trading days. Further, in the event of any default, the outstanding principal amount of the Notes, plus accrued but unpaid interest, liquidated damages, fees and other amounts owing in respect thereof through the date of acceleration (the "Note Balance"), shall become, at the Investor's election, immediately due and payable in cash at the Mandatory Default Amount. The Mandatory Default Amount means the investor's choice of (this choice may be made at any time without presentment, demand, or notice of any kind): (i) the Note Balance divided by the Conversion Price on the date of the default multiplied by the closing price on the date of the default; or (ii) the Note Balance divided by the Conversion Price on the date the Mandatory Default Amount is either (a) demanded or (b) paid in full, whichever has a lower Conversion Price, multiplied by the closing price on the date the Mandatory Default Amount is either (a) demanded or (b) paid in full, whichever has a higher closing price; or (iii) 150% of the Note Balance. If, at any time the Note is outstanding, the Company issues a Variable Security (as defined therein), then in such event the Investors shall have the right to convert all or any portion of the outstanding balance of the Notes into shares of Common Stock on the same terms as granted in any applicable Variable Security issued by the Company.

(33)	On November 17, 2017, the Company received cash advances from third parties totaling $60,000. On January 5, 2018, the advances converted into agreements with the same terms as the Bridge Financing entered into on December 11, 2017.

(34)	On December 11, 2017, Eric Robinson voluntarily resigned as Chief Financial Officer, Secretary and In-House Counsel, and all other positions with the Company to which he has been assigned regardless of whether he served in such capacity, effective immediately. On the same date, Jeffrey S. Peterson voluntarily resigned as Chairman of the Board of Directors, while acknowledging that he will continue to serve the Company as a Director and Executive Vice President. On the same date, Robert J. Welgos and Bradley Robinson voluntarily resigned as members of the Board of Directors and all other positions with the Company to which they may have been assigned, regardless of whether they served in such capacity, effective immediately. These resignations were not as a result of any disagreements with the Company.

(35)	On December 11, 2017, Isaac Onn was appointed as a member of the Company's board of Directors and Mark J. Rosenblum was appointed as the Company's Chairman of the Board of Directors and Chief Executive Officer in connection with the Bridge Financing. In connection with Mr. Rosenblum's appointment as the Company's Chief Executive Officer, on December 11, 2017, the Company and Mr. Rosenblum finalized the terms of his employment and entered into an employment agreement (the "Rosenblum Employment Agreement"). Mr. Rosenblum shall have such duties, responsibilities and authority which shall include, but not be limited to the responsibility for the overall management, direction and strategy of the Company. The Company shall pay Mr. Rosenblum a salary at a rate of Three Hundred Thousand and 00/100 Dollars ($300,000) per year (the "Initial Base Salary"). The Initial Base Salary shall increase to an annual rate of Three Hundred and Sixty Thousand Dollars ($360,000) (the "Base Salary") upon the Company closing a financing of at least Five Million Dollars ($5,000,000). Mr. Rosenblum shall be eligible for an annual performance-based cash bonus of up to 100% of the Base Salary (as further defined in the Rosenblum Employment Agreement"). The Rosenblum Employment Agreement is for a term of three (3) years and will be automatically renewed for one year periods, unless otherwise terminated by the Company or Mr. Rosenblum. Upon execution of the Rosenblum Employment Agreement the Company agreed to issue restricted shares equal to $300,000 valued at the offering price of the next equity offering of the Company ("RSU") and an option to purchase an aggregate $600,000 valued at the offering price of the next equity offering of the Company at an exercise price equal to the market price for the next equity offering of the Company (the "Options"). One-third of these Options shall vest immediately, another third on the first anniversary of the Rosenblum Employment Agreement, and the final third on the second anniversary of the Rosenblum Employment Agreement. The RSUs shall vest 50% immediately upon issuance and 25% on each of the first and second anniversaries of the Rosenblum Employment Agreement. If the Company terminates Mr. Rosenblum's employment without just cause or if Mr. Rosenblum's employment is terminated due to Disability (as defined therein), Mr. Rosenblum shall be entitled to receive, in addition to any accrued and unpaid Base Salary, plus any accrued but unused vacation time and unpaid expenses that have been earned as of the date of such termination, the following severance payments (the "Severance Payments"): (i) equal monthly installments at the applicable Base Salary rate then in effect, as determined on the first day of the calendar month immediately preceding the day of termination, to be paid beginning on the first day of the month following such termination and continuing until the later of (A) the expiration of the Term or (B) the expiration of (i) six (6) months following the effective termination date; provided, however, that if the Company terminates the Agreement without Just Cause (as defined in the Rosenblum Employment Agreement) within six (6) months of the effective date, then Mr. Rosenblum will only be entitled to three (3) months of severance instead of six (6) months; and (ii) during the Severance Period (as defined in the Rosenblum Employment Agreement), health and life insurance benefits substantially similar to those which Mr. Rosenblum was receiving or entitled to receive immediately prior to termination; provided, however, such insurance benefits shall be reduced to the extent comparable benefits during such period following Mr. Rosenblum's termination, and any benefits actually received shall be reported by Mr. Rosenblum to the Company. The Company will reimburse Mr. Rosenblum for any reasonably travel and relocation expenses.

(36)	During December 2017, the Company entered into those certain forbearance and lock up letter agreements with a debtor which holds convertible debentures in the principal amount of $25,312 as of December 5, 2017, whereby the debtor agreed that, without prior written consent of the Company, the debtor will not, directly or indirectly, (i) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of common stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, (ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, whether any such transaction is to be settled by delivery of common stock or other securities, in cash or otherwise, (iii) except as provided for, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of the Company, or (iv) publicly disclose the intention to do any of the foregoing for a period of the earlier of (a) June 5, 2018 or (2) the consummation of a qualified offering, herein deemed as an offering by the Company of $3,000,000 or more. Additionally, the debtor agreed that they will forbear from enforcing their rights and remedies against any defaults which may exist historically, currently or in the future through June 5, 2018 under the convertible debentures. The forbearance and lock up letter agreements automatically terminate upon the earlier of (i) inability to raise a minimum of $550,000 in capital on or before December 31, 2017; (ii) June 5, 2018; or (iii) the consummation of a qualified offering of at least $3,000,000 by the Company.

(37)	On January 12, 2018, the Company received letters from four (4) debtors which hold convertible debentures with principal balances totaling $3,162,955 as of June 30, 2017 where the debtors forbear against any historical and future events of default and remedies through February 15, 2018. Further, the maturity date was extended through February 15, 2018. As part of the letters, the Company agreed not to initiate any new financing arrangements without the consent of the debtors.

(38)	On January 12, 2018, the Company received a letter from a lender who holds two unsecured notes payable with principal balances totaling $550,000 as of June 30, 2017 where the lender forbears against any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018 in exchange for 12,000 shares of common stock.

(39)	On December 22, 2017, the Company entered into a Services Agreement (the "Cleveland Clinic Agreement") with the Cleveland Clinic Foundation d.b.a. Cleveland Clinic, an Ohio nonprofit corporation ("Cleveland Clinic"). Pursuant to the Cleveland Clinic Agreement, the Company will be providing services to Cleveland Clinic as agreed to by the parties in any mutually agreed form pursuant to a "Statement of Work". Pursuant to the Statement of Work included in the Cleveland Clinic Agreement, the Company will provide monitoring services to Cleveland Clinic's expected beneficiary diabetic population within the Cleveland Clinic Medicare ACO. The initial term of the Cleveland Clinic Agreement is for three years and shall automatically renew after the term for a successive twelve (12) month period from year to year unless sooner terminated by either party in accordance with the terms of the Cleveland Clinic Agreement. As consideration for the Company's Services, the Company is to receive a fixed monthly fee per Covered Diabetic Patient (as defined in the Cleveland Clinic Agreement). In addition, at such time the Cleveland Clinic Accountable Care Organization ("CCACO") shall receive a shared savings payment from the Centers for Medicare and Medicaid Services, CCACO shall share such savings with the Company based on a formula defined in the Cleveland Clinic Agreement. Cleveland Clinic may, by written notice to the Company, terminate the Agreement, any purchase order or any portion of a purchase order if the Company (i) is in material breach of any of the terms and conditions of the Cleveland Clinic Agreement or any Purchase Order, which breach in not cured within thirty (30) days after notification of such breach, (ii) terminates or suspends its business, becomes insolvent, or becomes subject to any bankruptcy or insolvency proceeding under Federal or State law. Cleveland Clinic further may terminate the Cleveland Clinic Agreement, any Purchase Order or any portion of any Purchase Order for convenience upon ninety (90) days' prior written notice to Company ("Termination for Convenience"). In connection with any Termination for Convenience, Cleveland Clinic will reimburse Company for the actual cost reasonably incurred for work in process up to the time of cancellation, as well as any non-cancellable contract of Company, or non-cancellable purchase order to a third party, entered into for the benefit of Cleveland Clinic. The Cleveland Clinic Agreement is nonexclusive, and Cleveland Clinic may contract with others to perform similar services. Accordingly, the Company may also perform similar services for others.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q and other reports filed by ActiveCare, Inc. (the "Company") from time to time with the SEC (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by Company's management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the Filings, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions as they relate to the Company or the Company's management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company's business, industry, and the Company's operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States ("US GAAP"). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by US GAAP and does not require management's judgment in its application. There are also areas in which management's judgment in selecting any available alternative would not produce a materially different result.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to assist in better understanding our operations and our present business environment. This MD&A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements for the fiscal years ended September 30, 2016 and 2015, and the accompanying notes thereto, contained in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016.

Overview

ActiveCare, Inc. is a Delaware corporation, formed March 5, 1998. Our fiscal year ends on September 30. Our focus is on the monitoring of individuals with diabetes. Diabetes is a pandemic that, as of 2014, affected approximately 9% of the U.S. population or 29 million Americans. Studies have shown that the annual cost of treating an individual with diabetes and the comorbidities associated with the disease is approximately $13,700 per year. This combination costs the U.S. health system up to $245 billion annually. A major driver of diabetic-related claims is the lack of adherence to regular glucose monitoring. It is estimated that less than 20% of diabetics monitor their blood glucose levels on a regular basis, despite physician recommendations. ActiveCare offers what it believes to be a unique approach to caring for chronic illnesses such as diabetes by adding a "human touch" and monitoring component to traditional disease management. To that end, ActiveCare has created a "CareCenter" where its highly trained staff reaches out to assist its members in real-time. Historically, disease management, such as diabetes has been reserved for only the extreme high risk and high claim members. However, the ActiveCare solution brings clarity and light to the diabetic population, identifying who needs help today. Knowing who to worry about allows for the necessary action to be taken today to avoid major and costly events in the future.

Going Concern

We have financed operations primarily through the sale of equity securities, long-term debt and short-term debt. Until revenues are sufficient to meet our needs, we will continue to attempt to secure financing through equity or debt securities. We continue to incur negative cash flows from operating activities and net losses. We had minimal cash, negative working capital, and negative total equity as of ~~March~~June 3130, 2017 and September 30, 2016. In addition, ~~and~~the ~~are~~Company is in technical default on certain notes payable although the lenders in each case are working with ~~respect~~the Company to ~~certain~~resolve ~~debt~~the defaults. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The financial statements included in this report do not include any adjustments that might result from the outcome of this uncertainty.

In order for us to eliminate substantial doubt about our ability to continue as a going concern, we must achieve profitability, generate positive cash flows from operating activities and obtain the necessary debt or equity funding to meet our projected capital investment requirements. Our management's plans with respect to this uncertainty consist of raising additional capital by issuing debt or equity securities and increasing the sales of our products and services. If we are successful in completing the Offering, we believe the net proceeds of the Offering together with anticipated growth of the business will be sufficient to eliminate substantial doubt about our ability to continue as a going concern. There can be no assurance, however, that we will be able to complete the Offering, raise sufficient additional capital or that revenues will increase rapidly enough to offset operating losses. If we are unable to increase revenues or obtain additional financing, we will be unable to continue the development of our products and services and may have to cease operations.

Research and Development Program

During the three and ~~six~~nine months ended ~~March~~June 3130, 2017, we spent approximately $8356,000 and $~~251~~307,000, respectively, compared to $5958,000 and $81139,000 during the same periods in 2016, on research and development related to chronic illness monitoring. The research and development program focuses on ongoing improvements to methods and systems along with new technologies for the capture and analysis of data, as well as scalable architectures to migrate to production applications and deployments.

Critical Accounting Policies

Our condensed consolidated financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (or US GAAP).

This Management's Discussion and Analysis of Financial Condition and Results of Operations discusses our condensed consolidated financial statements, which have been prepared in accordance with US GAAP. The preparation of these condensed consolidated financial statements requires making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenues and expenses for the reporting periods. On an ongoing basis, we evaluate such estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ (perhaps significantly) from these estimates under different assumptions or conditions. The following summary includes accounting policies that we deem to be most critical to our business. Management considers an accounting estimate to be critical if:

•	It requires assumptions to be made that were uncertain at the time the estimate was made, and

•	Changes in the estimate or different estimates that could have been selected could have a material impact on the consolidated results of operations or financial condition.

Our significant accounting policies are described in Note 2 to our audited consolidated financial statements appearing in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016 and are hereby incorporated by reference.

Liability Related to Options and Warrants

The fair value of each stock option or warrant is estimated on the date of grant using a binomial option-pricing model or the Monte Carlo valuation model. The expected life of stock options or warrants represents the period of time that the stock options or warrants are expected to be outstanding, based on the simplified method. Expected volatilities are based on historical volatility of the Company's common stock, among other factors. The Company uses the simplified method within the binomial option-pricing valuation model due to the Company's short trading history and limited history of exercises of stock options or warrants. The risk-free rate related to the expected term of the stock options or warrants is based on the US Treasury yield curve in effect at the time of grant. The dividend yield is zero.

During the three and ~~six~~nine months ended ~~March~~June 3130, 2017, the Company measured the fair value of warrants classified as liabilities on the date of issuance and on each re-measurement date using the Monte Carlo valuation model. For this liability, the Company and valuation specialists developed their own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company's common stock, stock price volatility, the contractual term of the warrants, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants uses Level 3 measurements.

Fair Value of Financial Instruments

We measure the fair values of our assets and liabilities using the US GAAP hierarchy. The carrying amounts reported in the condensed consolidated balance sheets for cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to the short-term nature and liquidity of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. The carrying amounts reported for notes payable approximate fair value because the underlying instruments are at interest rates which approximate current market rates.

Accounts Receivable

Inventory

Inventory consists of glucometers and diabetic supplies and is recorded at the lower of cost or market, cost being determined using the first-in, first-out ("FIFO") method. Inventory held by distributors is reported as inventory until the supplies are shipped to the end user by the distributor. We estimate an inventory reserve for obsolescence and excessive quantities. Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term.

Goodwill

Goodwill is reviewed for impairment annually or more frequently when an event occurs or circumstances change that indicate that the carrying value may not be recoverable. Our annual testing date is September 30. The estimates of fair value are based on the best information available as of the date of the assessment, which primarily incorporates management assumptions about expected future cash flows and the Company's overall market capitalization. Future cash flows can be affected by changes in industry or market conditions. Goodwill was impaired by $826,000 as of September 30, 2015, due, in part, to a potentially long-term reduction in the market capitalization of the Company subsequent to September 30, 2015. As a result, the Company no longer presents goodwill as an asset in its balance sheets.

Impairment of Long-Lived Assets

Purchased intangible assets with finite lives are amortized using the straight-line method over the estimated economic lives of the assets, which range from two to twenty years. Long-lived assets, including intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. No long-lived assets were considered to be impaired as of ~~March~~June 3130, 2017.

Extinguishment of Debt

We compare the cash flows of a modified note payable on the date of modification to the original terms of the note payable. The original note is derecognized and a gain or loss on the extinguishment is recognized if the present value of the cash outflows of the original note payable is 10% or more than the modified note payable.

Revenue Recognition

During the three and ~~six~~nine months ended ~~March~~June 3130, 2017 and the comparable periods from 2016, revenues came from Chronic Illness Monitoring products and services. Information regarding revenue recognition policies relating to Chronic Illness Monitoring is contained in the following paragraphs.

Chronic Illness Monitoring

Chronic Illness Monitoring revenues are recognized when persuasive evidence of an arrangement exists, delivery of the product or service to the end user has occurred, prices are fixed or determinable, and collection is reasonably assured.

3441

We enter into agreements with insurance companies, disease management companies, third-party administrators, and self-insured companies (collectively, the customers) to lower medical expenses by distributing diabetic testing products and supplies to employees (end users) covered by their health plans or the health plans they manage. Cash is due from the customer or the end user's health plan as the products and supplies are deployed to the end user. We also monitor the end user's test results in real-time with our 24x7 CareCenter. Customers who are billed separately for monitoring are obligated to pay as the service is performed and revenue is recognized ratably over the period of the contract. The term of these contracts is generally one year and, unless terminated by either party, will automatically renew annually until terminated. Collection terms are net 30 days after claims are submitted. There is no contingent revenue in these contracts.

We also enter into agreements with distributors who take title to products and distribute those products to the end user. Delivery is considered to occur when the supplies are delivered by the distributor to the end user. Cash is due from the distributor, the customer or the end user's health plan as initial products are deployed to the end user. Subsequent sales (resupplies) are shipped directly from us to the end user and cash is due from the customer or the end user's health plan.

Shipping and handling fees are typically not charged to end users. The related freight costs and supplies directly associated with shipping products to end users are included as a component of cost of revenues.

Multiple-Element Arrangements

Sales of Chronic Illness Monitoring products and services contain multiple elements. We evaluate each element in a multiple-element arrangement to determine whether it represents a separate unit of accounting. In order to account for elements in a multiple-element arrangement as separate units of accounting, the deliverables must have stand-alone value upon delivery. In determining whether monitoring services have stand-alone value, the nature of our monitoring services, whether we sell supplies to new customers without monitoring services, and availability of monitoring services from the other vendors are factors that are considered.

When multiple elements included in an arrangement are separable into different units of accounting, the arrangement consideration is allocated to the identified separate units of accounting based on the relative selling prices. Multiple-element arrangements accounting guidance provides a hierarchy to use when determining the relative selling price for each unit of accounting. Vendor-specific objective evidence (VSOE) of selling price, based on the price at which the item is regularly sold by the vendor on a stand-alone basis, should be used if it exists. If VSOE of selling price is not available, third-party evidence (TPE) of selling price is used to establish the selling price if it exists. If VSOE of selling price and TPE of selling price are not available, then the best estimate of selling price is to be used. Total consideration under our multiple-element contracts is allocated to supplies and monitoring through application of the relative fair value method or selling price.

Stock-Based Compensation

We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the statement of operations over the period during which the employee is required to provide service in exchange for the award — the requisite service period. The grant-date fair values of the equity instruments are estimated using option-pricing models adjusted for the unique characteristics of those instruments.

Results of Operations

Three Months Ended ~~March~~June 3130, 2017 and 2016

Revenues

Revenues for the three months ended ~~March~~June 3130, 2017 were $1,~~853~~196,000 compared to $12,~~597~~176,000 for the same period in 2016, ana ~~increase~~decrease of $~~256~~980,000. The ~~increase~~decrease is primarily due to anthe ~~increase~~loss inof ~~monitoring~~significant ~~supplies~~customers ~~revenues,~~during ~~which~~the ~~increase~~nine ~~was~~months ~~offset,~~ended inJune ~~part~~30, ~~by a decrease in monitoring revenues~~2017.

Cost of Revenues

Cost of revenues for the three months ended ~~March~~June 3130, 2017 was $1848,~~225,~~000, compared to $1,~~262~~382,000 for the same period in 2016, a decrease of $37534,000. The decrease in cost of revenues is primarily due to the loss of significant customers during the nine months ended June 30, 2017 and a decrease in the cost of supplies from our vendors.

Gross Profit

Gross profit for the three months ended ~~March~~June 3130, 2017 was $~~628~~348,000, compared to $~~335~~794,000 for the same period in 2016, ana ~~increase~~decrease of $~~293~~446,000 as a result of anthe ~~increase~~decrease in revenues and ~~a reduction in the~~ cost of revenues. ~~We expect gross profit to improve throughout the remainder of fiscal year 2017 as we acquire more Chronic Illness Monitoring members and retain existing members.~~

3542

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended ~~March~~June 3130, 2017 were $13,~~947~~225,000, compared to $2,~~428~~170,000 for the same period in 2016, aan ~~decrease~~increase of $~~481~~1,055,000. Included in selling, general and administrative expenses is $~~628~~1,461,000 and $1,~~073~~004,000 of stock-based compensation incurred during the three months ended ~~March~~June 3130, 2017 and 2016, respectively. The ~~decrease~~increase in expenses incurred is due primarily to ~~decreases~~a write off of prepaid legal and professional fees related to an equity financing during the three months ended June 30, 2017 and increases in stock-based compensation expense and ~~legal~~payroll and ~~professional~~payroll ~~fees~~tax expenses, offset, in part, by ana ~~increase~~decrease in ~~payroll~~other legal and ~~payroll~~professional ~~tax expenses~~fees.

Research and Development Expenses

Research and development expenses for the three months ended ~~March~~June 3130, 2017 were $8356,000, compared to $5957,000 for the same period in 2016, ana ~~increase~~decrease of $241,000. ~~The increase was due to continued investing in research and development as we develop new products and platforms for Chronic Illness Monitoring.~~ We expect to continue invest into innovating new products as funds become available.

Gain ~~(Loss)~~ on Derivatives Liability

Gain on derivatives liability for the three months ended ~~March~~June 3130, 2017 was $~~144~~64,000, compared to ~~a loss of~~ $25,~~853~~603,000 for the same period in 2016. The derivative liability recorded as of ~~March~~June 3130, 2017 and 2016 relate to variable conversion price adjustments and put options on outstanding notes payable and warrants.

Interest Expense

Interest expense for the three months ended ~~March~~June 3130, 2017 was $32,~~102~~199,000, compared to $~~631~~814,000 for the same period in 2016, an increase of $21,~~471~~385,000. The increase was primarily due to amortization of note payable discounts related to warrants, shares and other costs accrued, issued or paid in connection with notes payable agreements entered into and/or amended during the fiscal years 2017 and 2016 as well as fees and interest related to cash advances made during the fiscal years 2017 and 2016.

Loss on ~~Extinguishment of Debt~~Settlement

During ~~January~~the three months ended June 30, 2017, we ~~terminated~~assessed athe ~~note~~potential ~~payable~~outcome toof a ~~third~~lawsuit ~~party for cash~~ and ~~incurred~~recorded ~~no additional fees. The note had an associated derivative that resulted in~~ a ~~gain~~contingent onliability ~~extinguishment~~ of ~~debt of~~ $64750,000 for a potential settlement.

~~During~~Net ~~March~~Income 2017, we modified notes payable to third parties to add additional borrowing capabilities under existing note payable agreements. These modifications resulted in an aggregate loss on extinguishment of debt of $559,000.(Loss)

~~During~~Net ~~February~~loss ~~2016,~~for wethe ~~terminated~~three ~~notes~~months ~~payable~~ended toJune ~~third parties with outstanding principal~~30, ~~net of discounts~~2017, ofwas $~~697~~5,~~000 and accrued interest of $39~~815,000, ~~for~~compared ~~$1,123,000~~to innet ~~cash,~~income ~~and incurred fees in connection with these terminations~~ of $503,~~000 to third parties and $75~~350,000 tofor athe ~~related~~same ~~party,~~period ~~which resulted~~ in a2016, ~~loss~~for onthe ~~extinguishment~~reasons ofdescribed ~~debt of $512,000~~above.

Dividends on Preferred Stock

36Dividends on preferred stock for the three months ended June 30, 2017, were $59,000, compared to $46,000 for the same period in 2016. The decrease was primarily due to the accretion of dividends payable for July 1, 2016 through March 31, 2017 related to the expiration of letter agreements that ceased dividends beginning July 1, 2016.

~~During~~Nine ~~February~~Months ~~2016,~~Ended weJune ~~modified notes payable to related parties to subordinate to other notes payable also issued during February 2016. The modifications also reduced the conversion price of the related-party notes to $~~30~~.00 per common share~~, ~~which~~2017 ~~was below the fair value of the stock on the date of the modifications,~~ and ~~limited conversion to a maximum of 58,500 shares of common stock. The modifications resulted in a loss on extinguishment of debt of $2,032,000. Also during February~~ 2016, we modified a note payable to subordinate it to notes payable also issued during February 2016, and reduced the conversion price of the modified note to $30.00 per common share, which resulted in a loss on extinguishment of debt of $381,000.

During February 2016, we modified a note payable to related parties to bifurcate the note into two notes payable. We assigned the majority bifurcated note and part of the smaller bifurcated note to a third party, which then converted the amounts into a convertible note payable. The fair value of the conversion feature was recorded as a derivative liability and resulted in a loss on extinguishment of debt of $182,000.

During February 2016, notes payable with outstanding principal balances totaling $350,000 plus accrued interest of $16,000 were converted into 18,576 shares of common stock, at $20.00 per common share, which was below the fair value of the stock on the date of conversion. The conversion resulted in a loss on induced conversion of debt of $148,000 and a gain on extinguishment of debt of $64,000.

Loss on Induced Conversions of Debt

During February 2016, we converted notes payable with outstanding principal balances totaling $233,333 into 11,600 shares of common stock, at $20.00 per common share, which was below the fair value of the Company's stock on the date of conversion, which resulted in a loss on induced conversion of debt of $231,000.

During February 2016, we converted notes payable with outstanding principal balances totaling $350,000 plus accrued interest of $16,000 into 18,576 shares of common stock, at $20.00 per common share, which was below the fair value of the stock on the date of conversion. The conversion resulted in a loss on induced conversion of debt of $148,000 and a gain on extinguishment of debt of $64,000.

Net Loss

Net loss for the three months ended March 31, 2017, was $4,855,000 compared to a net loss of $8,772,000 for the same period in 2016, for the reasons described above.

Dividends on Preferred Stock

Dividends on preferred stock for the three months ended March 31, 2017, were $34,000, compared to $250,000 for the same period in 2016. The decrease was primarily due to the conversion of Series F Preferred into convertible notes payable and common stock during February 2016 and the reduction in the Series E Preferred dividend rate.

Deemed Dividends on Redemption of Preferred Stock

During February 2016, we redeemed all 5,361 outstanding shares of our Series F Convertible Preferred Stock ("Series F preferred stock") and related accrued dividends in exchange for 20,005 shares of common stock and notes payable of $5,900,000. We also exchanged warrants held by Series F preferred stockholders for the purchase 11,070 shares of common stock for new warrants for the purchase of the same number of shares with new terms. We recorded a deemed dividend of $6,484,000 as a result of these transactions.

Six Months Ended March 31, 2017 and 2016

Revenues

Revenues for the ~~six~~nine months ended ~~March~~June 3130, 2017 were $34,~~715~~911,000 compared to $35,~~685~~861,000 for the same period in 2016, ana ~~increase~~decrease of $30950,000. The ~~increase~~decrease is primarily due to anthe ~~increase~~loss inof ~~monitoring~~significant ~~supplies~~customers ~~revenues,~~during ~~which~~the ~~increase~~nine ~~was~~months ~~offset,~~ended inJune ~~part~~30, ~~by a decrease in monitoring revenues~~2017.

Cost of Revenues

Cost of revenues for the ~~six~~nine months ended ~~March~~June 3130, 2017 was $23,~~525~~373,000, compared to $24,~~855~~237,000 for the same period in 2016, a decrease of $~~330~~864,000. The decrease in cost of revenues is primarily due to the loss of significant customers during the nine months ended June 30, 2017 and a decrease in the cost of supplies from our vendors.

Gross Profit

Gross profit for the ~~six~~nine months ended ~~March~~June 3130, 2017 was $1,~~190~~538,000, compared to $~~829~~1,623,000 for the same period in 2016, ana ~~increase~~decrease of $~~361~~85,000 as a result of an increase in revenues and a reduction in the cost of revenues. ~~We expect gross profit to improve throughout the remainder of fiscal year 2017 as we acquire more Chronic Illness Monitoring members and retain existing members.~~

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the ~~six~~nine months ended ~~March~~June 3130, 2017 were $36,~~157~~382,000, compared to $46,~~774~~944,000 for the same period in 2016, a decrease of $1562,~~617,~~000. Included in selling, general and administrative expenses is $~~640~~2,101,000 and $23,~~253~~258,000 of stock-based compensation incurred during the ~~six~~nine months ended ~~March~~June 3130, 2017 and 2016, respectively. The decrease in expenses incurred is due primarily to decreases in stock-based compensation expense and legal and professional fees, offset, in part, by a write off of prepaid legal and professional fees related to an equity financing during the nine months ended June 30, 2017 and an increase in payroll and payroll tax expenses.

Research and Development Expenses

Research and development expenses for the ~~six~~nine months ended ~~March~~June 3130, 2017 were $~~251~~307,000, compared to $81139,000 for the same period in 2016, an increase of $~~170~~168,000. The increase was due to ~~continued~~more intense investing in research and development as we continue to develop new products and platforms for Chronic Illness Monitoring. We expect to continue invest into innovating new products as funds become available.

Gain ~~(Loss)~~ on Derivatives Liability

Gain on derivatives liability for the ~~six~~nine months ended ~~March~~June 3130, 2017 was $~~166~~230,000, compared to ~~a loss of~~ $2,~~807~~797,000 for the same period in 2016. The derivative liability recorded as of ~~March~~June 3130, 2017 and 2016 relate to variable conversion price adjustments and put options on outstanding notes payable and warrants.

Interest Expense

Interest expense for the ~~six~~nine months ended ~~March~~June 3130, 2017 was $46,~~658~~856,000, compared to $1,~~122~~935,000 for the same period in 2016, an increase of $34,~~536~~921,000. The increase was primarily due to amortization of note payable discounts related to warrants, shares and other costs accrued, issued or paid in connection with notes payable agreements entered into and/or amended during the fiscal years 2017 and 2016 as well as fees and interest related to cash advances made during the fiscal years 2017 and 2016.

37Loss on Settlement

During the nine months ended June 30, 2017, we assessed the potential outcome of a lawsuit and recorded a contingent liability of $750,000 for a potential settlement.

Loss on Extinguishment of Debt

During the ~~six~~nine months ended ~~March~~June 3130, 2017, in addition to the loss on extinguishment described below, we recognized a gain on extinguishment of debt of $40,000 on the partial extinguishment of a derivative on a note payable as payments were made.

During November 2016, we entered into a forbearance agreement related to a secured note payable and related line of credit which requires the issuance of a warrant for the purchase of 130,000 shares of common stock upon the closing of the offering, which resulted in a loss on extinguishment of debt of $2,044,000 related to the extinguishment of debt related to the forbearance agreement on a secured note payable and related line of credit.

During January 2017, we terminated a note payable to a third party for cash and incurred no additional fees. The note had an associated derivative that resulted in a gain on extinguishment of debt of $64,000.

During March 2017, we modified notes payable to third parties to add additional borrowing capabilities under existing note payable agreements. These modifications resulted in an aggregate loss on extinguishment of debt of $559,000.

During February 2016, we terminated notes payable to third parties with outstanding principal, net of discounts, of $697,000 and accrued interest of $39,000, for $1,123,000 in cash, and incurred fees of $50,000 to third parties and $75,000 to a related party, which resulted in a loss on extinguishment of debt of $512,000 in connection with these terminations.

During February 2016, we modified notes payable to related parties to subordinate to notes payable also issued during February 2016. The modifications also reduced the conversion price to $30.00 per common share, which was below the fair value of the stock on the date of the modifications, and limited conversion to a maximum of 58,500 shares of common stock, which was below the fair value of the stock on the date of the modifications. The modifications resulted in a loss on extinguishment of debt of $2,032,000. Also during February 2016, we modified a note payable to subordinate to notes payable also issued during February 2016, reducing the conversion price to $30.00 per common share, which resulted in a loss on extinguishment of debt of $381,000.

During June 2016, $14,000 of principal and $11,000 of accrued interest converted into 953 shares of common stock, pursuant to the terms of a note payable, which resulted in a loss on extinguishment of debt of $15,000.

Loss on Induced Conversions of Debt

Gain on Liability Settlements

During the nine months ending June 30, 2016, we entered into agreements which settled payables due to third parties, which resulted in gains totaling $295,000.

Net Loss

Net loss for the ~~six~~nine months ended ~~March~~June 3130, 2017, was $915,~~209~~024,000 compared to a net loss of $117,~~091~~741,000 for the same period in 2016, for the reasons described above.

Deemed Dividend on Preferred Stock

During February 2016, we redeemed all 5,361 outstanding shares of our Series F preferred stock and related accrued dividends in exchange for 20,005 shares of common stock and notes payable of $5,900,000. We also exchanged warrants held by Series F preferred stockholders for the purchase 11,070 shares of common stock for new warrants for the purchase of the same number of shares with new terms. We recorded a deemed dividend of $6,484,000 as a result of these transactions.

Dividends on Preferred Stock

Dividends on preferred stock for the ~~six~~nine months ended ~~March~~June 3130, 2017, were $68127,000, compared to $~~653~~699,000 for the same period in 2016. The decrease was primarily due to the conversion of Series F Preferred into convertible notes payable and common stock during February 2016 and the reduction in the Series E Preferred dividend rate.

Liquidity and Capital Resources

Our primary sources of liquidity are the proceeds from the sale of our equity securities and debt. We have not historically financed operations from cash flows from operating activities. We anticipate that we will continue to seek funding to supplement revenues from the sale of our products and services through the sale of equity and debt securities until we achieve positive cash flows from operating activities. There is no guarantee that we will be able to raise capital on terms to favorable to the Company or at all.

Our cash balance as of ~~March~~June 3130, 2017, was $~~493~~114,000. At that time, we had a working capital deficit of $2228,~~711~~732,000, compared to a working capital deficit of $12,871,000 as of September 30, 2016. The increase in working capital deficit is primarily due to additions to accounts payable, accrued expenses, notes payable, and derivatives liabilities related to the issuance of notes payable and related warrants and reduction of prepaid expenses and other current assets, offset, in part, by additions to ~~cash,~~inventory ~~accounts~~and ~~receivable,~~contingent ~~and~~notes ~~inventory~~receivable.

Operating activities for the ~~six~~nine months ended ~~March~~June 3130, 2017, used cash of $~~478~~618,000, compared to $2,~~244~~803,000 for the same period in 2016. The decrease in cash used in operating activities is primarily due to the increase in accounts payable and accrued expenses and decrease in prepaid expenses during the ~~six~~nine months ended ~~March~~June 3130, 2017, compared to the same period in 2016, offset, in part, by the increase in net loss after adjustment for non-cash items and increase in accounts receivable and inventory during the ~~six~~nine months ended ~~March~~June 3130, 2017, compared to the increase in accounts receivable and ~~decrease in~~ inventory for the same period in 2016.

Investing activities for the ~~six~~nine months ended ~~March~~June 3130, 2017, used cash of $3503,000, compared to $4,000 for the same period in 2016. The decrease in cash used in investing activities is primarily due to the acquisition of a contingent note receivable during the nine months ended June 30, 2017 and decreased purchases of property and equipment during the ~~six~~nine months ended ~~March~~June 3130, 2017, compared to the same period in 2016.

Financing activities for the ~~six~~nine months ended ~~March~~June 3130, 2017, provided cash of $~~806~~1,068,000, compared to $2,~~224~~779,000 for the same period in 2016. The decrease in cash provided by financing activities is primarily due to a net decrease in proceeds from the issuance of notes payable to related and third parties and net increase in principal payments on notes payable during the ~~six~~nine months ended ~~March~~June 3130, 2017, compared to the same period in fiscal year 2016.

We had an accumulated deficit as of March 31, 2017, of $117,456,000, compared to $108,179,000 as of September 30, 2016. Our total stockholders' deficit as of March 31, 2017, was $28,749,000 compared to $20,111,000 as of September 30, 2016. These changes were primarily due to our net loss during the six months ended March 31, 2017.45

~~During~~We ~~April~~had ~~2017,~~an ~~the~~accumulated ~~Company~~deficit ~~received~~as aof ~~letter~~June ~~from a significant customer dated April 25~~30, 2017, ~~notifying the Company~~ of ~~the~~$123,330,000, ~~termination~~compared ~~its~~to ~~customer~~$108,179,000 ~~agreement~~as ~~effective~~of ~~July~~September 130, ~~2017~~2016. Our ~~This~~total ~~customer~~stockholders' ~~represented~~deficit ~~56%~~as ~~and 47%~~ of ~~revenues~~June ~~during the three and six months ended March 31~~30, 2017, ~~respectively.~~was If$34,543,000 ~~the~~compared ~~Company is not able~~ to ~~replace~~$20,111,000 ~~the~~as ~~revenues~~of ~~generated~~September ~~by this customer~~30, of2016. These ~~which~~changes ~~there~~were ~~can~~primarily bedue noto ~~assurance,~~our itnet ~~will~~loss ~~result~~and individends aaccrued ~~material~~during ~~reduction~~the innine ~~revenues~~months ~~beginning~~ended inJune ~~July~~30, 2017.

AsDuring ofApril 2017, the ~~date~~Company ofreceived ~~this~~a ~~report,~~letter ~~notes~~from ~~payable~~a ~~due~~significant tocustomer ~~unrelated~~dated ~~parties~~April ~~with~~25, ~~total~~2017 ~~principal~~notifying ~~amounts~~the Company of ~~$11,501,114,~~the ~~owing~~termination asits ofcustomer ~~March~~agreement 31effective July 1, 2017,. ~~are~~This ~~past~~customer ~~due,~~represented inapproximately ~~default,~~67% and ~~unpaid. In~~52% ~~addition~~of revenues during the three and nine months ended June 30, ~~notes~~2017, ~~payable~~respectively. ~~due~~If the Company is not able to ~~related~~replace ~~parties~~the ~~with~~revenues ~~total~~generated ~~principal~~by ~~amounts~~this customer, of ~~$3,875,335,~~which asthere ofcan ~~March~~be ~~31,~~no ~~2017~~assurance, ~~are~~it ~~past~~will ~~due,~~result in ~~default~~a ~~and~~material ~~unpaid. These~~reduction ~~defaults~~in ~~include~~revenues ~~obligations~~beginning ~~owed~~in toJuly ~~Partners~~2017. ~~for~~On ~~Growth~~December 22, ~~which~~2017, ~~are~~the inCompany ~~excess~~entered ofinto ~~$2,875,000~~a ~~and~~Services ~~which~~Agreement ~~are~~that ~~secured~~is byexpected ~~substantially~~to ~~all~~significantly ~~assets~~improve ofrevenues during the ~~Company~~fiscal year ended September 30, 2018.

~~Recent~~As ~~Accounting~~of ~~Pronouncements~~the date of this report, notes payable due to unrelated parties with total principal amounts in the aggregate of $2,776,046, owing as of June 30, 2017, are past due, in default, and unpaid. In addition, notes payable due to related parties with total principal amounts of $27,980, as of June 30, 2017, are past due, in default and unpaid. These defaults include principal obligations owed to Partners for Growth, our secured lender, which are in excess of $2,700,000 and which are secured by substantially all assets of the Company. Other notes are currently in technical default. However, as of the time of this report, the lenders have informally agreed to work with us until such time as the notes can be repaid and some of the lenders have provided bridge capital since going in default.

Recent Accounting Pronouncements

In May 2017, the FASB issued ASU 2017-09, Stock Compensation: Scope of Modification Accounting. The amendments in this ASU provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years and interim periods beginning after December 15, 2017, which will be effective for the Company for the quarter ending December 31, 2018. Early adoption is permitted. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down-round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for fiscal years and interim periods beginning after December 15, 2018, which will be effective for the Company for the quarter ending December 31, 2019. Early adoption is permitted. The Company is assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity.

Recent Developments

Subsequent to ~~March~~June 3130, 2017, the Company entered into the following agreements and transactions:

(1)	On August 2, 2017, we received a cash advance from a third party in the amount of $100,000, which incurs fees of $1,500 per day until repaid. During November 2017, the Company amended the advance to be callable at any time, due May 30, 2018, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date.

(2)	On August 7, 2017, we received a cash advance from a third party in the amount of $50,000, which incurs fees of $750 per day until repaid. During November 2017, the Company amended the advance to be callable at any time, due May 30, 2018, and to become convertible into shares of the Company's common stock at the most favorable rate available as of the date of the agreement. The conversion rate may adjusted for any more favorable conversion terms provided to any other note holder at a future date.

(3)	During August 2017, we received letters related to unsecured notes payable with third parties with principal balances totaling $5,900,000 as of June 30, 2017 where the lenders waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017.

(4)	During August 2017, we received a letter related to an unsecured note payable with a third party with a principal balance of $334,464 as of June 30, 2017 wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017. On December 18, 2017, another letter was received wherein the lender waived any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018.

(5)	During August 2017, we received a letter related to secured and unsecured notes payable with entities controlled by our former chief executive officer and Executive Chairman of the Board of Directors, who was in office at the time, with principal balances of $1,721,100, $1,303,135, $250,000 and $25,463 as of June 30, 2017, wherein the lenders waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017. On December 18, 2017, another letter was received wherein the lender waived any historical and future events of default through January 12, 2018 and extended maturity date was extended through January 12, 2018.

(6)	During August 2017, we received a letter related to an unsecured note payable with a former Executive Chairman of the Board of Directors with a principal balance of $542,004 as of June 30, 2017 wherein the lender waived any historical and future events of default through August 24, 2017 and extended the maturity date through August 24, 2017. On December 18, 2017, another letter was received wherein the lender waived any historical and future events of default through January 12, 2018 and extended maturity date was extended through January 12, 2018.

(7)	During July 2017, we granted 1,562 shares of common stock, with a value of $12,496 on the date of grant, to the former Executive Chairman and Chief Executive Officer, who was in office at the time, as a bonus for services performed during the three months ended June 30, 2017. The value of the shares has been included in accrued expenses as of June 30, 2017.

(8)	On August 16, 2017, we sold $248,500 of future customer receipts to a third party for $175,000 in cash. The $73,500 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note and is guaranteed by our former Executive Chairman and Chief Executive Officer, who was in office at the time.

(2) On April 17, 2017 the Company and a customer entered into a Joint Venture Agreement, effective March 31, 2017 (the "JV Agreement") with Colorado Choice Health Plans ("CCHP"). Under the JV Agreement: (i) CCHP is providing various services to the Company to improve the Company's diabetes programs, (ii) the Company loaned CCHP $500,000 under a debenture note, and (iii) the JV Agreement will terminate upon the later of (a) repayment of the debenture note or (b) the one year anniversary of the JV Agreement. The debenture note: (i) bears interest at the rate of five percent per annum, (ii) is subordinated to the rights of CCHP policyholders, claimants and beneficiary claims and all other classes of CCHP creditors other than subordinated debenture holders, (iii) does not become a liability of CCHP until and unless the Commissioner of the Colorado Department of Regulatory Agencies, Division of Insurance ("Division of Insurance") authorizes repayment of the debenture agreement, and shall be treated by CCHP as surplus until the time of such approval, (iv) is only repayable from available funds in excess of CCHP's minimum net surplus required to be maintained by the Division of Insurance, and (v) is otherwise repayable on March 31, 2018, assuming approval by the Division of Insurance.47

(9)	During July 2017, we granted 50,000 shares of common stock, with a value of $400,000 on the date of grant, to a third party as part of a one-year consulting agreement. The value of the shares will be amortized to selling, general and administrative expenses evenly over the service period. On September 5, 2017, our Board of Directors granted the issuance of 500 shares of Series H Preferred stock in lieu of the 50,000 shares of common stock, to which the third party has verbally agreed. The Series H Preferred shares have not yet been issued.

(10)	During July 2017, we granted 3,937 shares of common stock to employees for bonuses. The $31,500 fair value of the shares has been included in accrued expenses as of June 30, 2017.

(11)	On August 28, 2017, we sold $224,850 of future customer receipts to a third party for $150,000 in cash. The $74,850 difference between the future customer receipts and cash received is being amortized to interest expense over the term of the note. The note is subordinated to another note and is guaranteed by our former Executive Chairman and Chief Executive Officer, who was in office at the time.

(12)	On August 31, 2017, we sold $119,920 of future customer receipts to a third party for $80,000 in cash. The $39,920 difference between the future customer receipts and cash received is being amortized to interest expense over the term of the note. The note is subordinated to another note and is guaranteed by our former Executive Chairman and Chief Executive Officer, who was in office at the time.

(13)	On September 5, 2017, our Board of Directors modified the terms of the Series G Convertible Preferred stock to remove the 18-month lock-up period. The amendment has not been filed with the State of Delaware as of the date of this filing.

(14)	On September 5, 2017, our Board of Directors ratified a change to the Series H Preferred stock, previously contemplated and approved by the Board of Directors, to where each share of the Series H Preferred stock is convertible into 100 shares of our common stock, is limited to a total ownership of 4.99% of the outstanding common stock at the time of conversion, is to be non-voting stock, does not bear interest or dividends, and is transferable with the same terms. The Certificate of Designation for the Series H Preferred stock has not been filed with the State of Delaware as of the time of this filing and no shares had been issued prior to September 5, 2017.

(15)	On September 5, 2017, we entered into a consulting agreement with a former Executive Chairman and Chief Executive Officer, which replaced and existing consulting agreement, for certain consulting services to us including, but not limited to (i) developing business plans, (ii) making introductions to potential customers and/or suppliers, (iii) identifying qualified employees and other service providers, (iv) sales, marketing, manufacturing and other operating activities, and (v) meeting with us and our affiliates' respective managers, officers, employees, agents, and other service providers regarding the business, prospects and our affairs and our affiliates. The former officer may not engage in and shall not be entitled to any fees or consideration for (i) negotiating the purchase and/or sale of our securities, (ii) making recommendations regarding transactions involving our securities, (iii) or any other matters involving transactions of our securities. The agreement is for one year and includes compensation of $250.00 per hour, but such compensation may not exceed $20,000 during any calendar month, plus 1,500 shares of our Series H Preferred stock. The shares of Series H Preferred stock have not been issued at the time of this filing.

(16)	On September 5, 2017, we renewed an existing license and royalty agreement with an entity controlled by a former Executive Chairman and Chief Executive Officer (the "licensee"). Under the agreement, the licensee receives the right to make, sell and use products related to our intellectual property regarding diabetics, cellular, GPS and CareCenter arena and generally characterized as the CareCenter Technology in a certain region. We shall receive a royalty of 15% of the licensee's gross sales price for the product. The initial term is for three years whereby the licensee must achieve a minimum royalty of $10,000 per month to maintain the agreement, whereby the agreement will be extended for one addition year unless terminated. If the minimum monthly royalty is not maintained, the licensee may pay a sum to bring the total payment up to $360,000 within 60 days of the end of the three-year term to extend the agreement for one additional year. The Company may terminate the agreement if the licensee does not commence to manufacture, distribute and sell product within a 6-month period after the execution of the agreement.

(17)	On September 5, 2017, we granted 1,500 shares of our Series H Preferred stock to an entity controlled by a former Executive Chairman of the Board of Directors for past services rendered in addition to amounts earned under an existing consulting agreement. The shares of Series H Preferred stock have not been issued at the time of this filing.

(5) During April, 2017 the Company issued 7,000 shares of common stock to business development contractor pursuant to a services arrangement in consideration for services rendered.

(18)	On September 5, 2017, we entered into an employment agreement with our former Executive Chairman and Chief Executive Officer, who was in office at the time, for a period of two years for services as our Executive Chairman and Chief Executive Officer. The initial term of the agreement is for two years and shall automatically renew on a year to year basis, unless terminated sooner. The base compensation is $360,000 per year plus 1,500 shares of our Series H Preferred stock. The shares of Series H Preferred stock have not yet been issued. The terms of the Series H Preferred stock have been approved by our Board of Directors, but no Certificate of Designation has been filed with the appropriate authoritative body. An additional cash or stock bonus may be awarded, subject to the attainment of such individual and ActiveCare objectives as our Board of Directors shall establish from time to time as determined by our Board of Directors. Upon certain termination conditions upon termination of the agreement, we may be required to pay severance of twice the base compensation of the former Executive Chairman and Chief Executive Officer at its highest point during the five-year period prior to termination. In addition, our Board of Directors approved compensation at a level of $360,000 per year retroactive from July 2017, when the former Executive Chairman and Chief Executive Officer was appointed, until the employment agreement was signed. Effective October 12, 2017, the agreement was amended to waive any constructive termination in relation to changes in title, working conditions or duties such that his powers are diminished, reduced or otherwise changed to include powers, duties, or working conditions which are note materially consistent with title, continuing after written notice and 10 days to cure.

(19)	On September 5, 2017, our Board of Directors granted 963 shares of Series H Preferred stock to our former Executive Chairman and Chief Executive Officer, who was in office at the time, in lieu of 96,275 shares of previously granted common stock as a bonus for services performed. The Series H Preferred shares have not yet been issued.

(20)	On September 5, 2017, our Board of Directors granted 200 shares of Series H Preferred stock to the holder of an unsecured note payable with a balance of $300,000 as of June 30, 2017 for the extension of the note payable. The Series H Preferred shares have not yet been issued.

(21)	From September 21, 2017 through December 1, 2017, we received cash advances totaling $230,000 from an entity controlled by our former Executive Chairman and Chief Executive Officer, who was in office at the time, and repaid $10,000 plus the reimbursement of bank fees of $200.

(22)	On September 25, 2017, we entered into agreements with its primary product vendor that supersedes all prior agreements with the vendor. Under the agreements, the vendor will provide all products and services to our service members as they are assigned to the vendor. In return, the vendor will pay us a fee for services rendered to the vendor and to the members for monitoring and reporting. We also earn commissions on all members assigned under the agreement to be paid upon completion of certain milestones met with each individual member. The agreements also modify the terms of an existing note payable to the vendor. The note accrues interest at 0.65% per annum, is reduced by the amount of commissions earned by us under the agreements and matures on September 25, 2019. The agreements also add interest fees on existing accounts payable at 0.65% per annum and the accounts payable are reduced by the amount of commissions earned by us under the agreements for a minimum of 24 months.

(23)	On September 27, 2017, we received a cash advance from a third party in the amount of $40,000, which incurs fees of $600 per day until repaid.

(24)	In October 2017, we entered into a settlement agreement related to an unsecured note payable with a principal balance of $300,000 as of June 30, 2017. As part of the agreement, the lender lent us an additional $200,000 which has been added to the principal balance of the note payable. The agreement modified the terms of the note payable to become secured by inventory owned by us, requires issuance of 3,000 shares of Series H Preferred Stock, which were granted by our Board of Directors on September 5, 2017 and are required to be able to convert the lender's shares into 300,000 shares of the Company's common stock, and requires payments of $8,600 for 72 consecutive weeks. If any payment is late, we are required to issue the lender an additional 86 shares of Series H Preferred Stock per late payment and an additional 172 shares of Series H Preferred stock if late payments are not cured within 30 days and for each subsequent 30-day period the note is in default. The amended note also requires payment of a key man life insurance policy on a former Executive Chairman of the Board of Directors naming the lender as the benefactor. The fair value of the shares will be amortized over the life of the amended note. The note terms are adjustable for any terms subsequently provided to other investors.

(25)	On November 7, 2017, we entered into individual agreements related to secured borrowings from four different parties that each previously purchased customer receivables that require daily payments. The agreements modified each agreement to reduce the amount of the respective daily payment to approximately half of the amount previously drawn through January 7, 2018, whereafter the amount of the payment returns to the payment required under the respective agreement plus an additional amount equal to the amount shorted during the period of lower payments divided by the number of remaining payments remaining on the original term of the respective note payable. Three of the four agreements are verbal. On January 5, 2018, we further modified each agreement to keep the amount of the daily payments at approximately the same level as the agreement on November 7, 2017 through mid-March 2018, except one where the lower payments are only through February 5, 2018. Three of the four agreements are verbal.

(26)	On November 13, 2017, an entity controlled by a former Executive Chairman of the Board of Directors, with whom we contracted for consulting, terminated the existing consulting arrangement.

(6) Effective April 1, 2017, the Company entered into a letter agreement (the "Telecare Letter Agreement"), with Telecare Medical Supply, LLC, the sole supplier of our cellular glucometers and other testing supplies ("Telecare"), and the payee of a certain Non-Negotiable Promissory Note in the original principal amount of approximately $2,524,000 (the "Amended and Restated Telecare Note"). Pursuant to the Telcare Letter Agreement, Telecare has agreed to convert all monies due it from the Company pursuant to the Telecare Note into restricted shares of common stock (the "Telecare Conversion Shares"), all contingent upon the completion of this offering. As of March 31, 2016, Telecare is owed the principal amount of $1,773,937 ("Telecare Principal Amount"), along with accrued interest of $3,675 through March 31, 2017 (the "Telecare Interest Amount" and, together with the Principal Amount, the "Telecare Note Obligation"). As incentive to enter into the Telecare Letter Agreement, the Company agreed to add approximately $502,388 to the Telecare Note Obligation effectively making the total obligation due to Telecare an aggregate of $2,280,000 (the "Total Telecare Obligation"). Pursuant to the Telecare Letter Agreement, the Total Telecare Obligation will automatically convert upon consummation of the Offering into the Telecare Conversion Shares at the combined price per share and warrant paid by investors in the Offering (the "Conversion Price"). If the Offering is not completed by April 30, 2017, the letter agreement and lock-up agreement will terminate.49

(7) Effective April 19, 2017, the Company amended a note payable with a principal balance of $1,700,000 to extend the maturity date to the earlier of May 20, 2017 or the third business day after the closing of the Offering.

(27)	On November 13, 2017, we entered into a sales broker agreement with an entity controlled by a former Executive Chairman of the Board (the "Sales Broker "). Under the Sales Broker agreement, the Company will provide services to certain customers referred to us and the Sales Broker will receive administration fees in the amount of 15% of gross revenues, as defined by the Sales Broker agreement, as long as the Company services the respective customer even in the event the Sales Broker agreement is terminated. The Sales Broker will promote the Company, its services and products, and introduce potential customers to us as a sales representative. The initial term of the Sales Broker agreement is one year, which automatically renews for additional one-year periods until cancelled by either party.

(28)	On November 30, 2017, we signed a letter of understanding with a former consultant where we agreed to convert $100,000 of past consulting fees owed into an equivalent value of our equity upon a qualifying capital raise.

(29)	On November 10, 2017, we signed a formal agreement replacing a former verbal agreement with an unsecured note holder, with principal due of $350,000 as of June 30, 2017. The new agreement memorialized previously agreed upon terms whereby the lender converted a $350,000 advance into an unsecured note payable, with interest at 2.8% of revenues, for $143,987 in fees and a future payoff fee of 20% of the principal, or $70,000, which are included in accrued liabilities and interest expense as of June 30, 2017. The written agreement adjusted the verbal agreement to where we are required to pay any outstanding interest at the end of the first month following a quarter end. The lender may call all amounts due under the note payable as due and payable after February 28, 2018, given 15 calendar days notice, and the written agreement includes a most favored nations clause in relation to conversion features.

(30)	On November 27, 2017, we signed a formal agreement memorializing previous agreements with the holder of an unsecured note and cash advance, with aggregate principal due of $1,200,000 as of June 30, 2017, as well as additional advances with aggregate principal of $190,000 that were received subsequent to June 30, 2017. The new agreement memorialized the terms of the note payable whereby the lender converted $617,500 in advances into a $1,100,000 unsecured note payable, with interest at 18% per annum for $95,226 in fees, which have been included in accrued liabilities and interest expense as of June 30, 2017. In addition, the new agreement allows for advances to incur fees at 1.5% of the advance principal per calendar day until paid in full. The written agreement adjusted the verbal agreements to where the note payable and advance balances and fees may be called by the lender at any time and are due by May 30, 2018, and the new agreement includes a most favored nations clause in relation to conversion features on the note payable and advances. The new agreement also assigned $2,000,000 of note payable principal held by an entity controlled by an officer to the lender. All interest accrued on the assigned balance is payable to the officer.

(31)	On December 6, 2017, we entered into those certain forbearance and lock up letter agreements with three (3) debtors which held convertible debentures in the aggregate principal amount of $1,109,345 at the time of the agreements, whereby the debtors agreed that, without prior written consent of the Company, the debtors will not, directly or indirectly, (i) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of common stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, (ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, whether any such transaction is to be settled by delivery of common stock or other securities, in cash or otherwise, (iii) except as provided for, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any of our other securities, or (iv) publicly disclose the intention to do any of the foregoing for a period of the earlier of (a) June 5, 2018 or (2) the consummation of a qualified offering, herein deemed as an offering of $3,000,000 or more. Additionally, the Debt Holders agreed that they will forbear from enforcing their rights and remedies against any defaults which may exist historically, currently or in the future through June 5, 2018 under the existing loan documents. The agreements automatically terminate upon the earlier of (i) inability to raise a minimum of $550,000 in capital on or before December 31, 2017; (ii) June 5, 2018; or (iii) the consummation of a qualified offering of at least $3,000,000 by the Company. In addition, two (2) of the debtor agreements waive their rights to default litigation only through December 31, 2017 and any new financing must receive their prior consent unless it is common equity.

(8) As of the date of this report, notes payable due to unrelated parties with total principal amounts of $11,501,114, owing as of March 31, 2017, are past due, in default, and unpaid. In addition, notes payable due to related parties with total principal amounts of $3,875,335, as of March 31, 2017, are past due, in default and unpaid. These defaults include obligations owed to Partners for Growth, which are in excess of $2,875,000 and which are secured by substantially all assets of the Company.50

(32)	Effective December 11, 2017, we entered into a Securities Purchase Agreement (the "Purchase Agreement") with four accredited investors, including our new Chief Executive Officer in connection with the closing of a bridge financing (the "Bridge Financing") in the gross amount of $600,000. The three remaining accredited investors hold notes payable with an aggregate principal balance of $3,865,865 as of June 30, 2017. Pursuant to the Purchase Agreements, the Investors purchased from us (i) Promissory Notes in the aggregate principal amount of $631,578.06 (the "Notes") due and payable six months from the Effective Date and (ii) Common Stock Purchase Warrants (the "Warrant"), exercisable for five years from the date of issuance, to purchase up that certain amount of shares with an aggregate exercise amount equal to $600,000 at an exercise price per share equal to the lesser of (i) 80% of the per share price of common stock in the companies contemplated private placement of securities of up to $5,000,000, contemplated to take place within six months of the effective date (the "Private Placement") (ii) $3.00 per share, (iii) 80% of the offering price in the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement, in each case subject to adjustment hereunder (the "Exercise Price"). The Notes were issued in favor of the Investors with an original issue discount equal to five percent (5%). Additionally, pursuant to the Purchase Agreement, we will issue the investors common stock (the "Origination Shares") worth 30% of the purchase price paid by each investor (the "Origination Dollar Amount") on the 5th trading day after the pricing of the Private Placement, but in no event later than six months from the Effective Date. The Origination Dollar amount will divided by the lowest of (i) $3.00 (subject to adjustment for stock splits), (ii) 80% of the common stock offering price in the Private Placement, (iii) 80% of the offering price of the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement. At the closing of the Private Placement the Note shall automatically convert into a subscription into the Private Placement in an amount equal to 125% of the Note balance, subject to certain conditions as outlined therein. If we fail to repay the balance due under the Note on its Maturity the Investors have the right, at any time, at their election, to convert all or part of the outstanding and unpaid principal sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of our common stock pursuant to the following conversion formula: number of shares receivable upon conversion equals the dollar amount being converted divided by the Conversion Price. The Conversion Price is the lesser of $3.00 (subject to adjustment for stock splits) or 60% of the lowest trade price in the 25 trading days. Further, in the event of any default, the outstanding principal amount of the Notes, plus accrued but unpaid interest, liquidated damages, fees and other amounts owing in respect thereof through the date of acceleration (the "Note Balance"), shall become, at the Investor's election, immediately due and payable in cash at the Mandatory Default Amount. The Mandatory Default Amount means the investor's choice of (this choice may be made at any time without presentment, demand, or notice of any kind): (i) the Note Balance divided by the Conversion Price on the date of the default multiplied by the closing price on the date of the default; or (ii) the Note Balance divided by the Conversion Price on the date the Mandatory Default Amount is either (a) demanded or (b) paid in full, whichever has a lower Conversion Price, multiplied by the closing price on the date the Mandatory Default Amount is either (a) demanded or (b) paid in full, whichever has a higher closing price; or (iii) 150% of the Note Balance. If, at any time the Note is outstanding, we issue a Variable Security (as defined therein), then in such event the Investors shall have the right to convert all or any portion of the outstanding balance of the Notes into shares of Common Stock on the same terms as granted in any applicable Variable Security issued by the Company.

(33)	On November 17, 2017, we received cash advances from third parties totaling $60,000. On January 5, 2018, the advances converted into agreements with the same terms as the Bridge Financing entered into on December 11, 2017.

(34)	On December 11, 2017, Eric Robinson voluntarily resigned as Chief Financial Officer, Secretary and In-House Counsel, and all other positions with the Company to which he has been assigned regardless of whether he served in such capacity, effective immediately. On the same date, Jeffrey S. Peterson voluntarily resigned as Chairman of the Board of Directors, while acknowledging that he will continue to serve the Company as a Director and Executive Vice President. On the same date, Robert J. Welgos and Bradley Robinson voluntarily resigned as members of the Board of Directors and all other positions with us to which they may have been assigned, regardless of whether they served in such capacity, effective immediately. These resignations were not as a result of any disagreements with us.

(35)	On December 11, 2017, Isaac Onn was appointed as a member of our board of Directors and Mark J. Rosenblum was appointed as our Chairman of the Board of Directors and Chief Executive Officer in connection with the Bridge Financing. In connection with Mr. Rosenblum's appointment as our Chief Executive Officer, on December 11, 2017, we and Mr. Rosenblum finalized the terms of his employment and entered into an employment agreement (the "Rosenblum Employment Agreement"). Mr. Rosenblum shall have such duties, responsibilities and authority which shall include, but not be limited to the responsibility for the overall management, direction and strategy of the Company. We shall pay Mr. Rosenblum a salary at a rate of Three Hundred Thousand and 00/100 Dollars ($300,000) per year (the "Initial Base Salary"). The Initial Base Salary shall increase to an annual rate of Three Hundred and Sixty Thousand Dollars ($360,000) (the "Base Salary") upon our closing a financing of at least Five Million Dollars ($5,000,000). Mr. Rosenblum shall be eligible for an annual performance-based cash bonus of up to 100% of the Base Salary (as further defined in the Rosenblum Employment Agreement"). The Rosenblum Employment Agreement is for a term of three (3) years and will be automatically renewed for one year periods, unless otherwise terminated by us or Mr. Rosenblum. Upon execution of the Rosenblum Employment Agreement we agreed to issue restricted shares equal to $300,000 valued at the offering price of the next equity offering of the Company ("RSU") and an option to purchase an aggregate $600,000 valued at the offering price of our next equity offering at an exercise price equal to the market price for our next equity offering (the "Options"). One-third of these Options shall vest immediately, another third on the first anniversary of the Rosenblum Employment Agreement, and the final third on the second anniversary of the Rosenblum Employment Agreement. The RSUs shall vest 50% immediately upon issuance and 25% on each of the first and second anniversaries of the Rosenblum Employment Agreement. If the Company terminates Mr. Rosenblum's employment without just cause or if Mr. Rosenblum's employment is terminated due to Disability (as defined therein), Mr. Rosenblum shall be entitled to receive, in addition to any accrued and unpaid Base Salary, plus any accrued but unused vacation time and unpaid expenses that have been earned as of the date of such termination, the following severance payments (the "Severance Payments"): (i) equal monthly installments at the applicable Base Salary rate then in effect, as determined on the first day of the calendar month immediately preceding the day of termination, to be paid beginning on the first day of the month following such termination and continuing until the later of (A) the expiration of the Term or (B) the expiration of (i) six (6) months following the effective termination date; provided, however, that if we terminate the Agreement without Just Cause (as defined in the Rosenblum Employment Agreement) within six (6) months of the effective date, then Mr. Rosenblum will only be entitled to three (3) months of severance instead of six (6) months; and (ii) during the Severance Period (as defined in the Rosenblum Employment Agreement), health and life insurance benefits substantially similar to those which Mr. Rosenblum was receiving or entitled to receive immediately prior to termination; provided, however, such insurance benefits shall be reduced to the extent comparable benefits during such period following Mr. Rosenblum's termination, and any benefits actually received shall be reported by Mr. Rosenblum to us. We will reimburse Mr. Rosenblum for any reasonably travel and relocation expenses.

(36)	During December 2017, we entered into those certain forbearance and lock up letter agreements with a debtor which holds convertible debentures in the principal amount of $25,312 as of December 5, 2017, whereby the debtor agreed that, without our prior written consent, the debtor will not, directly or indirectly, (i) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of common stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, (ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, whether any such transaction is to be settled by delivery of common stock or other securities, in cash or otherwise, (iii) except as provided for, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any of our other securities, or (iv) publicly disclose the intention to do any of the foregoing for a period of the earlier of (a) June 5, 2018 or (2) the consummation of a qualified offering, herein deemed as an offering of $3,000,000 or more. Additionally, the debtor agreed that they will forbear from enforcing their rights and remedies against any defaults which may exist historically, currently or in the future through June 5, 2018 under the convertible debentures. The forbearance and lock up letter agreements automatically terminate upon the earlier of (i) inability to raise a minimum of $550,000 in capital on or before December 31, 2017; (ii) June 5, 2018; or (iii) the consummation of a qualified offering of at least $3,000,000 by the Company.

(37)	On January 12, 2018, we received letters from four (4) debtors which hold convertible debentures with principal balances totaling $3,162,955 as of June 30, 2017 where the debtors forbear against any historical and future events of default and remedies through February 15, 2018 and extended the maturity date through February 15, 2018. As part of the letters, we agreed not to initiate any new financing arrangements without the consent of the debtors.

(38)	On January 12, 2018, we received a letter from a lender who holds two unsecured notes payable with principal balances totaling $550,000 as of June 30, 2017 where the lender forbears against any historical and future events of default through February 28, 2018 and extended the maturity date through February 28, 2018 in exchange for 12,000 shares of common stock.

(39)	On December 22, 2017, we entered into a Services Agreement (the "Cleveland Clinic Agreement") with the Cleveland Clinic Foundation d.b.a. Cleveland Clinic, an Ohio nonprofit corporation ("Cleveland Clinic"). Pursuant to the Cleveland Clinic Agreement, we will be providing services to Cleveland Clinic as agreed to by the parties in any mutually agreed form pursuant to a "Statement of Work". Pursuant to the Statement of Work included in the Cleveland Clinic Agreement, we will provide monitoring services to Cleveland Clinic's expected beneficiary diabetic population within the Cleveland Clinic Medicare ACO. The initial term of the Cleveland Clinic Agreement is for three years and shall automatically renew after the term for a successive twelve (12) month period from year to year unless sooner terminated by either party in accordance with the terms of the Cleveland Clinic Agreement. As consideration for our Services, we are to receive a fixed monthly fee per Covered Diabetic Patient (as defined in the Cleveland Clinic Agreement). In addition, at such time the Cleveland Clinic Accountable Care Organization ("CCACO") shall receive a shared savings payment from the Centers for Medicare and Medicaid Services, CCACO shall share such savings with us based on a formula defined in the Cleveland Clinic Agreement. Cleveland Clinic may, by written notice to us, terminate the Agreement, any purchase order or any portion of a purchase order if we (i) are in material breach of any of the terms and conditions of the Cleveland Clinic Agreement or any Purchase Order, which breach in not cured within thirty (30) days after notification of such breach, (ii) terminate or suspend our business, become insolvent, or become subject to any bankruptcy or insolvency proceeding under Federal or State law. Cleveland Clinic further may terminate the Cleveland Clinic Agreement, any Purchase Order or any portion of any Purchase Order for convenience upon ninety (90) days' prior written notice to us ("Termination for Convenience"). In connection with any Termination for Convenience, Cleveland Clinic will reimburse Company for the actual cost reasonably incurred for work in process up to the time of cancellation, as well as any non-cancellable contract of Company, or non-cancellable purchase order to a third party, entered into for the benefit of Cleveland Clinic. The Cleveland Clinic Agreement is nonexclusive, and Cleveland Clinic may contract with others to perform similar services. Accordingly, the Company may also perform similar services for others.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Information about our exposure to market risk was disclosed in our Annual Report on Form 10-K for the year ended September 30, 2016, which was filed with the Securities and Exchange Commission ("SEC") on January 13, 2017. There have been no material quantitative or qualitative changes in market risk exposure since the date of that filing.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our reports under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized, and reported within the time periods that are specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) under the Exchange Act). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of ~~March~~June 3130, 2017, our disclosure controls and procedures were not effective, for the reasons discussed below.

During the audit process for the year ended September 30, 2016 and the review process for the ~~six~~nine months ended ~~March~~June 3130, 2017, management identified ineffective controls over the accounting for 1) debt issuance costs and derivatives, and 2) debt extinguishments as material weaknesses in internal control over financial reporting.

We are in the process of improving our internal control over financial reporting in an effort to eliminate these material weaknesses through improved supervision and training of our staff. Our management, audit committee, and directors will continue to work to ensure that our controls and procedures become adequate and effective.

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Except as set forth below, there are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse to our Company or any of our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries. No director or executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years.

On May 28, 2015, an investor in the Company, filed a lawsuit against the Company, James Dalton, our former CEO and Chairman, ADP Management, an entity controlled by David Derrick, our former Executive Chairman, and 4G Biometrics, a wholly owned subsidiary of the Company in the District Court of Utah-Central Division (Case No. 2:15-CV-00373-BCW). The lawsuit alleges a breach of contract, breach of the implied covenant of good faith and fair dealing, fraud and conspiracy to commit fraud and seeks damages in excess of $1,000,000, exclusive of interest and costs. The Company has engaged legal counsel regarding the matter. AtThe ~~this~~Company ~~time,~~has itassessed isa ~~not~~high ~~possible~~probability toof ~~predict~~settling the ~~outcome of the~~ matter. ~~The~~for ~~Company~~$750,000 ~~intends~~in tocash, ~~vigorously~~equity, ~~dispute~~or ~~the~~a ~~litigation~~combination ~~and believes it has meritorious defenses to the claims~~thereof.

Item 1A. Risk Factors.

We believe there are no changes that constitute material changes from the risk factors previously disclosed in our Annual Report on Form 10-K, filed with the SEC on January 13, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~There~~During ~~were~~the nothree ~~unregistered~~months ~~sales~~ended June 30, 2017, we issued 7,000 shares of ~~equity~~common ~~securities~~stock for services provided by an independent consultant, with a value on the date of grant of $70,000 in reliance on an exemption from registration set forth in Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder.

There were no other unregistered sales of the Company's equity securities during the quarter ended June 30, 2017, that were not otherwise disclosed in a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities

As of the date of this report, notes payable due to unrelated parties with total principal amounts of $112,~~501~~776,~~114~~046, owing as of ~~March~~June 3130, 2017, are past due, in default, and unpaid. In addition, notes payable due to related parties with total principal amounts of $326,~~875~~721,~~335,~~ as of ~~March~~June 3130, 2017, are past due, in default and unpaid. These defaults include obligations owed to Partners for Growth, our secured lender, which are in excess of $2,~~875~~700,000 and ~~which~~ are secured by substantially all assets of the Company. We intend to make payments on these notes payable as funds are available. Other notes are currently in technical default. However, as of the time of this report, the lenders have informally agreed to work with us until such time as the notes can be repaid and some of the lenders have provided bridge capital since going in default.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information

There is no other information required to be disclosed under this item which was not previously disclosed.

Item 6. Exhibits

Exhibit Number Description

Exhibit Number		Description

4.1		Form of Warrant (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

10.1		Form of employment agreement with former chief executive officer.

10.2		Factoring Agreement by and between Complete Business Solutions Group, Inc. and ActiveCare, Inc. (incorporated by reference to Current Report on Form 8-K filed with the SEC on April 20, 2017).

10.3		Joint Venture Agreement by and between Colorado Choice Health Plans and ActiveCare, Inc. (incorporated by reference to Current Report on Form 8-K filed with the SEC on April 20, 2017).

10.4		Amendment # 5 to the Securities Purchase Agreement and the $2,000,000 Promissory Note dated September 19, 2016 (incorporated by reference to Current Report on Form 8-K filed with the SEC on April 20, 2017).

10.5		Form of Forbearance and Lock Up Agreement (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

10.6		Form of Securities Purchase Agreement (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

10.7		Form of Promissory Note (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

10.8		Employment Agreement by and Between Mark J. Rosenblum and ActiveCare, Inc. (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

17.1		Letter of Resignation from Bradley Robinson (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

17.2		Letter of Resignation from Eric Robinson (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

17.3		Letter of Resignation from Jeffrey S. Peterson (incorporated by reference to Current Report on Form 8-K filed with the SEC on December 14, 2017).

31.1		Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *

31.2		Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *

32		Certification pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

31.1		Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *
31.2		Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *
32		Certification pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

* Filed herewith

42* The XBRL related information in Exhibit 101 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ActiveCare, Inc.
Date: May 19, 2017	/s/ Jeffrey S. Peterson
Date: January 31, 2018	/s/Mark J. Rosenblum
	Jeffrey S. Peterson Chief Executive Officer (Principal Executive Officer)
	Mark J. Rosenblum Chief Executive Officer (Principal Executive Officer)

Date: ~~May~~January 1931, ~~2017~~2018 /s/~~Eric~~Jeffrey ~~Robinson~~S. ~~Eric~~Peterson ~~Robinson~~Jeffrey ~~Chief~~S. ~~Financial~~Peterson ~~Officer~~Executive Vice President (Principal Financial and Accounting Officer)

4355

Filing Compare · ACTIVECARE, INC.